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Toxoplasma gondii is a protozoan parasite of wide geographic and host range.  Although many 
infections in humans are asymptomatic, the potential exists for severe disease.  The parasite is 
highly successful given its ability to establish life-long infections.  To achieve this, the parasite 
must establish a delicate balance between activation and suppression of the host immune 
response.  The cytokine IFNγ is essential for host resistance to the parasite.  Therefore, 
Toxoplasma actively manipulates the IFNγ pathway in order to ensure parasite survival. 
 
It has become clear that Toxoplasma can evade the host IFNγ response in a variety of cell types.  
However, the exact mechanism by which this occurs remains unclear.  Furthermore, evasion of 
the IFNγ response has not been studied in the dendritic cell, an immune cell type important 
during in vivo infection.  I show that Toxoplasma can block STAT1 binding to IFNγ-responsive 
gene promoters in dendritic cells, preventing transcription.  However, STAT1 activation is not 
impaired.  In fact, I show that Toxoplasma alone causes STAT1 phosphorylation and nuclear 
translocation, as well as consensus sequence binding.  Phosphorylation and consensus sequence 
binding occur synergistically with IFNγ.  However, the parasite induces formation of aberrant 
STAT1 DNA-binding complexes. 
 
 Further work shows that Toxoplasma-induced STAT1 phosphorylation and/or synergy with IFNγ 
occur independently of the parasite kinases ROP16, ROP18, ROP21 as well as the parasite-
triggered host MyD88-, GiPCR-, and PI3K-dependent signaling pathways.  Furthermore, 
inhibition of STAT1 transcriptional activity occurs in a parasite strain-independent manner.  
Synergistic levels of phospho-STAT1 correlate with parasite mediated inhibition of IFNγ-
induced Socs1 expression.  Yet, the parasite alone induces modest Socs1 expression in a ROP16-
dependent manner, which may participate in regulation of other pathways such as TLR signaling. 
 
From this work it is clear that the impacts of Toxoplasma on dendritic cell STAT1 signaling are 
complex.  The parasite induces STAT1 phosphorylation, but how this occurs and whether this 
STAT1 participates in the transcription of a unique subset of genes remains to be determined.  
However, it is clear that the parasite can block STAT1 chromatin binding and transcription in 
dendritic cells in response to IFNγ, permitting evasion of this important host immune response. 
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TOXOPLASMOSIS 
Etiology and history 
Toxoplasma gondii is the protozoan responsible for the disease of humans and animals known as 
toxoplasmosis.  The parasite was initially discovered in 1908 in Tunis by Nicolle and Manceaux 
in a North African hamster-like rodent known as the gundi (Ctenodactylus gundi).  Around the 
same time, Splendore identified the same parasite in a rabbit, but mistook it for Leishmania.  
Nicolle and Manceaux named the parasite based on its form (Toxo = arc or bow; plasma = life) 
and host (the gundi, which they mistakenly identified as gondi initially) (1-3).  One of the first 
cases of acquired human toxoplasmosis was identified by Sabin and colleagues in a young boy 
who had experienced head trauma from a baseball bat and coincidentally died 30 days later as a 
result of a Toxoplasma infection in 1937.  The name of a parasite strain commonly used today in 
research laboratories, RH, was derived from the boy’s initials (2).  Around the same time, the 
first documented case of congenital toxoplasmosis resulting in a death of a newborn in 1938 was 
reported by Wolf, Cowen and Paige (4).  Since then, the parasite has been identified world-wide 
in virtually all warm-blooded vertebrates, with all isolates belonging to a single species (2). 
 
Toxoplasma belongs to the phylum Apicomplexa, which contains ~6000 organisms to date, most 
of which are obligate parasites at some point during their complex life cycles.  Some, like 
Toxoplasma, have been identified as pathogenic to humans and/or animals and cause other 
important diseases such as malaria (Plasmodium spp), babesiosis (Babesia spp), coccidiosis 
(Eimeria spp), cryptosporidiosis (Cryptosporidium spp), and theileriosis (Theileria spp) (5).  The 
Apicomplexans are named for the apical complex, which consists of various secretory organelles 
(micronemes, rhoptries, dense granules), the conoid (involved in invasion), and a microtubule 
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organizing center known as the apical polar ring (6).  In addition, many possess a non-
photosynthetic plastid known as the apicoplast, which is essential for Toxoplasma survival, 
presumably due to its role in fatty acid and isoprenoid synthesis (7-11).  
 
Like most other Apicomplexans, Toxoplasma relies on substrate-dependent gliding motility to 
travel across biological barriers and to invade and egress from host cells.  A macromolecular 
complex known as the “glideosome” facilitates movement, consisting of microneme-derived 
secreted adhesive proteins that are released apically and then translocated to the posterior pole of 
the parasite (12).  This complex is powered by the parasite’s actin-myosin system anchored in 
the inner membrane complex (13, 14).  Active invasion and establishment of the parasitophorous 
vacuole within the host cell requires gliding motility as well as sequential secretion of the apical 
organelles known as micronemes, rhoptries, and later, dense granules (15) (Figure 1.1).  In 
addition to motility, microneme proteins facilitate attachment to the host cell.  As Toxoplasma 
invades, a “moving junction” is formed with the host cell, which consists of a microneme protein 
(AMA1) on the parasite surface engaged with a rhoptry neck proteins (RONs) secreted into the 
host cell membrane (12, 16).  The moving junction slides over the parasite as it invades, acting as 
a sieve that removes the majority of host proteins in order to establish a non-fusogenic 
parasitophorous vacuole (PV) (12, 17-19).  Other rhoptry proteins (ROPs) help to further 
establish the PV or serve as virulence factors, modulating the host response to infection (20).  
The PV is further modified as dense granule proteins are continuously secreted to maintain the 
PV and assist in nutrient acquisition (21).  After several rounds of division, tachyzoites actively 
egress from the cell in a calcium-dependent manner very similar to the process of invasion (22). 
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Figure 1.1.  Host cell invasion and establishment of the parasitophorous vacuole by 
Toxoplasma gondii.  Upon contact with a target host cell, the parasite initiates invasion by 
secreting microneme proteins (MIC) that serve as attachment factors (1).  Shortly after 
attachment, the “moving junction” (red line) is established between the parasite and the host cell, 
consisting of the microneme protein AMA1 on the parasite surface interacting with rhoptry neck 
proteins (RON) secreted into the host plasma membrane (2).  Also during this time, rhoptry bulb 
proteins (ROP) are released.  Many are inserted into the parasitophorous vacuole membrane but 
others can be found in the host cell cytosol (3) or even in the nucleus (4).  Passage of the parasite 
through the moving junction permits establishment of the non-fusogenic parasitophorous vacuole 
within the host cell cytoplasm (5).  At this time, the parasite further modifies the parasitophorous 
vacuole by secreting dense granule proteins (GRA) into the vacuole membrane and lumen (5).  
Components of the ultrastructure of the parasite are indicated as shown.   
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Life cycle, population structure, and transmission 
Toxoplasma possesses a complicated life cycle, with both sexual and asexual stages, as reviewed 
by Dubey (23), summarized here, and depicted in Figure 1.2.  There are three infectious forms of 
the parasite, including the rapidly dividing tachyzoite, the slowly-dividing bradyzoite (found 
within tissue cysts), and the environmentally resistant stage, the sporozoite (found within 
sporulated oocysts).  The sole definitive host for the parasite is the cat.  A feline is most 
efficiently infected through the ingestion of tissue cysts in an intermediate host (often a rodent or 
bird), although sporulated oocysts or tachyzoites may also be a source.  The cyst wall is degraded 
in the gastric environment, releasing the bradyzoites which subsequently invade the cat’s 
intestinal epithelial cells.  Conversion to tachyzoites results in multiple rounds of asexual 
proliferation by endodyogeny, allowing for dissemination of the parasite throughout the cat, as in 
intermediate hosts.  In addition, the parasite undergoes an intensive enteroepithelial cycle within 
the cat’s intestine, forming schizonts of five types, A-E.  At the end of schizogony, merozoites 
are released to form male and female gametes, which in turn fuse to form a zygote enclosed 
within a wall (the oocyst).  Epithelial cells rupture to release the mature oocysts, which are 
subsequently transmitted into the environment through the feces.  It takes approximately 3-7 
days after ingestion of tissue cysts for a cat to shed oocysts.  Shedding can persist for up to 20 
days, with up to 100 million oocysts potentially released (23). 
 
Oocysts become infective approximately 1-5 days after being passed in the feces, once the 
process of sporogony has taken place.  The completely sporulated oocyst consists of 2 sporocysts 
containing 4 haploid sporozoites each.  Sporulated oocysts are environmentally resistant, with 
the ability to persist for years in soil and water under optimal conditions (24-26) as well as being 
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resistant to some chemical and physical methods of inactivation (27, 28).  A wide range of 
warm-blooded intermediate hosts, including humans, can ingest the oocysts present in 
contaminated food and water.  Upon ingestion, released sporozoites invade the intestinal 
epithelium, transform into tachyzoites, and disseminate from the intestine to the rest of the host’s 
tissues.  Tachyzoites dominate during the acute phase of infection and can invade nearly all 
nucleated cells.  After a number of divisions and under pressure from the host’s immune system, 
tachyzoites convert to the slowly dividing bradyzoite stage to establish chronic infection.  A cyst 
wall forms around multiple bradyzoites, generating tissue cysts.  Although cysts can form in 
various tissue types, they are most abundant within long-lived neural and muscular cells.  There 
they persist for the lifetime of the host.  The life cycle is complete when the intermediate host 
containing tissue cysts is ingested by a feline.  However, Toxoplasma does not require the sexual 
phase of the life cycle to reproduce (unlike other Coccidians) and thus can propagate asexually 
between intermediate hosts via ingestion of tissue cysts (23). 
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Figure 1.2.  The transmission and life cycle of Toxoplasma gondii.  Felines serve as the sole 
definitive host of the parasite, shedding oocysts in the feces.  After a few days, the oocysts 
undergo sporulation and become infective (1).  In addition to being present in cat feces, 
sporulated oocysts can also contaminate food and water supplies for people as well as other 
animals (2).  Small prey species such as rodents and birds become infected primarily through 
ingestion of oocyst-contaminated food or water (3).  The parasite rapidly replicates within the 
host as tachyzoites initially, but then undergoes conversion to the chronic stage, forming cysts in 
various tissues but particularly muscle and nervous tissue.  The cat becomes reinfected by 
ingesting prey species containing the tissue cysts (4), although they can also ingest oocyst-
contaminated material to a lesser extent (5).  Humans become infected by ingesting food or water 
contaminated with sporulated oocysts from cat feces (6) or by ingesting undercooked meat 
containing tissue cysts (7).  Undercooked meat is derived from animals serving as intermediate 
hosts that became infected through ingestion of food or water contaminated with sporulated 
oocysts (8).  Vertical transmission from an infected mother to the fetus can also occur and result 
in devastating consequences for the fetus.  Organ transplantation can also serve as a source if 
donors are infected.  People who are chronically infected and subsequently become 
immunocompromised, as with HIV/AIDS patients and those receiving immunosuppressive drug 
therapy, are also susceptible to developing toxoplasmosis. 
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The unique ability to propagate asexually may explain why three main clonal lineages of the 
parasite dominate infections of people and domestic animals in North America and Europe (29, 
30).  A fourth clonal type was also recently identified in North America, common in wildlife (31, 
32).  The Toxoplasma population likely underwent a bottleneck ~10,000 years ago, allowing the 
four clonal lineages to rapidly expand their host ranges since that time (33).  In contrast, strains 
in South America show much greater diversity within and between groups, indicating that more 
sexual recombination has taken place in that geographic area (34, 35).  The three clonal lineages 
initially identified are designated type I, type II and type III and differ from one another 
genetically by only 1-2% (29).  Despite this high similarity, they exhibit differences in terms of 
virulence.  Type I parasites are uniformly lethal in mice (LD50=1), whereas type II and III 
strains are much less virulent (LD50=10
3
-10
5
) and able to establish chronic infection (36).  
Several polymorphic effector proteins secreted by the parasite have been identified as key 
virulence factors, accounting in part for the observed strain differences (37).  Less is known 
about how strain type affects disease in humans and other animals.  Type II strains are most 
commonly identified in people in North American and Europe with toxoplasmosis while type III 
strains predominate in other animals and do not appear to cause much disease (38).  Type I 
strains appear to dominate in severe congenital infections (38), and are also implicated, along 
with atypical strains, in some cases of severe ocular toxoplasmosis in non-immunosuppressed 
patients (39, 40).  Cases of severe ocular toxoplasmosis in patients who are otherwise healthy are 
common with South American isolates (41, 42).  Thus, knowledge of mechanisms by which 
different strains cause disease may prove useful in future therapies for human cases. 
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Knowledge of the life cycle is essential for identifying means by which people can become 
infected (Figure 1.2).  One primary area of concern is food safety, as people are most apt to 
acquire Toxoplasma via the ingestion of contaminated food and water supplies.  In fact, a recent 
study published by the Centers for Disease Control ranked toxoplasmosis as the 2
nd
 leading cause 
of foodborne-related deaths and 4
th
 highest in terms of causing hospitalizations (43).  People 
acquire foodborne toxoplasmosis primarily through ingestion of undercooked meat containing 
tissue cysts or via ingestion of food or water contaminated with oocysts (44).  The parasite can 
also be transmitted across the placenta to the fetus in pregnant women who are infected for the 
first time during pregnancy (45).  Vertical transmission may also play a role in maintaining 
infections in other animal species, such as sheep (46).  The clinical implications of Toxoplasma 
infection in humans and other animals are addressed in the next section. 
 
Clinical aspects of Toxoplasmosis 
It is estimated that Toxoplasma infects approximately 25-30% of the world’s human population 
(47), highlighting the widespread success of this parasite.  In the United States, prevalence 
ranges from 10-20%, whereas seroprevalence exceeds 60% in parts of South America, Oceania, 
and Africa (48).  For most immunocompetent individuals, the infection is asymptomatic or 
presents with mild flu-like symptoms during the acute phase.  However, serious and potentially 
fatal consequences can occur in patients with compromised immune systems or who are pregnant 
(47).  Immunosuppression most commonly results in disease by allowing cyst rupture and 
resultant reactivation of a chronic infection.  In this situation, the strain of parasite becomes less 
important as the host immune status largely dictates the response to infection (49).  Those at risk 
include HIV/AIDs patients, organ transplant recipients, and those undergoing chemotherapy for 
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cancer or immune-mediated disease.  Patients infected with human immunodeficiency virus 
(HIV) become more likely to develop toxoplasmosis as CD4
+
 T cells drop below 100 cells/μl, 
which can be minimized through effective anti-retroviral drug therapy (50).  Toxoplasmic 
encephalitis is the primary manifestation of the disease in immunocompromised individuals.  
Symptoms are variable and may include headache, fever, dementia, ataxia, hemiparesis, memory 
loss, seizures, coma, and death.  Other organs may also be affected and in particular the lungs 
(pneumonia), heart (myocarditis), and eyes (retinochoroiditis) (51).  Disseminated or pulmonary 
toxoplasmosis is more commonly seen in transplant recipients (52). 
 
Congenital infections resulting from vertical transmission of Toxoplasma are another source of 
concern.  Usually, vertical transmission is only thought to occur in women who are infected with 
the parasite for the first time during pregnancy, but exceptions do occur and may be related to 
parasite strain type in such cases (53).  The likelihood of successful transmission and the 
outcome for the fetus depend on the time during pregnancy at which the woman is infected.  In 
the first trimester, the frequency of transmission is only 10%; however, the consequences for the 
fetus are severe, resulting in severe abnormalities or abortion.  By the third trimester, 
transmission frequency is high at 60-70% whereas 80% of infected neonates are asymptomatic at 
the time of birth (54, 55).  However, ocular lesions such as retinochoroiditis can develop as late 
as the second or third decade of life if infants are not treated sufficiently (56).  Manifestations of 
congenital toxoplasmosis are varied and can mimic other diseases but may include 
hydrocephalus, intracranial calcifications, retinochoroiditis and other ocular abnormalities, 
mental retardation, and/or seizures (57).   
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Immunocompetent and otherwise healthy individuals can also develop disease secondary to 
Toxoplasma infection.  Usually this consists only of mild, non-specific clinical signs such as 
fever and lymphadenopathy.  However, cases of severe ocular toxoplasmosis have also occurred 
in the absence of immunosuppression or history of congenital exposure.  Many studies have 
shown higher incidences and severities of retinochoroiditis in Brazil with both primary infections 
in immunocompetent individuals as well as in those congenitally-infected (58).  These cases are 
most often linked to atypical strain types originating from South America or Africa (39, 59, 60).  
Therefore, a better understanding of virulence mechanisms by these strains may be beneficial in 
future therapies and preventative measures. 
 
In addition to causing disease in humans, Toxoplasma can cause serious economic loss in terms 
of livestock infections.  In particular, sheep and goats have been severely affected with outbreaks 
resulting in reproductive losses such as embryonic loss/resorptions, abortions, fetal 
mummifications, stillbirths, and neonatal deaths (61).  Illness in pigs in countries like Japan has 
also been reported with cases of abortion, myocarditis, pneumonia, and encephalitis (62).  
Devastating consequences can also occur for certain wildlife and zoo animal species infected 
with the parasite.  Kangaroos/wallabies (63), new world monkeys (64), and marine mammals are 
particularly susceptible (65). 
 
Diagnosis, treatment, and prevention 
In cases where Toxoplasma exposure is suspected, serology testing is most frequently performed.  
Most commonly, testing is performed to detect both IgM and IgG.  IgM is produced as early as 
the first week of infection, reaching a plateau at 1 month and then rapidly declining to minimal 
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or undetectable levels after about 6 months (49).  Depending on the test used, IgG can be 
detected 1-3 weeks after the IgM peak, reaching a plateau at 2-3 months and then decreasing 
rapidly to a lifelong residual titer (49).  There are multiple tests available to detect antibody 
production including the Sabin-Feldman dye test, ELISA, IFA, and various agglutination assays; 
however, most laboratories today use ELISAs for parasite-specific IgM and IgG to look for 
evidence of acute and chronic infection, respectively (49).  However, given that IgM titers can 
persist for 1-2 years in some cases, IgG avidity testing can also be employed to rule out a recent 
infection within the past four months (66).  PCR for parasite specific antigens can also be 
performed on fluid or tissue samples in the case of congenital infections or in immuno-
compromised patients exhibiting disease symptoms.  The Toxoplasma B1 gene has been most 
consistently used in PCR detection, but recently a test for the REP-529 has been developed, 
which is more sensitive given that this gene is repeated 200-300 times versus 35 times for the B1 
gene (67).  Immunohistochemistry or Giemsa staining may also be performed on tissue samples 
for a diagnosis.  If desired, parasite strains can be isolated and typed following inoculation into a 
mouse (bioassay) or cell culture.  Ocular toxoplasmosis is most commonly diagnosed based on 
lesions found on ophthalmological exam in combination with serology (49). 
 
Treatment usually consists of a long-term course of potentiated sulfa antibiotics.  The most 
effective standard course of therapy combines pyrimethamine (50-100 mg) and sulfadiazine (4-8 
mg) daily, which act synergistically to inhibit tachyzoite folic acid synthesis (68).  However, the 
chronic cyst form of the parasite is unaffected.  Folinic acid (10 mg/day) is often added to 
combat bone-marrow suppression.  Clinical improvement is seen in 70-90% of patients.  
However, adverse side effects occur 20-50% of the time and include a rash, anemia, 
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thrombocytopenia, neutropenia, and allergic reaction (69).  In patients that cannot tolerate a sulfa 
drug, clindamycin may be used instead (70).  Multiple alternative drugs have been tested in small 
trials such as atovaquone, various macrolide antibiotics, doxycycline, and others, but none have 
been shown to be more effective than standard therapy (68).  The macrolide spiramycin is 
commonly used to treat at risk pregnant women during the first 18 weeks of gestation, as this 
antibiotic is thought to decrease the likelihood of vertical transmission and is not teratogenic 
(71).  However, if fetal infection is confirmed at 18 weeks or later when amniocentesis is 
typically performed, the woman is switched to the standard therapy as spiramycin is unable to 
cross the placenta.  Sulfa drugs cannot be administered during the first trimester due to risk of 
teratogenesis (71).  Relapses of toxoplasmosis following therapy are common, occurring 40-80% 
of the time.  Future advances in immunotherapy may help to prevent relapses in the 
immunocompromised, but additional treatments that target the cyst stage of the parasite will be 
needed if a sterile cure is to be obtained. 
 
Prevention of toxoplasmosis relies heavily on avoiding contact with viable parasite tissue cysts 
and oocysts and is summarized as follows (49). Pregnant women should be especially careful 
given the risk to the unborn child.  People should wash their hands thoroughly after handling raw 
meat, and ideally cook all meat to well done or at least freeze meat ahead of time for at least two 
weeks to eliminate viable tissue cysts.  Meat obtained from wild game or organically raised 
production systems provides the most risk.  Soil can become contaminated with oocysts shed by 
felids in the environment, and thus it is wise to wash all fruits and vegetables thoroughly prior to 
eating them raw.  It is also important to wear gloves while gardening to minimize soil contact.  
Sources of unfiltered water should be avoided as much as possible since water transmission of 
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oocysts has caused toxoplasmosis outbreaks.  House cats are not considered a major cause of 
infection in people, given that cats generally only shed oocysts once in their lives for about 2 
weeks, typically as kittens.  However, pregnant women should still take precautions to wash their 
hands after cat contact, avoid contact with cat litter, and have someone else change the litter 
daily since oocysts take 2-3 days to become infectious in the environment.  Keeping cats indoors 
to minimize exposure to wild prey and feeding only commercial cat foods is also advised.  No 
vaccines are currently available for people.  A variety of vaccine strategies have been attempted 
in rodent models, but are generally unsuccessful in inducing sterile immunity upon subsequent 
challenge (72).  A live attenuated vaccine (S48) is available, however, to reduce Toxoplasma-
induced abortion in sheep (73). 
 
Toxoplasmosis is a widespread disease of serious concern to pregnant women and immuno-
compromised individuals, yet treatment measures pose risks of side effects and relapse while no 
effective vaccine exists to protect those at highest risk.  Therefore, a better understanding of the 
host’s immune response to the parasite is critical to future rational design of more effective 
treatment and prevention measures.  
 
THE IMMUNE RESPONSE TO TOXOPLASMA GONDII 
A robust host immune response is necessary to mitigate the impacts of Toxoplasma infection.  
The human immune response to the parasite has not been well characterized, as most people are 
asymptomatic or develop disease symptoms long after initial infection.  Thus, the focus here will 
be on the extensively studied murine immune response.   
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Th1-based immunity during acute infection 
Survival of acute in vivo Toxoplasma infection in mice relies upon induction of a strong Th1 
cell-mediated immune response (Figure 1.3).  Innate immune cells including dendritic cells, 
macrophages, inflammatory monocytes and neutrophils play key roles in the Th1 response by 
secreting the pro-inflammatory cytokine interleukin 12 (IL12) in response to the parasite (74).  
This cytokine induces differentiation of CD4
+
 T cells into the Th1 subset, which, along with 
CD8
+
 T cells and NK cells, produce the pro-inflammatory cytokine interferon gamma (IFNγ) 
(75, 76).  IFNγ in turn acts back on the innate immune cells, inducing further IL12 production 
along with various antimicrobial effector mechanisms that serve to control the parasite (74).  The 
importance of both Th1 cytokines is highlighted by studies where depletion or genetic ablation of 
IL-12 or IFNγ renders mice acutely susceptible to Toxoplasma infection (77-79). 
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Figure 1.3.  The Th1 immune response to Toxoplasma gondii.  Cells of innate immunity, 
including dendritic cells, macrophages, neutrophils, and inflammatory monocytes, sense the 
presence of tachyzoite antigens through pattern recognition receptors (1).  Recognition results in 
innate immune cell activation, followed by secretion of the pro-inflammatory cytokine 
interleukin 12 (IL12) (2).  IL12 triggers differentiation of naïve CD4
+
 T cells into the Th1 subset 
(3), while also promoting secretion of IFNγ from Th1 T cells, CD8+ T cells, and NK cells (4).  
IFNγ in turn acts back on innate immune cells to induce further IL12 production (5).  In addition, 
IFNγ enhances antigen presentation, chemokine production, and activation of various 
antimicrobial effector mechanisms in innate immune cells (6).  Through these activities, the end 
result of the Th1 immune response is destruction of the parasite (7). 
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Innate immune responses are sufficient during the early phase of infection, as studies in infected 
SCID mice (which are deficient in B and T cells) demonstrate (80).  The major early producer of 
IFNγ is the NK cell (81).  However, after about 20 days of infection, SCID mice die unless 
reconstituted with T cells, highlighting the importance of T cells during the chronic phase (80).  
Both CD4
+
 and CD8
+
 T cells are required to prevent reactivation of a chronic Toxoplasma 
infection in mice, in large part due to T cell-mediated IFNγ secretion (82).  Endogenous IFNγ is 
required to prevent toxoplasmic encephalitis development in infected mice (83).  In addition, 
both T cell types act synergistically to provide required IFNγ-dependent protective immunity 
upon challenge in an attenuated Toxoplasma vaccine model (84).  In addition to IFNγ 
production, CD4
+
 T cells produce IL2 which serves to amplify CD8
+
 T cell IFNγ production 
(84), while CD8
+
 T cells also induce perforin-mediated cytolysis that contributes to resistance to 
toxoplasmic encephalitis (85).  In addition to IFNγ and perforin, other contributors to resistance 
during chronic Toxoplasma infection include TNFα (86) and inducible nitric oxide synthase (87).  
B cells and antibody production are not thought to be major contributors to acute resistance to 
Toxoplasma, as transfer of serum from infected mice to uninfected animals is not sufficient for 
protection against parasite challenge.  However, μMT mice that lack B cells are susceptible 
during the chronic phase, suggesting that B cells may indeed play some role at later time points 
(88).  The B cell requirement may depend on cytokine secreting effector B cell subsets rather 
than antibody production or antigen presentation (89), but further work must be done to address 
this. 
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The toxoplasmacidal properties of IFNγ 
IFNγ is widely considered the primary mediator of host resistance to Toxoplasma infection (77).  
This cytokine is critical in the control of intracellular parasite replication under in vitro and in 
vivo conditions in both mice and humans (77, 78, 90-92).  IFNγ mediates this effect through 
various methods including reactive oxygen intermediates (ROIs), nitric oxide (NO), iron 
deprivation, tryptophan starvation, immunity-related p47 GTPases (IRGs), and guanylate-
binding proteins (GBPs) (74, 93).  ROIs include various free radicals that damage cell 
constituents.  Although they have been shown to be toxoplasmacidal in human macrophages 
(92), Toxoplasma-infected murine macrophages are relatively ROI resistant (94) and mice 
lacking inducible oxidative burst capacity (p47 phox
-/-
) survive acute and chronic in vivo 
infection (95).  IFNγ-induced NO is synthesized by the inducible nitric oxide synthase (iNOS) 
enzyme and kills parasites directly by targeting essential mitochondrial and nuclear enzymes of 
the tachyzoite (96). TNFα produced by activated macrophages synergizes with IFNγ to induce 
NO synthesis (97).  Although iNOS activity is dispensable during acute infection in mice, it is 
required to control the chronic phase of infection within the brain (87).  This is likely in part due 
to the role NO plays in promoting conversion of the tachyzoite into the chronic, cyst-contained 
bradyzoite (98).  Iron is a crucial co-factor in metabolic processes for many pathogens, 
Toxoplasma included.  Enterocytes in the intestines have been shown to sequester iron in 
response to IFNγ, thereby limiting parasite replication (99).  IFNγ can also induce expression of 
indoleamine-2,3-dioxygenase (IDO), an enzyme that degrades the amino acid tryptophan which 
Toxoplasma must scavenge from the host in order to replicate.  IDO contributes to Toxoplasma 
control in human fibroblasts (100), glioblastoma cells (101), brain endothelial cells (102), and 
retinal pigment epithelium (103), but does not appear to be important in human macrophages or 
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murine fibroblasts, astrocytes, and macrophages (102).  IDO may still play some role in mice in 
the control of Toxoplasma infection, given evidence of enzyme activity and expression in the 
lungs and brain of infected mice (104).  However, there is strong evidence that the families of 
immunity related GTPases play the key role in IFNγ-mediated resistance to Toxoplasma (105). 
 
The p47 GTPases localize to the endoplasmic reticulum and Golgi apparatus of a variety of cell 
types in mice (106).  They are dramatically upregulated in response to IFNγ stimulation, and are 
of particular importance for pathogen clearance in innate immune cells such as macrophages and 
DCs (107).  There are 23 known members in mice but only 2 in humans, which also lack IFNγ 
response elements and thus are not part of the IFNγ resistance program (108).  The following 
four play a role in the resistance to Toxoplasma infection in vivo in mice: IRGM1 (LRG-47) 
(109), IRGD (IRG-47) (109), IRGM3 (IGTP) (110), and IRGA6 (IIGP1) (111).  Upon infection 
of an IFNγ-activated cell, the IRGs are recruited to and mediate destruction of the 
parasitophorous vacuole membrane (PVM), resulting in eventual lysosome-mediated degradation 
of the parasite (112, 113).  Additional IRGs have been shown to traffic to the PVM, including 
IRGB6 (TGTP), IRGM2 (GTPI), and IRGB10 (114, 115).  Members of the IFNγ-inducible p65 
family of GTPases known as GBPs are found in 13 copies in mice and 7 in copies in humans 
(116).  They have also been shown to accumulate at the PVM in Toxoplasma infected murine 
cells (117).  Furthermore, mice deficient in a cluster of 6 Gbp genes are susceptible to acute 
Toxoplasma infection in vivo (118).  Macrophages from these mice are defective in IFNγ-
dependent control of parasite growth and are unable to recruit the p47 GTPases IRGB6 and 
IRGB10 to the PVM, suggesting that GBPs may function in part through regulation of IRG 
recruitment (118).  In addition, Gbp2 and Gbp1 have recently been shown to play important roles 
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during acute in vivo infection with Toxoplasma (119, 120).  What role GBPs may play in the 
IFNγ-mediated resistance to Toxoplasma in human cells remains to be determined. 
 
Dendritic cell function and importance during Toxoplasma infection 
Dendritic cells (DC) are particularly important in the Th1-mediated immune response to the 
parasite.  DCs serve as an important bridge between innate and adaptive arms of the immune 
response.  As part of innate immunity, DCs survey the tissues for pathogens, recognizing 
pathogen-derived danger signals through pattern recognition receptors such as toll-like receptors 
(TLRs) (121).  In response, DCs migrate to secondary lymphoid tissue where they up-regulate 
MHC and co-stimulatory molecules and secrete IL12 or other cytokines that serve to initiate 
adaptive immune responses carried out by lymphocytes (122, 123).  Other DCs remain resident 
in lymphoid tissues where they scan the blood for antigen and then present to T cells locally 
(123).   
 
Dendritic cells comprise a heterogeneous population with numerous subsets that may be 
classified based on cell surface marker expression, location in the body, and type of immune 
function (124).  Mature DCs express the integrin CD11c to varying degrees and can be broadly 
divided into two main categories: conventional DCs and non-conventional DCs (125).  
Conventional DCs (cDCs) predominate in the steady state and can be divided into migratory and 
lymphoid-resident DC populations.  Migratory DCs can be found in organs such as the intestine, 
skin, lung, liver, and kidney and will migrate to secondary lymphoid tissues upon activation.  
They can be further distinguished based on CD103 and CD11b expression (125).  Lymphoid 
resident DCs can be found in the thymus, lymph nodes, and spleen, do not migrate, and can be 
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further classified on the basis of CD4 and CD8 expression.  CD8
+
 DCs in mice are highly 
efficient in the cross-presentation of exogenous antigen to CD8
+
 T cells and are of particular 
importance in the immune response to intracellular pathogens (126).  CD4
+
 DCs on the other 
hand are unable to cross-present efficiently in vivo but may be better at MHCII-restricted antigen 
presentation to CD4
+
 T cells (127).   
 
Non-conventional DCs can also be found to some extent under steady state conditions but are 
primarily induced under inflammatory conditions and include the plasmacytoid DCs (pDCs) and 
the monocyte-derived DCs (moDCs, TipDCs) (125).  In contrast to cDCs, pDCs are spherical in 
shape rather than possessing a dendritic morphology and express distinct surface markers B220, 
Siglec H, and Bst-2 in mice (128).  pDCs are found in both lymphoid and non-lymphoid tissues 
and express both TLR7 and TLR9, which sense viral RNA and DNA, respectively.  As a result, 
pDCs are important producers of type 1 interferon in response to viral infections (129).  Type 1 
interferon and IL-6 production by pDCs has also been shown to drive plasma cell differentiation 
from activated B cells (130).  Monocyte-derived DCs are found in the periphery, where some 
also have the ability to migrate to lymphoid tissues upon acquiring antigen.  Two types of 
monocytes have been characterized in mice (131).  CX3CR1
lo
CCR2
hi
Ly6C
hi
 cells are known as 
inflammatory monocytes that home to sites of inflammation and can give rise not only to 
inflammatory macrophages but also inflammatory DCs (moDCs) and TNF and inducible nitric 
oxide synthase (iNOS)-producing DCs (TipDCs) (132-134). Patrolling monocytes 
(CX3CR1
hi
CCR2
lo
Ly6C
lo
), which initially contribute to early inflammation and then transition to 
tissue repair, can also differentiate into DCs (132).  In addition, DCs can play a regulatory role in 
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controlling inflammation, but whether this depends on certain committed DC subsets and/or the 
local tissue conditions remains to be established (125).   
 
Given the importance of DCs in the immune system, it comes as no surprise that they are 
essential in controlling Toxoplasma infection in vivo.  In fact, although Toxoplasma can infect 
any nucleated cell, DCs serve as preferential targets.  Transient ablation of all conventional 
CD11c
+ 
DCs via a diphtheria toxin approach resulted in decreased IL12 production and acute 
susceptibility to intraperitoneal Toxoplasma infection (135).  In addition, DC IL12 production 
was found to be dependent on MyD88/TLR signaling in vivo when Cre recombinase was used to 
delete MyD88 exclusively in CD11c
+
 cells (136).  However, CD11c can also be expressed by 
other cell types including pDCs, macrophages, inflammatory monocytes and NK cells (137).  A 
recent study identified a new marker unique to the conventional DC (cDC) lineage, the 
transcription factor zDC (Zbtb46, Btbd4).  Diphtheria toxin-mediated depletion of zDC-
expressing cells resulted in increased parasite tissue burden and decreased numbers of CD4
+
 T 
cells, but not to the extent that that depletion of CD11c did, indicating that CD11c-expressing 
non-cDCs also play important roles in immunity to Toxoplasma (138).  Indeed, recruitment of 
inflammatory monocytes to sites of infection has been shown to be crucial in controlling parasite 
replication during acute toxoplasmosis (139, 140).  Although inflammatory monocytes and DCs 
derived from them are important in the local production of IL12 at infection sites (140, 141), 
lymphoid-resident CD8
+
 DCs and the related CD103
+
 peripheral DCs are the key systemic early 
IL12 producers during in vivo infection.  CD8+ splenic DCs are also the primary IL12 producers 
in response to intravenous soluble tachyzoite antigen administration (142).  pDCs (143), 
macrophages (144, 145), and neutrophils (146, 147) have also been shown to produce IL12 in 
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response to Toxoplasma in vitro but IL12 from these cell types is not likely to be critical in vivo.  
In addition to serving as key IL12 producers and initiators of adaptive immunity, DC also 
acquire a hypermotility phenotype upon Toxoplasma infection and subsequently potentiate 
parasite dissemination throughout the host (148-150). 
 
Innate sensing of Toxoplasma 
Early recognition of the parasite by cells of the innate immune system is crucial in shaping the 
ensuing immune response and outcome of infection.  The Toll-like receptor (TLR) pathway 
dependent on the adaptor protein MyD88 has emerged as the major means of innate parasite 
recognition.  Mice deficient in MyD88 are highly susceptible to Toxoplasma infection, with 
impaired production of the key Th1 cytokines IL12 and IFNγ (151, 152).  Mice lacking MyD88 
solely in CD11c
+
 cells are also acutely susceptible, emphasizing the important role DCs play in 
initial pathogen sensing and immune initiation (136).  Various parasite molecules have been 
identified as inducers of specific TLR signaling.  The cell surface TLRs 2 and 4 can recognize 
parasite glycosylphosphatidylinositol (GPI) anchored proteins, but have little impact on survival 
of acute infection (153, 154).  TLR11 was initially identified as the sensor of Toxoplasma 
profilin, a protein that plays an essential role during parasite invasion (155).  Parasite profilin-
induced TLR11 signaling results in IL12 production by DC; however, deletion of this TLR alone 
does not recapitulate the severity of the MyD88 deficient phenotype (155, 156).  Recently, 
TLR12 has been recognized as the key sensor of parasite profilin, as mice deficient in this TLR 
demonstrate acute susceptibility to Toxoplasma (157).  Furthermore, the nucleic acid-sensing 
(NAS) TLRs 7 and 9 can sense parasite RNA and DNA, respectively, although deficiency of 
either TLR has little to no impact on infection survival (158).  It has recently become apparent, 
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however, that the parasite-sensing endosomal MyD88-coupled TLRs as a group (TLRs 7, 9, 11 
& 12) are essential to mediate resistance to infection, as mutation of the chaperone UNC93B1 
demonstrates (158).  However, human cells lack TLRs 11 and 12 while TLRs 7 and 9 respond to 
parasite RNA and DNA with robust pro-inflammatory cytokine production.  Therefore, the NAS-
TLRs may play a more vital role during human toxoplasmosis (158). 
 
Toxoplasma recognition can also be achieved through MyD88-independent pathways.  Studies in 
infected bone marrow-derived macrophages have demonstrated MyD88-, GiPCR-, and CCR5-
independent IL12 production, with the amount dependent on parasite genotype and requiring p38 
MAPK autophosphorylation (159, 160).  Another parasite molecule, cyclophilin-18 (TgCyc18), 
has been shown to induce splenic DC IL12 production in dependence upon the chemokine 
receptor CCR5, a GiPCR (161, 162).  In addition, TgCyc18 and CCR5 have been shown to 
contribute to stage conversion to bradyzoites via NO production and to elicit IL12 and TNFα 
from macrophages (163).  GiPCRs other than CCR5 have also been implicated in Toxoplasma 
sensing, as the parasite triggers GiPCR and PI3K-dependent phosphorylation of PKB/AKT in the 
absence of CCR5 (164).  This pathway contributes to inhibition of apoptosis in Toxoplasma-
infected cells.  In addition, the parasite induces PI3K-dependent chemokine production in 
infected macrophages (165).  Finally, MyD88-independent protection occurs in vivo as MyD88-
deficient mice vaccinated with an attenuated uracil auxotroph strain survive challenge with a 
virulent strain (152).  Thus, Toxoplasma initiates recognition in innate immune cells through a 
combination of MyD88-dependent and independent pathways, ultimately leading to development 
of a protective Th1 immune response. 
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Regulation of the immune response to Toxoplasma 
Although induction of a strong Th1 immune response is normally protective, overproduction of 
pro-inflammatory cytokines can lead to tissue destruction and death.  Therefore, the host must 
counteract the inflammation through production of key anti-inflammatory mediators including 
IL10, TGFβ, and IL27.  Mice lacking IL10 are acutely susceptible to Toxoplasma infection by 
both the intraperitoneal and oral routes (166, 167).  In these mice, pathogen replication is 
controlled, but overproduction of IL12, IFNγ, and TNFα leads to necrotic tissue death.  The 
source of IL10 required to abrogate immunopathology is derived from IFNγ+, T-bet+ Th1 cells 
that are negative for the T regulatory (Treg) cell marker Foxp3 (168).  TGFβ also plays a role in 
immune regulation.  When mice are depleted of TGFβ and infected with Toxoplasma via the oral 
route, they succumb to ileitis due to removal of a key immunoregulatory function of 
intraepithelial lymphocytes (169).  The cytokine IL27 is also critical as demonstrated through 
infection of IL27 receptor knock-out mice.  These mice develop lethal disease characterized by 
overproduction of IFNγ, enhanced T cell proliferation, and persistence of highly activated T cells 
(170).  In addition, chronically infected mice develop severe neuroinflammation in association 
with the cytokine IL17 in the absence of the IL27R (171).  IL27 also drives formation of a 
unique subset of Tregs responsible for control of immunopathology at mucosal sites during oral 
Toxoplasma infection (172).  Thus, the host immune system has devised mechanisms of limiting 
parasite growth through a robust Th1 response while simultaneously limiting immunopathology. 
 
PARASITE-MEDIATED EVASION OF INNATE IMMUNITY 
In order for Toxoplasma to survive long enough to successfully establish chronic infection, the 
parasite must evade the destructive consequences of the Th1 response.  In part, this is achieved at 
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the level of the infected cell through establishment of the non-fusogenic intracellular niche 
known as the parasitophorous vacuole.  However, as described previously, the host cell possesses 
MyD88-dependent and independent means of recognizing the parasite, which are capable of 
inducing pro-inflammatory cytokine production and parasite destruction.  Thus, the parasite must 
employ mechanisms to block immune cell recognition within infected cells.  This is achieved 
primarily through interference with host cell signaling and transcriptional responses. 
 
Inhibition of TLR signaling 
Toxoplasma is known to block the expression of a wide variety of pro-inflammatory cytokines 
and chemokines normally induced by TLR signaling (173).  In particular, the parasite inhibits 
lipopolysaccharide (LPS) signaling through TLR4, resulting in suppression of IL-12 and TNF-α 
in infected macrophages (174, 175).  After ~12 hours, parasite infection leads to renewed IL-12 
synthesis, but TNF-α remains inhibited (174).  In addition, the parasite can block MyD88-
independent TLR3 signaling by blocking IL-12 and IFN-β production after poly I:C stimulation 
(176).  Further evidence of inhibition of TLR-induced cytokine production is found in other cell 
types, including bone marrow-derived dendritic cells (BMDCs) (177), splenic DCs (150), and 
peritoneal macrophages (175).  Infected immature BMDCs also fail to upregulate MHCII and co-
stimulatory molecules in response to LPS, with resultant deficits in T cell activation (177).  
 
The blockade in TLR-triggered cytokine production is accompanied by interference with the 
main downstream effectors of TLR signaling, NF-κB and the MAP kinase cascade.  This should 
come as no surprise as both pathways play important roles in the host immune response to the 
parasite (178, 179).  Toxoplasma infected macrophages display a transient, early defect in NF-κB 
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nuclear accumulation (180-183).  However, the early blockade in NF-κB nuclear accumulation 
may not be the only mechanism of suppression given that nuclear accumulation resumes after 6 
hours of infection (180).  The parasite is also able to impair chromatin remodeling at the TNF-α 
promoter in infected macrophages, preventing binding of NF-κB along with other transcription 
factors and thereby blocking transcription of TNF-α in response to LPS stimulation (184).  
Toxoplasma can also induce transient activation of MAP kinase cascades including p38, ERK1/2 
and JNK/SAPK in a human monocytic cell line and in murine macrophages (182, 185).  
However, LPS-induced MAPK activation, particularly activation of p38, is reduced in parasite-
infected murine macrophages, contributing in part to impaired cytokine production (182).  The 
mechanism of how Toxoplasma inactivates TLR-induced MAPK signaling remains unclear.  It is 
likely the parasite has evolved these mechanisms of inhibition of TLR signaling to prevent the 
host response to the parasite’s own TLR ligands (176).  Given that the oral route is the natural 
route of infection, it is also possible that blockade of TLR signaling is vital in preventing a 
hyper-inflammatory response secondary to gut flora exposure (186, 187). 
 
Impact of secreted Toxoplasma virulence effectors 
As previously described, Toxoplasma strains from North America and Europe comprise three 
main clonal lineages (I, II, and III) that differ in virulence in the mouse model (30).  Forward 
genetic studies involving pair-wise crosses between strains of these three lineages have identified 
polymorphic parasite effectors that contribute to differences in acute virulence and impacts on 
host cell signaling.  These effectors consist primarily of kinases or pseudokinases released from 
parasite rhoptries (ROP16, ROP18, ROP5) or dense granules (GRA15) upon or shortly after cell 
invasion (188). 
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ROP18 is an active parasite serine/threonine rhoptry kinase whose expression is high in type I 
and II strains but low in type III strains (189, 190).  Transgenic expression of ROP18 from a type 
I or type II strain in a type III strain confers enhanced virulence in the latter, confirming 
ROP18’s role in strain-specific virulence (189, 190).  After parasite invasion, the host responds 
through recruitment of immunity-related GTPases to the PVM, under the influence of IFNγ (114, 
115). However, IRG recruitment is impaired in type I strains (191).  Upon invasion by a type I 
parasite, ROP18 is secreted and localizes to the surface of the parasitophorous vacuole 
membrane (PVM), where it catalyzes phosphorylation of several IRGs including IRGA6, 
IRGB6, and IRGB10 (192, 193).  IRG phosphorylation results in their reduced recruitment to the 
PVM, preventing IRG-mediated destruction of the parasite and helping explain the high 
virulence of type I strains (192, 193).  However, these results do not explain why type II strains 
are unable to block IRG recruitment and subsequent parasite destruction, given their high level 
of ROP18 expression.  In addition, although type I parasites deficient in ROP18 are highly 
avirulent in vitro, virulence is only partially diminished in vivo (192).  In addition to impairing 
innate immunity through effects on IRG recruitment, ROP18 has been shown to phosphorylate 
the ER-resident activating transcription factor 6 beta (ATF6β) (194), resulting in impaired 
initiation of CD8
+
 T cell-mediated adaptive immunity by DCs (195). 
 
Further knowledge of ROP18 function arose when ROP5 was identified as another key virulence 
determinant.  Type I parasites lacking ROP5 were found to be highly attenuated in vivo, by over 
one million-fold (196, 197).  However, ROP5 is a pseudokinase, and therefore does not require 
kinase activity to mediate its function (198).   Further work identified interactions between ROP5 
and ROP18.  ROP5 has been shown to impair oligomerization of IRGA6 (199, 200), while also 
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allosterically activating ROP18, thereby enhancing ROP18 phosphorylation of IRGA6 and 
IRGB6 (199, 201).  The ROP5 variant present in type II strains is considered inactive, explaining 
why high levels of ROP18 expression is not enough to confer the virulence of type I strains.  By 
contrast, ROP18 from type II strains can enhance virulence when combined with ROP5 of type I 
and III strains (189, 190).  Although type III strains express functional ROP5, the absence of 
sufficient ROP18 explains the avirulence of this strain.  ROP5 likely plays a role in the activation 
of other parasite kinases, although additional targets have yet to be identified (201). 
 
The rhoptry kinase ROP16 is another key virulence determinant with activity in type I and III 
strains, but not type II strains (202).  This kinase, although predicted to be a serine/threonine 
kinase, has been shown to directly phosphorylate host STAT3 (203) and STAT6 (204) 
transcription factors on key tyrosine residues.  ROP16 from a type I or III parasite is required for 
maintenance of STAT3/6 phosphorylation in infected macrophages (202, 205).  A key amino 
acid substitution at position 503 accounts for the difference in activity of type I/III ROP16 versus 
that of type II (203).  Prolonged ROP16-dependent STAT3 activation leads to reduced IL12 
production during infection with type I or III strains, and also impairs LPS-induced synthesis of 
IL12 and TNFα (202, 205).  Despite these impacts on host gene transcription, ROP16 appears to 
have little impact on acute virulence following intra-peritoneal infection, as deletion of ROP16 
does not reduce mouse mortality (205).  However, parasite growth and dissemination were 
enhanced in vivo (205).  This effect may be the result of ROP16 impacts on nutrient availability 
for the parasite.  ROP16 also targets STAT6, leading to increased host arginase I expression, an 
enzyme that degrades the amino acid arginine (205).  The impact of increased arginase activity 
on the parasite is complex, as both arginine and the polyamine products of arginine degradation 
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are essential for Toxoplasma growth; however, arginine appears to be limiting in vivo (206).  
STAT6 activation by type I and III parasites also contributes to early polarization of infected 
macrophages to an alternative activation (M2) phenotype, promoting an anti-inflammatory state 
(207).  Finally, ROP16 has also recently been shown to cause sustained phosphorylation and 
nuclear translocation of STAT5 in infected cells, although what role this may play remains to be 
determined (208). 
 
Type II strains produce more IL12 than Type I or III strains in infected macrophages (145, 159).  
In part this is due to the lack of ROP16-dependent STAT3 activation that limits MyD88-
dependent IL-12 production by type I and III strains.  However, type II strains also express 
GRA15, a dense granule protein that induces substantial NF-κB activation and subsequent IL12 
production (209).  GRA15 activates NFκB in a TLR-independent fashion, but the exact 
mechanism is unclear (209).  In contrast to type I ROP16, type II GRA15 induces classical 
activation of macrophages, promoting antimicrobial activity (207).  A recent study found that 
type I ROP16 and type II GRA15 must act synergistically to promote host resistance to 
Toxoplasma-induced ileitis during oral infection, limiting both parasite burden and inflammation 
(208).  The influence of type I ROP16 in that study occurred independently of STAT3/6, 
suggesting that ROP16-activated STAT5 may instead be important during oral infection, but this 
awaits formal proof (208).  Regardless, it is clear that parasite-mediated manipulation of the 
innate immune response requires a carefully orchestrated interplay between parasite proteins and 
the host molecules they target, as summarized in Figure 1.4. 
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Figure 1.4.  The relationships between Toxoplasma strain types, known virulence effectors, 
and impacts on host cell immune responses.  Type I strains possess active ROP18, ROP5, and 
express high levels of ROP16.  Type II strains possess active ROP18 and GRA15.  Type III 
strains possess active ROP5 and express high levels of ROP16.  Impacts of ROP18, ROP5, 
ROP16, and GRA15 on the infected host cell’s immune response are indicated in the blue boxes. 
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Interference with IFNγ/STAT1 activity 
Given that IFNγ is considered the chief mediator of immunity, it is no surprise that Toxoplasma 
also targets this cytokine and its signaling pathway as part of an immune evasion strategy.   To 
better appreciate how the parasite targets this pathway, it is first necessary to review how IFNγ 
signals.  IFNγ exerts many of its effects on antimicrobial function through a Janus kinase (JAK)/ 
signal transducer and activator of transcription 1 (STAT1)-dependent pathway.  In the canonical 
pathway (as reviewed in (210) and summarized in Figure 1.5), IFNγ binds to its receptor 
subunits (IFNγR1 and IFNγR2), causing them to oligomerize.  This conformational change 
results in auto-phosphorylation and activation of JAK2, which in turn activates JAK1 via trans-
phosphorylation.  JAK1 phosphorylates tyrosine residue 440 within the intracellular domains of 
the IFNγR1 subunits, which in turn recruits STAT1 monomers that bind via SH2 domains.  
STAT1 is then phosphorylated by JAK1 on a key tyrosine residue, Y701.  Activated STAT1 
monomers dissociate from the receptor complex and form STAT1 homodimers through 
reciprocal SH2-phosphotyrosine interactions, with subsequent translocation to the nucleus.  
There, they recognize interferon gamma-activated sequence (GAS) elements (TTCN3GAA) in 
the promoters of responsive genes and initiate transcription (211).  Phosphorylation of a key 
serine residue, S727, is required to achieve maximal transcriptional activity, but not for DNA 
binding (212-214).  A variety of kinases have been identified as contributors to STAT1 serine 
phosphorylation, depending on the type of cell and stimulus (215).  Calcium/calmodulin-
dependent  protein kinase II/CaMKII (216) and PI3K/AKT/PKCδ-dependent pathways (217, 
218) have been implicated in IFNγ-triggered serine phosphorylation, while p38 MAPK 
involvement has also been demonstrated with stress stimuli (219). 
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Figure 1.5.  The canonical JAK/STAT1 signaling pathway initiated by IFNγ.  IFNγ binds to 
both receptor subunits, IFNγR1 and IFNγR2, causing them to oligomerize (1).  This results in 
autophosphorylation and activation of JAK2, which in turn phosphorylates and activates JAK1 
(2).  The activated JAKS in turn phosphorylate tyrosine residues in cytoplasmic portions of the 
receptor subunits (3).  STAT1 is recruited to the receptor, interacting with the phospho-tyrosine 
residues of the receptor through an SH2 domain.  JAK1 then phosphorylates STAT1 on tyrosine 
residue 701, causing STAT1 to dissociate from the receptor and dimerize (4).  At some point, 
phospho-STAT1 dimers are also phosphorylated on serine residue 727, which is required for 
maximal transcriptional activity (5).  Phospho-STAT1 dimers translocate to the nucleus (6), 
where they recognize interferon gamma-activated sequence (GAS) elements in the promoters of 
responsive genes, initiating transcription (7).  The IFNγ/STAT1 pathway also undergoes 
negative regulation, as indicated by the orange ovals.  Suppressor of cytokine signaling (SOCS)-
1, protein tyrosine phosphatase 1B (PTP1B), and Src homology 2 domain-containing 
phosphatases (SHP) 1 and 2 target the JAKs and IFNγ receptor subunits for inactivation.  T cell 
phosphatase 45 (TC45) serves as the primary phosphatase for STAT1 inactivation in the nucleus.  
PIAS1 interferes with STAT1 DNA binding while PIASy acts as a co-repressor of STAT1. 
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However, JAK/STAT signaling is not quite that simple, as various studies have demonstrated 
(reviewed by Mohr et al (220)).  In some cases, pre-formed dimers of the cytokine receptors are 
present, which are then stabilized by ligand binding rather than ligand binding triggering 
dimerization/oligomerization.  Pre-formed dimers of STATs may also exist, undergoing a 
conformational change to achieve activation upon phosphorylation.  In addition, a fraction of 
unphosphorylated STAT molecules can be found in the nucleus in the steady-state as a result of 
constant nucleo-cytoplasmic shuttling (220).  These U-STATs can also mediate gene regulation 
(221).  STATs may also play additional roles outside of the nucleus under certain conditions.  
Finally, STATs such as STAT1 undergo additional post-translational modifications in addition to 
tyrosine and serine phosphorylation that affect STAT activity, including methylation, 
SUMOylation, and ISGylation (ISG15 – a small ubiquitin-like protein) (210). 
 
Depending on the specific target gene involved, STAT1 cooperates with other transcription 
factors to facilitate recruitment of histone modifying enzymes necessary for establishment of 
permissive chromatin at gene promoters.  In turn, chromatin binding and initiation of 
transcription by RNA polymerase II occurs.  Several different covalent histone modifications can 
occur including methylation, acetylation, phosphorylation, ubiqutinylation, and SUMOylation, 
which can impact transcription positively or negatively (222).  Histone acetylation at key 
residues is more frequently associated with permissive chromatin.  Serine phosphorylation at 
S727 is important in the recruitment of the key histone acetyltransferase, CBP/p300, to STAT1-
regulated promoters (223).  In addition, a unique histone methyltransferase, DOT1L, is required 
for STAT1 activation of Irf1 expression (224).  However, chromatin remodeling complexes such 
as the BAF (BRG/BRM) complex also play a role by disrupting histone/DNA contacts in an 
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ATP-dependent manner.  BAF has also been implicated in the remodeling of some STAT1-
responsive genes, such as the class II transactivator (CIITA) (225) although not for Irf1 (226).  In 
addition, STAT1 can interact with other transcription co-factors or DNA binding proteins 
including Nmi, Sp1, Mcm5 and Mcm3 (210).  Thus, the activation of transcription by STAT1 is 
complex, involving cooperation with wide variety of other transcription factors and histone 
modifiers that differ depending on the gene and cell type. 
 
Finally, STAT1 activity in response to IFNγ stimulation must be tightly regulated to control 
biologic functions (Figure 1.5).  Phosphorylated STAT1 in the nucleus is dephosphorylated by a 
key nuclear phosphatase, the nuclear isoform of T cell phosphatase 45 (TC45), allowing return of 
unphosphorylated STAT1 to the cytoplasm (227).  Another form of regulation in nucleus 
involves interaction of STAT1 with the protein inhibitor of activated STAT (PIAS) family of 
proteins.  PIAS1 binds phosphorylated STAT1 and blocks its recruitment to promoters; however, 
PIAS1 expression is low in DCs and only regulates a subset of STAT1-dependent genes which 
do not include Irf1 (228).  PIASy also regulates STAT1 and is found in DCs; however it 
functions as a co-repressor of STAT1 without affecting DNA binding (229).  Un- or partially de-
phosphorylated STAT1 can also be conjugated to small ubiquitin-like modifier (SUMO) at 
residue K703, which prevents hyperresponsiveness to IFNγ (230, 231).  SUMOylation in turn 
increases STAT1 solubility, preventing formation of nuclear paracrystalline arrays that would 
normally protect other phosphorylated STAT1 dimers from dephosphorylation (230, 231).  It is 
also necessary to down-regulate receptor/JAK-mediated STAT1 phosphorylation in the 
cytoplasm, which can be accomplished by various phosphatases.   These phosphatases target 
JAKs or cytokine receptors and include the protein tyrosine phosphatase 1B and the SH2-
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containing phosphatases SHP1 and SHP2 in the case of STAT1 regulation (210).  In addition, the 
suppressor of cytokine signaling (SOCS) family of proteins participates in regulation by direct 
inhibition of receptor/JAK signaling or indirectly by targeting signaling components for 
ubiquitin/proteasome-mediated degradation (210).  SOCS1 is the key SOCS protein known to 
regulate IFNγ responses (232, 233).  Finally, STAT1 can also be expressed as an alternative 
splice variant, STAT1β, which lacks a portion of the C-terminal transactivation domain and 
therefore acts as a dominant negative form of STAT1 (210).   
 
An understanding of the complexities of IFNγ-mediated STAT1 activation, activity and 
regulation sets the stage for determining how Toxoplasma may target this pathway for immune 
evasion.  STAT1 is essential for survival of acute Toxoplasma infection in vivo as it is required 
for key IFNγ-triggered antimicrobial effector mechanisms (234, 235).  The parasite has been 
shown to potently repress expression of certain IFNγ-inducible genes including those involved in 
antigen presentation (MHCII, MHCI, CIITA) (236-240), the key transcription factor IRF1 (238, 
240-242), the chemokine monokine induced by IFNγ (MIG) (243), and various antimicrobial 
effector molecules including iNOS/NO (234, 243-246) and the p47 family of GTPases (234, 
243).  These effects have been demonstrated in a variety of cell types including primary bone 
marrow-derived macrophages, the RAW264.7 mouse macrophage cell line, human fibroblasts, 
peritoneal macrophages, astrocytes, and microglia.  In addition, a global picture of Toxoplasma-
inhibition of IFNγ transcription has been achieved in human fibroblasts (241), murine 
macrophages (247), and the RAW264.7 cell line (242) through microarray studies.   
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It has become clear that targeting the IFNγ pathway to avoid immune-mediated elimination is a 
key defensive strategy for the parasite.  A question remains as to how the parasite achieves this.  
One study in the RAW264.7 cell line showed that the parasite can induce expression of Socs1, 
thereby decreasing IFNγ-induced STAT1 phosphorylation and preventing STAT1 activity (243).  
Another study suggested that the parasite may enhance dephosphorylation of STAT1 within the 
nucleus of infected human fibroblasts (241).   However, most studies confirm that Toxoplasma 
does not interfere with IFNγ-induced STAT1 phosphorylation and nuclear translocation (240, 
242, 247).  The mechanism appears to involve inhibition of transcription in the nucleus, with 
evidence of impairment of chromatin remodeling at certain IFNγ-regulated gene promoters 
(247).  How exactly Toxoplasma orchestrates this potent inhibition of IFNγ/STAT1-mediated 
transcriptional activity remains a question for further study. 
 
OUTLINE OF DISSERTATION RESEARCH 
IFNγ and its key signaling intermediate, STAT1, are crucial to host defense during Toxoplasma 
infection.  The parasite possesses many mechanisms for immune evasion, but paramount among 
them is evasion of the toxoplasmacidal IFNγ response.  Clues as to how the parasite carries out 
this subterfuge have emerged in macrophages, fibroblasts, astrocytes/microglia, and various cell 
lines.  However, the precise mechanism by which Toxoplasma hijacks this pathway remains 
unclear.  In addition, the importance of this evasion in the dendritic cell has not been examined, 
despite its essential role in the immune response to the parasite.   
 
This dissertation examines the impact of Toxoplasma on the IFNγ/STAT1 pathway in murine 
dendritic cells. Chapter 2 reveals an unexpected finding that the parasite can trigger sustained 
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STAT1 phosphorylation and nuclear translocation in dendritic cells in the absence of exogenous 
IFNγ.  Furthermore, IFNγ stimulation of cells pre-infected with the parasite results in synergistic 
levels of phosphorylated STAT1 as well as binding of an aberrant STAT1-containing complex to 
consensus nucleotides.  Despite evidence of activation, STAT1 cannot bind to native promoters 
and thus transcription of IFNγ/STAT1-responsive genes remains blocked.  The importance of 
parasite-mediated blockade of the IFNγ/STAT1 pathway in dendritic cells is demonstrated.  
Chapter 3 further explores the mechanisms behind inhibition of IFNγ/STAT1-responsive gene 
transcription, parasite-triggered STAT1 phosphorylation, and synergy with IFNγ.  Inhibition of 
gene transcription is shown to occur independently of parasite strain type and the virulence factor 
ROP16.  Key secreted parasite molecules are eliminated as initiators of STAT1 phosphorylation.  
In addition, signaling pathways known to be triggered by Toxoplasma are excluded as causes for 
STAT1 phosphorylation and synergy with IFNγ.   Finally, downregulation of IFNγ-induced 
Socs1 expression by the parasite is shown, which explains the synergistic phosphorylated STAT1 
levels observed.  Chapter 4 summarizes the data and results from chapters 2 and 3 and discusses 
the overall relevance and importance of these findings to the fields of Toxoplasma biology and 
immune evasion of IFNγ-mediated responses by pathogens.  Unanswered questions and future 
directions for this project are also discussed. 
 
 
 
 
 
 
 
42 
 
REFERENCES 
 
1. Ferguson DJ. 2009. Toxoplasma gondii: 1908-2008, homage to Nicolle, Manceaux and 
Splendore. Mem Inst Oswaldo Cruz 104: 133-48 
2. Dubey JP. 2008. The history of Toxoplasma gondii--the first 100 years. J Eukaryot 
Microbiol 55: 467-75 
3. Innes EA. 2010. A brief history and overview of Toxoplasma gondii. Zoonoses Public 
Health 57: 1-7 
4. Wolf A, Cowen D, Paige B. 1939. Human toxoplasmosis: occurrence in infants as an 
encephalomyelitis verification  by transmission to animals. Science 89: 226-7 
5. Sato S. 2011. The apicomplexan plastid and its evolution. Cell Mol Life Sci 68: 1285-96 
6. Morrissette NS, Sibley LD. 2002. Cytoskeleton of apicomplexan parasites. Microbiol 
Mol Biol Rev 66: 21-38; table of contents 
7. Seeber F, Soldati-Favre D. 2010. Metabolic pathways in the apicoplast of apicomplexa. 
Int Rev Cell Mol Biol 281: 161-228 
8. Brooks CF, Johnsen H, van Dooren GG, Muthalagi M, Lin SS, Bohne W, Fischer K, 
Striepen B. 2010. The Toxoplasma apicoplast phosphate translocator links cytosolic and 
apicoplast metabolism and is essential for parasite survival. Cell Host Microbe 7: 62-73 
9. Mazumdar J, E HW, Masek K, C AH, Striepen B. 2006. Apicoplast fatty acid synthesis is 
essential for organelle biogenesis and parasite survival in Toxoplasma gondii. Proc Natl 
Acad Sci U S A 103: 13192-7 
10. Nair SC, Brooks CF, Goodman CD, Sturm A, McFadden GI, Sundriyal S, Anglin JL, 
Song Y, Moreno SN, Striepen B. 2011. Apicoplast isoprenoid precursor synthesis and the 
molecular basis of fosmidomycin resistance in Toxoplasma gondii. J Exp Med 208: 1547-
59 
11. Ramakrishnan S, Docampo MD, Macrae JI, Pujol FM, Brooks CF, van Dooren GG, 
Hiltunen JK, Kastaniotis AJ, McConville MJ, Striepen B. 2012. Apicoplast and 
43 
 
endoplasmic reticulum cooperate in fatty acid biosynthesis in apicomplexan parasite 
Toxoplasma gondii. J Biol Chem 287: 4957-71 
12. Keeley A, Soldati D. 2004. The glideosome: a molecular machine powering motility and 
host-cell invasion by Apicomplexa. Trends Cell Biol 14: 528-32 
13. Wetzel DM, Hakansson S, Hu K, Roos D, Sibley LD. 2003. Actin filament 
polymerization regulates gliding motility by apicomplexan parasites. Mol Biol Cell 14: 
396-406 
14. Meissner M, Schluter D, Soldati D. 2002. Role of Toxoplasma gondii myosin A in 
powering parasite gliding and host cell invasion. Science 298: 837-40 
15. Carruthers VB, Sibley LD. 1997. Sequential protein secretion from three distinct 
organelles of Toxoplasma gondii accompanies invasion of human fibroblasts. Eur. J. Cell 
Biol. 73: 114-23 
16. Tonkin ML, Roques M, Lamarque MH, Pugniere M, Douguet D, Crawford J, Lebrun M, 
Boulanger MJ. 2011. Host cell invasion by apicomplexan parasites: insights from the co-
structure of AMA1 with a RON2 peptide. Science 333: 463-7 
17. Mordue DG, Dessai N, Dustin M, Sibley LD. 1999. Invasion by Toxoplasma gondii 
establishes a moving junction that selectively excludes host cell plasma membrane 
proteins on the basis of their membrane anchoring. J. Exp. Med. 190: 1783-92 
18. Mordue DG, Hakansson S, Niesman I, Sibley LD. 1999. Toxoplasma gondii resides in a 
vacuole that avoids fusion with host cell endocytic and exocytic vesicular trafficking 
pathways. Exp. Parasitol. 92: 87-99 
19. Charron AJ, Sibley LD. 2004. Molecular partitioning during host cell penetration by 
Toxoplasma gondii. Traffic 5: 855-67 
20. Boothroyd JC, Dubremetz JF. 2008. Kiss and spit: the dual roles of Toxoplasma 
rhoptries. Nat Rev Microbiol 6: 79-88 
21. Mercier C, Adjogble KD, Daubener W, Delauw MF. 2005. Dense granules: are they key 
organelles to help understand the parasitophorous vacuole of all apicomplexa parasites? 
Int J Parasitol 35: 829-49 
44 
 
22. Sibley LD. 2010. How apicomplexan parasites move in and out of cells. Curr Opin 
Biotechnol 21: 592-8 
23. Dubey JP. 1998. Advances in the life cycle of Toxoplasma gondii. Int. J. Parasitol. 28: 
1019-24 
24. Frenkel JK, Ruiz A, Chinchilla M. 1975. Soil survival of Toxoplasma oocysts in Kansas 
and Costa Rica. Am. J. Trop. Med. Hyg. 24: 439-43 
25. Dubey JP. 1998. Toxoplasma gondii oocyst survival under defined temperatures. J 
Parasitol 84: 862-5 
26. Lindsay DS, Dubey JP. 2009. Long-term survival of Toxoplasma gondii sporulated 
oocysts in seawater. J Parasitol 95: 1019-20 
27. Wainwright KE, Lagunas-Solar M, Miller MA, Barr BC, Gardner IA, Pina C, Melli AC, 
Packham AE, Zeng N, Truong T, Conrad PA. 2007. Physical inactivation of Toxoplasma 
gondii oocysts in water. Appl Environ Microbiol 73: 5663-6 
28. Wainwright KE, Miller MA, Barr BC, Gardner IA, Melli AC, Essert T, Packham AE, 
Truong T, Lagunas-Solar M, Conrad PA. 2007. Chemical inactivation of Toxoplasma 
gondii oocysts in water. J Parasitol 93: 925-31 
29. Sibley LD, Ajioka JW. 2008. Population structure of Toxoplasma gondii: clonal 
expansion driven by infrequent recombination and selective sweeps. Annu Rev Microbiol 
62: 329-51 
30. Howe DK, Sibley LD. 1995. Toxoplasma gondii comprises three clonal lineages: 
correlation of parasite genotype with human diseases. J. Infect. Dis. 172: 1561-6 
31. Khan A, Dubey JP, Su C, Ajioka JW, Rosenthal BM, Sibley LD. 2011. Genetic analyses 
of atypical Toxoplasma gondii strains reveal a fourth clonal lineage in North America. Int 
J Parasitol 41: 645-55 
32. Dubey JP, Velmurugan GV, Rajendran C, Yabsley MJ, Thomas NJ, Beckmen KB, 
Sinnett D, Ruid D, Hart J, Fair PA, McFee WE, Shearn-Bochsler V, Kwok OC, Ferreira 
LR, Choudhary S, Faria EB, Zhou H, Felix TA, Su C. 2011. Genetic characterisation of 
45 
 
Toxoplasma gondii in wildlife from North America revealed widespread and high 
prevalence of the fourth clonal type. Int J Parasitol 41: 1139-47 
33. Su C, Evans D, Cole RH, Kissinger JC, Ajioka JW, Sibley LD. 2003. Recent expansion 
of Toxoplasma through enhanced oral transmission. Science 299: 414-6 
34. Khan A, Fux B, Su C, Dubey JP, Darde ML, Ajioka JW, Rosenthal BM, Sibley LD. 
2007. Recent transcontinental sweep of Toxoplasma gondii driven by a single 
monomorphic chromosome. Proc Natl Acad Sci U S A 104: 14872-7 
35. Khan A, Miller N, Roos DS, Dubey JP, Ajzenberg D, Darde ML, Ajioka JW, Rosenthal 
B, Sibley LD. 2011. A monomorphic haplotype of chromosome Ia is associated with 
widespread success in clonal and nonclonal populations of Toxoplasma gondii. MBio 2: 
e00228-11 
36. Sibley LD, Boothroyd JC. 1992. Virulent strains of Toxoplasma gondii comprise a single 
clonal lineage. Nature 359: 82-5 
37. Melo MB, Jensen KD, Saeij JP. 2011. Toxoplasma gondii effectors are master regulators 
of the inflammatory response. Trends Parasitol 27: 487-95 
38. Boothroyd JC, Grigg ME. 2002. Population biology of Toxoplasma gondii and its 
relevance to human infection: do different strains cause different disease? Curr. Opin. 
Micro. 5: 438-42 
39. Khan A, Jordan C, Muccioli C, Vallochi AL, Rizzo LV, Belfort R, Jr., Vitor RW, Silveira 
C, Sibley LD. 2006. Genetic divergence of Toxoplasma gondii strains associated with 
ocular toxoplasmosis, Brazil. Emerg Infect Dis 12: 942-9 
40. Grigg ME, Ganatra J, Boothroyd JC, Margolis TP. 2001. Unusual abundance of atypical 
strains associated with human ocular toxoplasmosis. J. Infect. Dis. 184: 633-9 
41. Roberts F, McLeod R. 1999. Pathogenesis of toxoplasmic retinochoroiditis. Parasitol 
Today 15: 51-7 
42. Holland GN. 1999. Reconsidering the pathogenesis of ocular toxoplasmosis. Am J 
Ophthalmol 128: 502-5 
46 
 
43. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, 
Griffin PM. 2011. Foodborne illness acquired in the United States--major pathogens. 
Emerg Infect Dis 17: 7-15 
44. Jones JL, Dubey JP. 2012. Foodborne toxoplasmosis. Clin Infect Dis 55: 845-51 
45. Hill DE, Chirukandoth S, Dubey JP. 2005. Biology and epidemiology of Toxoplasma 
gondii in man and animals. Anim Health Res Rev 6: 41-61 
46. Williams RH, Morley EK, Hughes JM, Duncanson P, Terry RS, Smith JE, Hide G. 2005. 
High levels of congenital transmission of Toxoplasma gondii in longitudinal and cross-
sectional studies on sheep farms provides evidence of vertical transmission in ovine 
hosts. Parasitology 130: 301-7 
47. Montoya JG, Liesenfeld O. 2004. Toxoplasmosis. Lancet 363: 1965-76 
48. Pappas G, Roussos N, Falagas ME. 2009. Toxoplasmosis snapshots: global status of 
Toxoplasma gondii seroprevalence and implications for pregnancy and congenital 
toxoplasmosis. Int J Parasitol 39: 1385-94 
49. Robert-Gangneux F, Darde ML. 2012. Epidemiology of and diagnostic strategies for 
toxoplasmosis. Clin Microbiol Rev 25: 264-96 
50. Luft BJ, Remington JS. 1992. Toxoplasmic encephalitis in AIDS. Clin. Infect. Dis. 15: 
211-22 
51. Liesenfeld O, Wong SY, Remington JS. 1999. Toxoplasmosis in the setting of AIDS. In 
Textbook of AIDS medicine, ed. JG Bartlett, TC Merigan, D Bolognesi, pp. 225-59. 
Baltimore: Williams and Wilkins 
52. Sing A, Leitritz L, Roggenkamp A, Kolb HJ, Szabados A, Fingerle V, Autenrieth IB, 
Heesemann J. 1999. Pulmonary toxoplasmosis in bone marrow transplant recipients: 
report of two cases and review. Clin Infect Dis 29: 429-33 
53. Elbez-Rubinstein A, Ajzenberg D, Darde ML, Cohen R, Dumetre A, Yera H, Gondon E, 
Janaud JC, Thulliez P. 2009. Congenital toxoplasmosis and reinfection during pregnancy: 
case report, strain characterization, experimental model of reinfection, and review. J 
Infect Dis 199: 280-5 
47 
 
54. Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. 1999. Mother-to-child 
transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 353: 1829-
33 
55. Desmonts G, Couvreur J. 1974. Congenital toxoplasmosis: a prospective study of 378 
pregnancies. N. Eng. J. Med. 290: 1110-6 
56. Phan L, Kasza K, Jalbrzikowski J, Noble AG, Latkany P, Kuo A, Mieler W, Meyers S, 
Rabiah P, Boyer K, Swisher C, Mets M, Roizen N, Cezar S, Sautter M, Remington J, 
Meier P, McLeod R. 2008. Longitudinal study of new eye lesions in children with 
toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol 146: 
375-84 
57. Jones J, Lopez A, Wilson M. 2003. Congenital toxoplasmosis. Am Fam Physician 67: 
2131-8 
58. Gilbert RE, Freeman K, Lago EG, Bahia-Oliveira LM, Tan HK, Wallon M, Buffolano W, 
Stanford MR, Petersen E. 2008. Ocular sequelae of congenital toxoplasmosis in Brazil 
compared with Europe. PLoS Negl Trop Dis 2: e277 
59. Carme B, Bissuel F, Ajzenberg D, Bouyne R, Aznar C, Demar M, Bichat S, Louvel D, 
Bourbigot AM, Peneau C, Neron P, Darde ML. 2002. Severe acquired toxoplasmosis in 
immunocompetent adult patients in French Guiana. J Clin Microbiol 40: 4037-44 
60. Mercier A, Devillard S, Ngoubangoye B, Bonnabau H, Banuls AL, Durand P, Salle B, 
Ajzenberg D, Darde ML. 2010. Additional haplogroups of Toxoplasma gondii out of 
Africa: population structure and mouse-virulence of strains from Gabon. PLoS Negl Trop 
Dis 4: e876 
61. Dubey JP. 2009. Toxoplasmosis in sheep--the last 20 years. Vet Parasitol 163: 1-14 
62. Dubey JP. 2009. Toxoplasmosis in pigs--the last 20 years. Vet Parasitol 164: 89-103 
63. Portas TJ. 2010. Toxoplasmosis in macropodids: a review. J Zoo Wildl Med 41: 1-6 
64. Dietz HH, Henriksen P, Bille-Hansen V, Henriksen SA. 1997. Toxoplasmosis in a colony 
of New World monkeys. Vet Parasitol 68: 299-304 
48 
 
65. Conrad PA, Miller MA, Kreuder C, James ER, Mazet J, Dabritz H, Jessup DA, Gulland 
F, Grigg ME. 2005. Transmission of Toxoplasma: clues from the study of sea otters as 
sentinels of Toxoplasma gondii flow into the marine environment. Int J Parasitol 35: 
1155-68 
66. Lappalainen M, Hedman K. 2004. Serodiagnosis of toxoplasmosis. The impact of 
measurement of IgG avidity. Ann Ist Super Sanita 40: 81-8 
67. Sterkers Y, Varlet-Marie E, Cassaing S, Brenier-Pinchart MP, Brun S, Dalle F, Delhaes 
L, Filisetti D, Pelloux H, Yera H, Bastien P. 2010. Multicentric comparative analytical 
performance study for molecular detection of low amounts of Toxoplasma gondii from 
simulated specimens. J Clin Microbiol 48: 3216-22 
68. Fung HB, Kirschenbaum HL. 1996. Treatment regimens for patients with toxoplasmic 
encephalitis. Clin Ther 18: 1037-56; discussion 6 
69. Leport C, Raffi F, Matheron S, Katlama C, Regnier B, Saimot AG, Marche C, Vedrenne 
C, Vilde JL. 1988. Treatment of central nervous system toxoplasmosis with 
pyrimethamine/sulfadiazine combination in 35 patients with the acquired 
immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am J Med 84: 
94-100 
70. Dannemann B, McCutchan JA, Israelski D, Antoniskis D, Leport C, Luft B, Nussbaum J, 
Clumeck N, Morlat P, Chiu J, et al. 1992. Treatment of toxoplasmic encephalitis in 
patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to 
pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann 
Intern Med 116: 33-43 
71. Montoya JG, Remington JS. 2008. Management of Toxoplasma gondii infection during 
pregnancy. Clin Infect Dis 47: 554-66 
72. Jongert E, Roberts CW, Gargano N, Forster-Waldl E, Petersen E. 2009. Vaccines against 
Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz 104: 252-66 
73. Buxton D, Innes EA. 1995. A commercial vaccine for ovine toxoplasmosis. Parasitology 
110 Suppl: S11-6 
74. Miller CM, Boulter NR, Ikin RJ, Smith NC. 2009. The immunobiology of the innate 
response to Toxoplasma gondii. Int J Parasitol 39: 23-39 
49 
 
75. Scharton-Kersten T, Denkers EY, Gazzinelli RT, Sher A. 1995. Role of IL-12 in the 
induction of cell-mediated immunity to Toxoplasma gondii. Res. Immunol. 146: 539-45 
76. Trinchieri G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive 
immunity. Nat. Rev. Immunol. 3: 133-46 
77. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. 1988. Interferon-: The major 
mediator of resistance against Toxoplasma gondii. Science 240: 516-8 
78. Scharton-Kersten TM, Wynn TA, Denkers EY, Bala S, Showe L, Grunvald E, Hieny S, 
Gazzinelli RT, Sher A. 1996. In the absence of endogenous IFN- mice develop 
unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute 
infection. J. Immunol. 157: 4045-54 
79. Yap G, Pesin M, Sher A. 2000. IL-12 is required for the maintenance of IFN- production 
in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii. 
J. Immunol 165: 628-31 
80. Beaman MH, Araujo FG, Remington JS. 1994. Protective reconstitution of the SCID 
mouse against reactivation of toxoplasmic encephalitis. J. Infect. Dis. 169: 375-83 
81. Sher A, Oswald IO, Hieny S, Gazzinelli RT. 1993. Toxoplasma gondii induces a T-
independent IFN- response in NK cells which requires both adherent accessory cells and 
TNF-. J. Immunol. 150: 3982-9 
82. Gazzinelli R, Xu Y, Hieny S, Cheever A, Sher A. 1992. Simultaneous depletion of CD4
+
 
and CD8
+
 T lymphocytes is required to reactivate chronic infection with Toxoplasma 
gondii. J. Immunol. 149: 175-80 
83. Suzuki Y, Conley FK, Remington JS. 1989. Importance of endogenous IFN- for the 
prevention of toxoplasmic encephalitis in mice. J. Immunol. 143: 2045-50 
84. Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A. 1991. Synergistic role of  CD4
+
 
and CD8
+
 T lymphocytes in IFN- production and protective immunity induced by an 
attenuated T. gondii vaccine. J. Immunol. 146: 286-92 
50 
 
85. Denkers EY, Yap G, Scharton-Kersten T, Charest H, Butcher B, Caspar P, Heiny S, Sher 
A. 1997. Perforin-mediated cytolysis plays a limited role in host resistance to 
Toxoplasma gondii. J. Immunol. 159: 1903-8 
86. Johnson LL. 1992. A protective role for endogenous tumor necrosis factor in Toxoplasma 
gondii infection. Infect. Immun. 60: 1979-85 
87. Scharton-Kersten T, Yap G, Magram J, Sher A. 1997. Inducible nitric oxide is essential 
for host control of persistent but not acute infection with the intracellular pathogen 
Toxoplasma gondii. J. Exp. Med. 185: 1-13 
88. Kang H, Remington JS, Suzuki Y. 2000. Decreased resistance of B cell-deficient mice to 
infection with Toxoplasma gondii despite unimpaired expression of IFN-, TNF-, and 
inducible nitric oxide synthase. J. Immunol. 164: 2629-34 
89. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, Johnson LL, Swain 
SL, Lund FE. 2000. Reciprocal regulation of polarized cytokine production by effector B 
and T cells. Nat Immunol 1: 475-82 
90. McCabe RE, Luft BJ, Remington JS. 1984. Effect of murine interferon gamma on murine 
toxoplasmosis. J. Infect. Dis. 150: 961-2 
91. Nathan CF, Murray HW, Wiebe ME, Rubin BY. 1983. Identification of interferon- as 
the lymphokine that activates human macrophage oxidative metabolism and 
antimicrobial activity. J. Exp. Med. 158: 670-89 
92. Murray HW, Rubin BY, Carriero SM, Harris AM, Jaffee EA. 1985. Human mononuclear 
phagocyte antiprotozoal mechanisms: oxygen-dependent vs oxygen-independent activity 
against intracellular Toxoplasma gondii. J Immunol 134: 1982-8 
93. Shenoy AR, Kim BH, Choi HP, Matsuzawa T, Tiwari S, MacMicking JD. 2007. 
Emerging themes in IFN-gamma-induced macrophage immunity by the p47 and p65 
GTPase families. Immunobiology 212: 771-84 
94. Chang HR, Pechere JC. 1989. Macrophage oxidative metabolism and intracellular 
Toxoplasma gondii. Microb Pathog 7: 37-44 
51 
 
95. Alexander J, Scharton-Kersten TM, Yap G, Roberts CW, Liew FY, Sher A. 1997. 
Mechanisms of innate resistance to Toxoplasma gondii infection. Philos Trans R Soc 
Lond B Biol Sci 352: 1355-9 
96. Brunet LR. 2001. Nitric oxide in parasitic infections. Int Immunopharmacol 1: 1457-67 
97. Langermans JAM, Van der Hulst MEB, Nibbereing PH, Hiemstra PS, Fransen L, Van 
Furth R. 1992. IFN--induced L-arginine-dependent toxoplasmastatic activity in murine 
peritoneal macrophages is mediated by endogenous tumor necrosis factor-. J. Immunol. 
148: 568-78 
98. Bohne W, Heesemann J, Gros U. 1994. Reduced replication of Toxoplasma gondii is 
necessary for induction of bradyzoite-specific antigens: a possible role for nitric oxide in 
triggering stage conversion. Infect. Immun. 62: 1761-7 
99. Dimier IH, Bout DT. 1997. Inhibition of Toxoplasma gondii replication in IFN-gamma-
activated intestinal epithelial cells. Immunol. Cell Biol. 75: 511-4 
100. Pfefferkorn ER. 1984. Interferon- blocks the growth of Toxoplasma gondii in human 
fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl. Acad. Sci. USA 
81: 908-12 
101. Daubner W, Spors B, Hucke C, Adam R, Stins M, Kim KS, Schroten H. 2001. 
Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells 
by activation of indoleamine 2,3-dioxygenase. Infect. Immun. 69: 6527-31 
102. Daubener W, Spors B, Hucke C, Adam R, Stins M, Kim KS, Schroten H. 2001. 
Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells 
by activation of indoleamine 2,3-dioxygenase. Infect Immun 69: 6527-31 
103. Nagineni CN, Pardhasaradhi K, Martins MC, Detrick B, Hooks JJ. 1996. Mechanisms of 
interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment 
epithelial cells. Infect Immun 64: 4188-96 
104. Silva NM, Rodrigues CV, Santoro MM, Reis LFL, Alvarez-Leite JI, Gazzinelli RT. 
2002. Expression of indolamine 2, 3-dioxygenase, tryptophan degradation, and 
kynurenine formation during in vivo infection with Toxoplasma gondii: induction by 
endogenous gamma interferon and requirement of interferon regulatory factor 1. Infect. 
Immun. 70: 859-68 
52 
 
105. Hunn JP, Feng CG, Sher A, Howard JC. 2011. The immunity-related GTPases in 
mammals: a fast-evolving cell-autonomous resistance system against intracellular 
pathogens. Mamm Genome 22: 43-54 
106. Martens S, Sabel K, Lange R, Uthaiah R, Wolf E, Howard JC. 2004. Mechanisms 
regulating the positioning of mouse p47 resistance GTPases LRG-47 and IIGP1 on 
cellular membranes: retargeting to plasma membrane induced by phagocytosis. J 
Immunol 173: 2594-606 
107. Kim BH, Shenoy AR, Kumar P, Bradfield CJ, MacMicking JD. 2012. IFN-inducible 
GTPases in host cell defense. Cell Host Microbe 12: 432-44 
108. Bekpen C, Hunn JP, Rohde C, Parvanova I, Guethlein L, Dunn DM, Glowalla E, Leptin 
M, Howard JC. 2005. The interferon-inducible p47 (IRG) GTPases in vertebrates: loss of 
the cell autonomous resistance mechanism in the human lineage. Genome Biol 6: R92 
109. Collazo CM, Yap GS, Sempowski GD, Lusby KC, Tessarollo L, Vande Woude GF, Sher 
A, Taylor GA. 2001. Inactivation of LRG-47 and IRG-47 reveals a family of interferon-
-inducible genes with essential, pathogen-specific roles in resistance to infection. J. Exp. 
Med. 194: 181-7 
110. Taylor GA, Collazo CM, Yap GS, Nguyen K, Gregorio TA, Taylor LS, Eagleson B, 
Secret L, Southon EA, Reid SW, Tessarollo L, Bray M, McVicar DW, Komschlies KL, 
Young HA, Biron CA, Sher A, Vande Woude GF. 2000. Pathogen-specific loss of host 
resistance in mice lacking the IFN--inducible gene IGTP. Proc. Natl. Acad. Sci. USA 97: 
751-5 
111. Liesenfeld O, Parvanova I, Zerrahn J, Han SJ, Heinrich F, Munoz M, Kaiser F, Aebischer 
T, Buch T, Waisman A, Reichmann G, Utermohlen O, von Stebut E, von Loewenich FD, 
Bogdan C, Specht S, Saeftel M, Hoerauf A, Mota MM, Konen-Waisman S, Kaufmann 
SH, Howard JC. 2011. The IFN-gamma-Inducible GTPase, Irga6, Protects Mice against 
Toxoplasma gondii but Not against Plasmodium berghei and Some Other Intracellular 
Pathogens. PLoS One 6: e20568 
112. Ling YM, Shaw MH, Ayala C, Coppens I, Taylor GA, Ferguson DJ, Yap GS. 2006. 
Vacuolar and plasma membrane stripping and autophagic elimination of Toxoplasma 
gondii in primed effector macrophages. J Exp Med 203: 2063-71 
113. Taylor GA. 2007. IRG proteins: key mediators of interferon-regulated host resistance to 
intracellular pathogens. Cell Microbiol 9: 1099-107 
53 
 
114. Martens S, Parvanova I, Zerrahn J, Griffiths G, Schell G, Reichmann G, Howard JC. 
2005. Disruption of Toxoplasma gondii Parasitophorous Vacuoles by the Mouse p47-
Resistance GTPases. PLoS Pathog 1: e24 
115. Khaminets A, Hunn JP, Konen-Waisman S, Zhao YO, Preukschat D, Coers J, Boyle JP, 
Ong YC, Boothroyd JC, Reichmann G, Howard JC. 2010. Coordinated loading of IRG 
resistance GTPases on to the Toxoplasma gondii parasitophorous vacuole. Cell Microbiol 
12: 939-61 
116. Kresse A, Konermann C, Degrandi D, Beuter-Gunia C, Wuerthner J, Pfeffer K, Beer S. 
2008. Analyses of murine GBP homology clusters based on in silico, in vitro and in vivo 
studies. BMC Genomics 9: 158 
117. Degrandi D, Konermann C, Beuter-Gunia C, Kresse A, Wurthner J, Kurig S, Beer S, 
Pfeffer K. 2007. Extensive Characterization of IFN-Induced GTPases mGBP1 to 
mGBP10 Involved in Host Defense. J Immunol 179: 7729-40 
118. Yamamoto M, Okuyama M, Ma JS, Kimura T, Kamiyama N, Saiga H, Ohshima J, Sasai 
M, Kayama H, Okamoto T, Huang DC, Soldati-Favre D, Horie K, Takeda J, Takeda K. 
2012. A Cluster of Interferon-gamma-Inducible p65 GTPases Plays a Critical Role in 
Host Defense against Toxoplasma gondii. Immunity  
119. Degrandi D, Kravets E, Konermann C, Beuter-Gunia C, Klumpers V, Lahme S, 
Wischmann E, Mausberg AK, Beer-Hammer S, Pfeffer K. 2013. Murine guanylate 
binding protein 2 (mGBP2) controls Toxoplasma gondii replication. Proc Natl Acad Sci 
U S A 110: 294-9 
120. Selleck EM, Fentress SJ, Beatty WL, Degrandi D, Pfeffer K, IV HWV, MacMicking JD, 
Sibley LD. 2013. Guanylate-binding protein 1 (Gbp1) contributes to cell-autonomous 
immunity against Toxoplasma gondii. PLoS Pathog 9: e1003320 
121. Medzhitov R, Janeway C, Jr. 2000. The Toll receptor family and microbial recognition. 
Trends Microbiol 8: 452-6 
122. Banchereau J, Steinman RM. 1998. Dendritic cells and the control of immunity. Nature 
392: 245-52 
123. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. 
2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18: 767-812 
54 
 
124. Shortman K, Liu Y-J. 2002. Mouse and human dendritic cell subtypes. Nature Rev. 
Immunol. 2: 151-61 
125. Kushwah R, Hu J. 2011. Complexity of dendritic cell subsets and their function in the 
host immune system. Immunology 133: 409-19 
126. Shortman K, Heath WR. 2010. The CD8+ dendritic cell subset. Immunol Rev 234: 18-31 
127. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, 
Cheong C, Liu K, Lee HW, Park CG, Steinman RM, Nussenzweig MC. 2007. 
Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107-11 
128. Satpathy AT, Wu X, Albring JC, Murphy KM. 2012. Re(de)fining the dendritic cell 
lineage. Nat Immunol 13: 1145-54 
129. Gilliet M, Cao W, Liu YJ. 2008. Plasmacytoid dendritic cells: sensing nucleic acids in 
viral infection and autoimmune diseases. Nat Rev Immunol 8: 594-606 
130. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. 2003. 
Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon 
and interleukin 6. Immunity 19: 225-34 
131. Geissmann F, Jung S, Littman DR. 2003. Blood monocytes consist of two principal 
subsets with distinct migratory properties. Immunity 19: 71-82 
132. Auffray C, Sieweke MH, Geissmann F. 2009. Blood monocytes: development, 
heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 27: 669-92 
133. Nakano H, Lin KL, Yanagita M, Charbonneau C, Cook DN, Kakiuchi T, Gunn MD. 
2009. Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T 
helper type 1 immune responses. Nat Immunol 10: 394-402 
134. Serbina NV, Salazar-Mathar TP, Biron CA, Kuziel WA, Pamer EA. 2003. TNF/iNOS-
producing dendritic cells mediate innate immune defense against bacterial infection. 
Immunity 19: 59-70 
135. Liu CH, Fan YT, Dias A, Esper L, Corn RA, Bafica A, Machado FS, Aliberti J. 2006. 
Cutting Edge: Dendritic Cells Are Essential for In Vivo IL-12 Production and 
55 
 
Development of Resistance against Toxoplasma gondii Infection in Mice. J Immunol 
177: 31-5 
136. Hou B, Benson A, Kuzmich L, DeFranco AL, Yarovinsky F. 2011. Critical coordination 
of innate immune defense against Toxoplasma gondii by dendritic cells responding via 
their Toll-like receptors. Proc Natl Acad Sci U S A 108: 278-83 
137. Bennett CL, Clausen BE. 2007. DC ablation in mice: promises, pitfalls, and challenges. 
Trends Immunol 28: 525-31 
138. Meredith MM, Liu K, Darrasse-Jeze G, Kamphorst AO, Schreiber HA, Guermonprez P, 
Idoyaga J, Cheong C, Yao KH, Niec RE, Nussenzweig MC. 2012. Expression of the zinc 
finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell 
lineage. J Exp Med 209(6): 1153-65. 
139. Robben PM, LaRegina M, W.A. K, Sibley LD. 2005. Recruitment of Gr-1+ monocytes is 
essential for control of acute toxoplasmosis. J. Exp. Med. 201: 1761-9 
140. Dunay IR, Damatta RA, Fux B, Presti R, Greco S, Colonna M, Sibley LD. 2008. Gr1(+) 
Inflammatory Monocytes Are Required for Mucosal Resistance to the Pathogen 
Toxoplasma gondii. Immunity 29: 306-17 
141. Goldszmid RS, Caspar P, Rivollier A, White S, Dzutsev A, Hieny S, Kelsall B, Trinchieri 
G, Sher A. 2012. NK Cell-Derived Interferon-gamma Orchestrates Cellular Dynamics 
and the Differentiation of Monocytes into Dendritic Cells at the Site of Infection. 
Immunity 36: 1047-59 
142. Reis e Sousa C, Hieny S, Scharton-Kersten T, Jankovic D, Charest H, Germain RN, Sher 
A. 1997. In vivo microbial stimulation induces rapid CD40L-independent production of 
IL-12 by dendritic cells and their re-distribution to T cell areas. J. Exp. Med. 186: 1819-
29 
143. Pepper M, Dzierszinski F, Wilson E, Tait E, Fang Q, Yarovinsky F, Laufer TM, Roos D, 
Hunter CA. 2008. Plasmacytoid Dendritic Cells Are Activated by Toxoplasma gondii to 
Present Antigen and Produce Cytokines. J Immunol 180: 6229-36 
144. Gazzinelli RT, Wysocka M, Hayashi S, Denkers EY, Hieny S, Caspar P, Trinchieri G, 
Sher A. 1994. Parasite-induced IL-12 stimulates early IFN- synthesis and resistance 
during acute infection with Toxoplasma gondii. J. Immunol. 153: 2533-43 
56 
 
145. Robben PM, Mordue DG, Truscott SM, Takeda K, Akira S, Sibley LD. 2004. Production 
of IL-12 by macrophages infected with Toxoplasma gondii depends on the parasite 
genotype. J Immunol 172: 3686-94 
146. Bliss SK, Zhang Y, Denkers EY. 1999. Murine neutrophil stimulation by Toxoplasma 
gondii antigen drives high level production of IFN--independent IL-12. J. Immunol. 163: 
2081-8 
147. Bliss SK, Butcher BA, Denkers EY. 2000. Rapid recruitment of neutrophils with 
prestored IL-12 during microbial infection. J. Immunol. 165: 4515-21 
148. Lambert H, Hitziger N, Dellacasa I, Svensson M, Barragan A. 2006. Induction of 
dendritic cell migration upon Toxoplasma gondii infection potentiates parasite 
dissemination. Cell Microbiol 8: 1611-23 
149. Courret N, Darche S, Sonigo P, Milon G, Buzoni-Gatel D, Tardieux I. 2006. CD11c and 
CD11b expressing mouse leukocytes transport single Toxoplasma gondii tachyzoites to 
the brain. Blood 107: 309-16 
150. Bierly AL, Shufesky WJ, Sukhumavasi W, Morelli A, Denkers EY. 2008. Dendritic cells 
expressing plasmacytoid marker PDCA-1 are Trojan horses during Toxoplasma gondii 
infection. J. Immunol. 181: 8445-91 
151. Scanga CA, Aliberti J, Jankovic D, Tilloy F, Bennouna S, Denkers EY, Medzhitov R, 
Sher A. 2002. Cutting edge: MyD88 is required for resistance to Toxoplasma gondii 
infection and regulates parasite-induced IL-12 production by dendritic cells. J. Immunol. 
168: 5997-6001 
152. Sukhumavasi W, Egan CE, Warren AL, Taylor GA, Fox BA, Bzik DJ, Denkers EY. 
2008. TLR adaptor MyD88 is essential for pathogen control during oral Toxoplasma 
gondii infection but not adaptive immunity induced by a vaccine strain of the parasite. J 
Immunol 181: 3464-73 
153. Debierre-Grockiego F, Azzouz N, Schmidt J, Dubremetz J-F, Geyer H, Geyer R, 
Weingardt R, Schmidt RR, Schwartz RT. 2003. Roles of glycosylphosphatidylinositols of 
Toxoplasma gondii. Induction of TNF- production in macrophages. J. Biol. Chem. 278: 
32987-93 
57 
 
154. Debierre-Grockiego F, Campos MA, Azzouz N, Schmidt J, Bieker U, Resende MG, 
Mansur DS, Weingart R, Schmidt RR, Golenbock DT, Gazzinelli RT, Schwarz RT. 2007. 
Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from 
Toxoplasma gondii. J Immunol 179: 1129-37 
155. Plattner F, Yarovinsky F, Romero S, Didry D, Carlier MF, Sher A, Soldati-Favre D. 
2008. Toxoplasma profilin is essential for host cell invasion and TLR dependent 
induction of interleukin-12. Cell Host and Microbe 14: 77-87 
156. Yarovinsky F, Zhang D, Anderson JF, Bannenberg GL, Serhan CN, Hayden MS, Hieny 
S, Sutterwala FS, Flavell RA, Ghosh S, Sher A. 2005. TLR11 activation of dendritic cells 
by a protozoan profilin-like protein. Science 308: 1626-9 
157. Koblansky AA, Jankovic D, Oh H, Hieny S, Sungnak W, Mathur R, Hayden MS, Akira 
S, Sher A, Ghosh S. 2013. Recognition of profilin by Toll-like receptor 12 is critical for 
host resistance to Toxoplasma gondii. Immunity 38: 119-30 
158. Andrade WA, Souza MD, Ramos-Martinez E, Nagpal K, Dutra MS, Melo MB, 
Bartholomeu DC, Ghosh S, Golenbock DT, Gazzinelli RT. 2013. Combined Action of 
Nucleic Acid-Sensing Toll-like Receptors and TLR11/TLR12 Heterodimers Imparts 
Resistance to Toxoplasma gondii in Mice. Cell Host Microbe  
159. Kim L, Butcher BA, Lee CW, Uematsu S, Akira S, Denkers EY. 2006. Toxoplasma 
gondii genotype determines MyD88-dependent signaling in infected macrophages. J 
Immunol 177: 2584-91 
160. Kim L, Del Rio L, Butcher BA, Mogensen TH, Paludan SR, Flavell RA, Denkers EY. 
2005. p38 MAPK autophosphorylation drives macrophage IL-12 production during 
intracellular infection. J Immunol 174: 4178-84 
161. Aliberti J, Reis e Sousa C, Schito M, Hieny S, Wells T, Huffnage GB, Sher A. 2000. 
CCR5 provides a signal for microbial induced production of IL-12 by CD8+ dendritic 
cells. Nature Immunol. 1: 83-7 
162. Aliberti J, Valenzuela JG, Carruthers VB, Hieny S, Andersen J, Charest H, Reis e Sousa 
C, Fairlamb A, Ribeiro JM, Sher A. 2003. Molecular mimicry of a CCR5 binding-domain 
in the microbial activation of dendritic cells. Nature Immunol. 4: 485-90 
58 
 
163. Ibrahim HM, Bannai H, Xuan X, Nishikawa Y. 2009. Toxoplasma gondii cyclophilin 18-
mediated production of nitric oxide induces Bradyzoite conversion in a CCR5-dependent 
manner. Infect Immun 77: 3686-95 
164. Kim L, Denkers EY. 2006. Toxoplasma gondii triggers Gi-dependent PI 3-kinase 
signaling required for inhibition of host cell apoptosis. J Cell Sci 119: 2119-26 
165. Lee CW, Sukhumavasi W, Denkers EY. 2007. Phosphoinositide-3-kinase-dependent, 
MyD88-independent induction of CC-type chemokines characterizes the macrophage 
response to Toxoplasma gondii strains with high virulence. Infect Immun 75: 5788-97 
166. Gazzinelli RT, Wysocka M, Hieny S, Scharton-Kersten T, Cheever A, Kuhn R, Muller 
W, Trinchieri G, Sher A. 1996. In the absence of endogenous IL-10, mice acutely 
infected with Toxoplasma gondii succumb to a lethal immune response dependent upon 
CD4
+
 T cells and accompanied by overproduction of IL-12, IFN-, and TNF-. J. 
Immunol. 157: 798-805 
167. Suzuki Y, Sher A, Yap G, Park D, Ellis Neyer L, Liesenfeld O, Fort M, Kang H, Gufwoli 
E. 2000. IL-10 is required for prevention of necrosis in the small intestine and mortality 
in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral 
infection with Toxoplasma gondii. J. Immunol. 164: 5375-82 
168. Jankovic D, Kullberg MC, Feng CG, Goldszmid RS, Collazo CM, Wilson M, Wynn TA, 
Kamanaka M, Flavell RA, Sher A. 2007. Conventional T-bet+Foxp3- Th1 cells are the 
major source of host-protective regulatory IL-10 during intracellular protozoan infection. 
J Exp Med 204: 273-83 
169. Buzoni-Gatel D, Debbabi H, Mennechet FJD, Martin V, LePage AC, Schwartzman JD, 
Kasper LH. 2001. Murine ileitis after intracellular parasite infection is controlled by 
TGF--producing intraepithelial lymphocytes. Gastroenterol. 120: 914-24 
170. Villarino A, Hibbert L, Lieberman L, Wilson E, Mak t, Yoshida H, Kaselein RA, Saris C, 
Hunter CA. 2003. The IL-27R (WSX-1) is required to suppress T cell hyperactivity 
during infection. Immunity 19: 645-55 
171. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, Villarino AV, 
Huang Q, Yoshimura A, Sehy D, Saris CJ, O'Shea J J, Hennighausen L, Ernst M, Hunter 
CA. 2006. Interleukin 27 negatively regulates the development of interleukin 17-
producing T helper cells during chronic inflammation of the central nervous system. Nat 
Immunol 7: 937-45 
59 
 
172. Hall AO, Beiting DP, Tato C, John B, Oldenhove G, Lombana CG, Pritchard GH, Silver 
JS, Bouladoux N, Stumhofer JS, Harris TH, Grainger J, Wojno ED, Wagage S, Roos DS, 
Scott P, Turka LA, Cherry S, Reiner SL, Cua D, Belkaid Y, Elloso MM, Hunter CA. 
2012. The cytokines interleukin 27 and interferon-gamma promote distinct Treg cell 
populations required to limit infection-induced pathology. Immunity 37: 511-23 
173. Lee CW, Bennouna S, Denkers EY. 2006. Screening for Toxoplasma gondii regulated 
transcriptional responses in LPS-activated macrophages. Infect. Immun. 74: 1916-23 
174. Butcher BA, Denkers EY. 2002. Mechanism of entry determines the ability of 
Toxoplasma gondii to inhibit macrophage proinflammatory cytokine production. Infect 
Immun 70: 5216-24 
175. Leng J, Butcher BA, Egan CE, Abi Abdallah DS, Denkers EY. 2009. Toxoplasma gondii 
prevents chromatin remodeling initiated by Toll-like receptor-triggered macrophages 
activation. J. Immunol. 182: 489-97 
176. Leng J, Butcher BA, Denkers EY. 2009. Dysregulation of macrophage signal 
transduction by Toxoplasma gondii: Past progress and recent advances. Parasite 
Immunol. 31: 717-28 
177. McKee AS, Dzierszinski F, Boes M, Roos DS, Pearce EJ. 2004. Functional inactivation 
of immature dendritic cells by the intracellular parasite Toxoplasma gondii. J. immunol. 
173: 2632-40 
178. Denkers EY, Butcher BA, Del Rio L, Kim L. 2004. Manipulation of mitogen-activated 
protein kinase/nuclear factor-B-signaling cascades during intracellular Toxoplasma 
gondii infection. Immunol. Rev. 201: 191-205 
179. Mason NJ, Artis D, Hunter CA. 2004. New lessons from old pathogens: what parasitic 
infections have taught us about the role of nuclear factor-B in the regulation of 
immunity. Immunol. Rev. 201: 48-56 
180. Butcher BA, Kim L, Johnson PF, Denkers EY. 2001. Toxoplasma gondii tachyzoites 
inhibit proinflammatory cytokine induction in infected macrophages by preventing 
nuclear translocation of the transcription factor NFB. J. Immunol. 167: 2193-201 
181. Shapira SS, Speirs K, Gerstein A, Caamano J, Hunter CA. 2002. Suppression of NF-B 
activation by infection with Toxoplasma gondii. J. Infect. Dis. 185: S66-72 
60 
 
182. Kim L, Butcher BA, Denkers EY. 2004. Toxoplasma gondii interferes with 
lipopolysaccharide-induced mitogen-activated protein kinase activation by mechanisms 
distinct from endotoxin tolerance. J. Immunol. 172: 3003-10 
183. Shapira S, Harb O, Margarit J, Matrajt M, Han J, Hoffmann A, Freedman B, May MJ, 
Roos DS, Hunter CA. 2005. Initiation and termination of NFB signaling by the 
intracellular protozoan parasite Toxoplasma gondii. J. Cell Sci. 118: 3501-8 
184. Leng J, Butcher BA, Egan CE, Abdallah DS, Denkers EY. 2009. Toxoplasma gondii 
prevents chromatin remodeling initiated by TLR-triggered macrophage activation. J 
Immunol 182: 489-97 
185. Valere A, Garnotel R, Villena I, Guenounou M, Pinon JM, Aubert D. 2003. Activation of 
the cellular mitogen-activated protein kinase pathways ERK. p38 and JNK during 
Toxoplasma gondii invasion. Parasite 10: 59-64 
186. Heimesaat MM, Bereswill S, Fischer A, Fuchs D, Struck D, Niebergall J, Jahn HK, 
Dunay IR, Moter A, Gescher DM, Schumann RR, Gobel UB, Liesenfeld O. 2006. Gram-
Negative Bacteria Aggravate Murine Small Intestinal Th1-Type Immunopathology 
following Oral Infection with Toxoplasma gondii. J Immunol 177: 8785-95 
187. Heimesaat MM, Fischer A, Jahn HK, Niebergall J, Freudenberg M, Blaut M, Liesenfeld 
O, Schumann RR, Gobel UB, Bereswill S. 2007. Exacerbation of Murine Ileitis By Toll-
Like Receptor 4 Meditated Sensing of Lipopolysaccharide From Commensal Escherichia 
coli. Gut 56: 941-8 
188. Hunter CA, Sibley LD. 2012. Modulation of innate immunity by Toxoplasma gondii 
virulence effectors. Nat Rev Microbiol 10: 766-78 
189. Taylor S, Barragan A, Su C, Fux B, Fentress SJ, Tang K, Beatty WL, Hajj HE, Jerome 
M, Behnke MS, White M, Wootton JC, Sibley LD. 2006. A secreted serine-threonine 
kinase determines virulence in the eukaryotic pathogen Toxoplasma gondii. Science 314: 
1776-80 
190. Saeij JP, Boyle JP, Coller S, Taylor S, Sibley LD, Brooke-Powell ET, Ajioka JW, 
Boothroyd JC. 2006. Polymorphic secreted kinases are key virulence factors in 
toxoplasmosis. Science 314: 1780-3 
61 
 
191. Zhao Y, Ferguson DJ, Wilson DC, Howard JC, Sibley LD, Yap GS. 2009. Virulent 
Toxoplasma gondii evade immunity-related GTPase-mediated parasite vacuole disruption 
within primed macrophages. J Immunol 182: 3775-81 
192. Fentress SJ, Behnke MS, Dunay IR, Mashayekhi M, Rommereim LM, Fox BA, Bzik DJ, 
Taylor GA, Turk BE, Lichti CF, Townsend RR, Qiu W, Hui R, Beatty WL, Sibley LD. 
2010. Phosphorylation of Immunity-Related GTPases by a Toxoplasma gondii-Secreted 
Kinase Promotes Macrophage Survival and Virulence. Cell Host Microbe 8: 484-95 
193. Steinfeldt T, Konen-Waisman S, Tong L, Pawlowski N, Lamkemeyer T, Sibley LD, 
Hunn JP, Howard JC. 2010. Phosphorylation of Mouse Immunity-Related GTPase (IRG) 
Resistance Proteins Is an Evasion Strategy for Virulent Toxoplasma gondii. PLoS Biol 8: 
e1000576 
194. Yamamoto M, Ma JS, Mueller C, Kamiyama N, Saiga H, Kubo E, Kimura T, Okamoto 
T, Okuyama M, Kayama H, Nagamune K, Takashima S, Matsuura Y, Soldati-Favre D, 
Takeda K. 2011. ATF6{beta} is a host cellular target of the Toxoplasma gondii virulence 
factor ROP18. J Exp Med 208(7): 1533-46 
195. Yamamoto M, Takeda K. 2012. Inhibition of ATF6beta-dependent host adaptive immune 
response by a Toxoplasma virulence factor ROP18. Virulence 3: 77-80 
196. Reese ML, Zeiner GM, Saeij JP, Boothroyd JC, Boyle JP. 2011. Polymorphic family of 
injected pseudokinases is paramount in Toxoplasma virulence. Proc Natl Acad Sci U S A 
108: 9625-30 
197. Behnke MS, Khan A, Wootton JC, Dubey JP, Tang K, Sibley LD. 2011. Virulence 
differences in Toxoplasma mediated by amplification of a family of polymorphic 
pseudokinases. Proc Natl Acad Sci U S A 108: 9631-6 
198. Reese ML, Boothroyd JC. 2011. A conserved non-canonical motif in the pseudoactive 
site of the ROP5 pseudokinase domain mediates its effect on Toxoplasma virulence. J 
Biol Chem 286: 29366-75 
199. Fleckenstein MC, Reese ML, Konen-Waisman S, Boothroyd JC, Howard JC, Steinfeldt 
T. 2012. A Toxoplasma gondii Pseudokinase Inhibits Host IRG Resistance Proteins. 
PLoS Biol 10: e1001358 
62 
 
200. Niedelman W, Gold DA, Rosowski EE, Sprokholt JK, Lim D, Farid Arenas A, Melo MB, 
Spooner E, Yaffe MB, Saeij JP. 2012. The Rhoptry Proteins ROP18 and ROP5 Mediate 
Toxoplasma gondii Evasion of the Murine, But Not the Human, Interferon-Gamma 
Response. PLoS Pathog 8: e1002784 
201. Behnke MS, Fentress SJ, Mashayekhi M, Li LX, Taylor GA, Sibley LD. 2012. The 
Polymorphic Pseudokinase ROP5 Controls Virulence in Toxoplasma gondii by 
Regulating the Active Kinase ROP18. PLoS Pathog 8: e1002992 
202. Saeij JP, Coller S, Boyle JP, Jerome ME, White MW, Boothroyd JC. 2007. Toxoplasma 
co-opts host gene expression by injection of a polymorphic kinase homologue. Nature 
445: 324-7 
203. Yamamoto M, Standley DM, Takashima S, Saiga H, Okuyama M, Kayama H, Kubo E, 
Ito H, Takaura M, Matsuda T, Soldati-Favre D, Takeda K. 2009. A single polymorphic 
amino acid on Toxoplasma gondii kinase ROP16 determines the direct and strain-specific 
activation of Stat3. J Exp Med 206: 2747-60 
204. Ong YC, Reese ML, Boothroyd JC. 2010. Toxoplasma rhoptry protein 16 (ROP16) 
subverts host function by direct tyrosine phosphorylation of STAT6. J Biol Chem 285: 
28731-40 
205. Butcher BA, Fox BA, Rommereim LM, Kim SG, Maurer KJ, Yarovinsky F, Herbert DR, 
Bzik DJ, Denkers EY. 2011. Toxoplasma gondii Rhoptry Kinase ROP16 Activates 
STAT3 and STAT6 Resulting in Cytokine Inhibition and Arginase-1-Dependent Growth 
Control. PLoS Pathog 7: e1002236 
206. Denkers EY, Bzik DJ, Fox BA, Butcher BA. 2012. An inside job: hacking into Janus 
kinase/signal transducer and activator of transcription signaling cascades by the 
intracellular protozoan Toxoplasma gondii. Infect Immun 80: 476-82 
207. Jensen KD, Wang Y, Wojno ED, Shastri AJ, Hu K, Cornel L, Boedec E, Ong YC, Chien 
YH, Hunter CA, Boothroyd JC, Saeij JP. 2011. Toxoplasma polymorphic effectors 
determine macrophage polarization and intestinal inflammation. Cell Host Microbe 9: 
472-83 
208. Jensen KD, Hu K, Whitmarsh RJ, Hassan MA, Julien L, Lu D, Chen L, Hunter CA, Saeij 
JP. 2013. Toxoplasma rhoptry kinase ROP16 promotes host resistance to oral infection 
and intestinal inflammation only in the context of the dense granule protein GRA15. 
Infect Immun  
63 
 
209. Rosowski EE, Lu D, Julien L, Rodda L, Gaiser RA, Jensen KD, Saeij JP. 2011. Strain-
specific activation of the NF-kappaB pathway by GRA15, a novel Toxoplasma gondii 
dense granule protein. J Exp Med 208: 195-212 
210. Brierley MM, Fish EN. 2005. Stats: multifaceted regulators of transcription. J Interferon 
Cytokine Res 25: 733-44 
211. Decker T, Kovarik P, Meinke A. 1997. GAS elements: a few nucleotides with a major 
impact on cytokine-induced gene expression. J Interferon Cytokine Res 17: 121-34 
212. Wen Z, Zhong Z, Darnell JE, Jr. 1995. Maximal activation of transcription by Stat1 and 
Stat3 requires both tyrosine and serine phosphorylation. Cell 82: 241-50 
213. Wen Z, Darnell JE, Jr. 1997. Mapping of Stat3 serine phosphorylation to a single residue 
(727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 
and Stat3. Nucleic Acids Res 25: 2062-7 
214. Zhu X, Wen Z, Xu LZ, Darnell JE, Jr. 1997. Stat1 serine phosphorylation occurs 
independently of tyrosine phosphorylation and requires an activated Jak2 kinase. Mol 
Cell Biol 17: 6618-23 
215. Decker T, Kovarik P. 2000. Serine phosphorylation of STATs. Oncogene 19: 2628-37 
216. Nair JS, DaFonseca CJ, Tjernberg A, Sun W, Darnell JE, Jr., Chait BT, Zhang JJ. 2002. 
Requirement of Ca2+ and CaMKII for Stat1 Ser-727 phosphorylation in response to IFN-
gamma. Proc Natl Acad Sci U S A 99: 5971-6 
217. Nguyen H, Ramana CV, Bayes J, Stark GR. 2001. Roles of phosphatidylinositol 3-kinase 
in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation 
of gene expression. J Biol Chem 276: 33361-8 
218. Deb DK, Sassano A, Lekmine F, Majchrzak B, Verma A, Kambhampati S, Uddin S, 
Rahman A, Fish EN, Platanias LC. 2003. Activation of protein kinase C delta by IFN-
gamma. J Immunol 171: 267-73 
219. Kovarik P, Stoiber D, Eyers PA, Menghini R, Neininger A, Gaestel M, Cohen P, Decker 
T. 1999. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-
64 
 
activated protein kinase whereas IFN-gamma uses a different signaling pathway. Proc 
Natl Acad Sci U S A 96: 13956-61 
220. Mohr A, Chatain N, Domoszlai T, Rinis N, Sommerauer M, Vogt M, Muller-Newen G. 
2012. Dynamics and non-canonical aspects of JAK/STAT signalling. Eur J Cell Biol 91: 
524-32 
221. Stark GR, Darnell JE, Jr. 2012. The JAK-STAT pathway at twenty. Immunity 36: 503-14 
222. Musselman CA, Lalonde ME, Cote J, Kutateladze TG. 2012. Perceiving the epigenetic 
landscape through histone readers. Nat Struct Mol Biol 19: 1218-27 
223. Ramsauer K, Farlik M, Zupkovitz G, Seiser C, Kroger A, Hauser H, Decker T. 2007. 
Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate 
transcription of the IFN-gamma-inducible gbp2 gene. Proc Natl Acad Sci U S A 104: 
2849-54 
224. Shah S, Henriksen MA. 2011. A novel disrupter of telomere silencing 1-like (DOT1L) 
interaction is required for signal transducer and activator of transcription 1 (STAT1)-
activated gene expression. J Biol Chem 286: 41195-204 
225. Pattenden SG, Klose R, Karaskov E, Bremner R. 2002. Interferon-gamma-induced 
chromatin remodeling at the CIITA locus is BRG1 dependent. EMBO J 21: 1978-86 
226. Wang Y, Gao B, Xu W, Xiong S. 2011. BRG1 is indispensable for IFN-gamma-induced 
TRIM22 expression, which is dependent on the recruitment of IRF-1. Biochem Biophys 
Res Commun 410: 549-54 
227. ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, Zhu W, Tremblay M, David M, Shuai K. 
2002. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 22: 
5662-8 
228. Liu B, Mink S, Wong KA, Stein N, Getman C, Dempsey PW, Wu H, Shuai K. 2004. 
PIAS1 selectively inhibits interferon-inducible genes and is important in innate 
immunity. Nat Immunol 5: 891-8 
65 
 
229. Tahk S, Liu B, Chernishof V, Wong KA, Wu H, Shuai K. 2007. Control of specificity 
and magnitude of NF-kappa B and STAT1-mediated gene activation through PIASy and 
PIAS1 cooperation. Proc Natl Acad Sci U S A 104: 11643-8 
230. Begitt A, Droescher M, Knobeloch KP, Vinkemeier U. 2011. SUMO conjugation of 
STAT1 protects cells from hyperresponsiveness to IFNgamma. Blood 118: 1002-7 
231. Droescher M, Begitt A, Marg A, Zacharias M, Vinkemeier U. 2011. Cytokine-induced 
paracrystals prolong the activity of signal transducers and activators of transcription 
(STAT) and provide a model for the regulation of protein solubility by small ubiquitin-
like modifier (SUMO). J Biol Chem 286: 18731-46 
232. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, Corbin JE, 
Cornish AL, Darwiche R, Owczarek CM, Kay TW, Nicola NA, Hertzog PJ, Metcalf D, 
Hilton DJ. 1999. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents 
the potentially fatal neonatal actions of this cytokine. Cell 98: 597-608 
233. Marine JC, Topham DJ, McKay C, Wang D, Parganas E, Stravopodis D, Yoshimura A, 
Ihle JN. 1999. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 
98: 609-16 
234. Gavrilescu LC, Butcher BA, Del Rio L, Taylor GA, Denkers EY. 2004. STAT1 is 
essential for antimicrobial function but dispensable for gamma interferon production 
during Toxoplasma gondii infection. Infect. Immun. 72: 1257-64 
235. Lieberman LA, Banica M, Reiner SL, Hunter CA. 2004. STAT1 plays a critical role in 
the regulation of antimicrobial effector mechanisms, but not in the development of Th1-
type responses during toxoplasmosis. J. Immunol. 172: 457-63 
236. Yang TH, Aosai F, Norose K, Ueda M, Yano A. 1996. Differential regulation of HLA-
DR expression and antigen presentation in Toxoplasma gondii-infected melanoma cells 
by interleukin 6 and interferon gamma. Microbiol Immunol 40: 443-9 
237. Luder CGK, Lang T, Beurle B, Gross U. 1998. Down-regulation of MHC class II 
molecules and inability to up-regulate class I molecules in murine macrophages after 
infection with Toxoplasma gondii. Clin. Exp. Immunol. 112: 308-16 
238. Luder CGK, Walter W, Beuerle B, Maeurer MJ, Gross U. 2001. Toxoplasma gondii 
down-regulates MHC class II gene expression and antigen presentation by murine 
66 
 
macrophages via interference with nuclear translocation of STAT1. Eur. J. Immunol. 
31: 1475-84 
239. Luder CGK, Lang C, Giraldo-Velasquez M, Algner M, Gerdes J, Gross U. 2003. 
Toxoplasma gondii inhibits MHC class II expression in neural antigen-presenting cells by 
down-regulating the class II transactivator CIITA. J. Neuroimmunol. 134: 12-24 
240. Lang C, Algner M, Beinert N, Gross U, Luder CG. 2006. Diverse mechanisms employed 
by Toxoplasma gondii to inhibit IFN-gamma-induced major histocompatibility complex 
class II gene expression. Microbes Infect 8: 1994-2005 
241. Kim SK, Fouts AE, Boothroyd JC. 2007. Toxoplasma gondii dysregulates IFN-gamma-
inducible gene expression in human fibroblasts: insights from a genome-wide 
transcriptional profiling. J Immunol 178: 5154-65 
242. Rosowski EE, Saeij JP. 2012. Toxoplasma gondii Clonal Strains All Inhibit STAT1 
Transcriptional Activity but Polymorphic Effectors Differentially Modulate IFNgamma 
Induced Gene Expression and STAT1 Phosphorylation. PLoS One 7: e51448 
243. Zimmermann S, Murray PJ, Heeg K, Dalpke AH. 2006. Induction of Suppressor of 
Cytokine Signaling-1 by Toxoplasma gondii Contributes to Immune Evasion in 
Macrophages by Blocking IFN-{gamma} Signaling. J Immunol 176: 1840-7 
244. Seabra SH, de Souza W, DaMatta RA. 2002. Toxoplasma gondii partially inhibits nitric 
oxide production of activated murine macrophages. Exp Parasitol 100: 62-70 
245. Luder CGK, Algner M, Lang C, Bleicher N, Gross U. 2003. Reduced expression of the 
inducible nitric oxide synthase after infection with Toxoplasma gondii facilitates parasite 
replication in activated murine macrophages. Internat. J. Parasitol. 33: 833-44 
246. Rozenfeld C, Martinez R, Seabra S, Sant'anna C, Goncalves JG, Bozza M, Moura-Neto 
V, De Souza W. 2005. Toxoplasma gondii prevents neuron degeneration by interferon-
gamma-activated microglia in a mechanism involving inhibition of inducible nitric oxide 
synthase and transforming growth factor-beta1 production by infected microglia. Am J 
Pathol 167: 1021-31 
247. Lang C, Hildebrandt A, Brand F, Opitz L, Dihazi H, Luder CG. 2012. Impaired 
chromatin remodelling at STAT1-regulated promoters leads to global unresponsiveness 
of Toxoplasma gondii-Infected macrophages to IFN-gamma. PLoS Pathog 8: e1002483 
3 
 67 
 
 
 
 
 
 
 
CHAPTER 2 
Toxoplasma gondii Triggers Phosphorylation and Nuclear Translocation of Dendritic Cell 
STAT1 While Simultaneously Blocking IFNγ-Induced STAT1 Transcriptional Activity
1
 
 
 
 
 
 
 
 
                                                 
1
 Reprinted from Anne G. Schneider, Delbert S. Abi Abdallah, Barbara A. Butcher and Eric Y. Denkers.  
Toxoplasma gondii triggers phosphorylation and nuclear translocation of dendritic cell STAT1 while simultaneously 
blocking IFNγ-induced STAT1 transcriptional activity.  (2013) PLoS One 8: e60215.  © 2013 by Anne G. Schneider 
et al under the Creative Commons Attribution License (CCAL). 
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Abstract 
The protozoan Toxoplasma gondii actively modulates cytokine-induced JAK/STAT signaling 
pathways to facilitate survival within the host, including blocking IFNγ-mediated STAT1-
dependent proinflammatory gene expression. We sought to further characterize inhibition of 
STAT1 signaling in infected murine dendritic cells (DC) because this cell type has not 
previously been examined, yet is known to serve as an early target of in vivo infection. 
Unexpectedly, we discovered that T. gondii infection alone induced sustained STAT1 
phosphorylation and nuclear translocation in DC in a parasite strain-independent manner.  
Maintenance of STAT1 phosphorylation required active invasion, but intracellular parasite 
replication was dispensable. The parasite rhoptry protein ROP16, recently shown to mediate 
STAT3 and STAT6 phosphorylation, was not required for STAT1 phosphorylation. In 
combination with IFNγ, T. gondii induced synergistic STAT1 phosphorylation and binding of 
aberrant STAT1-containing complexes to IFNγ consensus sequence oligonucleotides.  Despite 
these findings, parasite infection blocked STAT1 binding to the native promoters of the IFNγ-
inducible genes Irf-1 and Lrg47, along with subsequent gene expression.  These results reinforce 
the importance of parasite-mediated blockade of IFNγ responses in dendritic cells, while 
simultaneously showing that T. gondii alone induces STAT1 phosphorylation. 
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Introduction 
Toxoplasma gondii is among the most successful parasitic microorganisms, infecting virtually all 
warm-blooded animals. Up to one-third of the human population worldwide is infected with this 
protozoan (1). Most infections are asymptomatic or present with mild flu-like symptoms, and the 
parasite establishes life-long infection characterized by presence of latent cysts in host tissues.  
Should immunocompromise develop, as in organ transplant recipients and AIDs patients, cyst 
reactivation can occur and lead to deadly encephalitis (2).  Fetuses can also become infected in 
utero during primary maternal infection with devastating consequences including blindness, 
mental retardation, and death (3). Three main clonal lineages of the parasite have been identified 
in humans and domestic animals in North America, which differ in terms of virulence in mice (4).  
Type I strains are the most virulent (LD50=1), resulting in death of the mouse during acute 
infection, whereas types II and III strains are much less virulent and capable of establishing 
chronic infection (5).  All three strain types can cause disease in humans, although type I strains 
may be more common in cases of ocular disease (6).  Recently, a fourth clonal lineage has been 
identified in wildlife populations of North America (7, 8).  
 
Cell-mediated immunity is crucial to limiting severity of Toxoplasma infection.  Widely 
considered the major mediator of host resistance is the cytokine interferon-gamma (IFNγ), 
produced primarily by T cells and NK cells.  This cytokine is necessary for the control of 
intracellular parasite replication both in vivo and in vitro, in both mice and humans (9-14).  
Among many effects, IFNγ activates antimicrobial effector mechanisms such as the immunity-
related p47-GTPases that facilitate degradation of the parasitophorous vacuole (15-17). 
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Critical to the action of IFNγ in inducing antimicrobial effector mechanisms is the transcription 
factor signal transducer and activator of transcription 1 (STAT1) (18, 19).  Indeed, in the absence 
of STAT1, Toxoplasma-infected mice succumb rapidly to infection (20, 21).  In the classical 
signaling pathway, IFNγ binds its receptor and signals through a Janus kinase (JAK)/STAT1 
cascade.  Activated JAKs phosphorylate the IFNγ-receptor, permitting recruitment of STAT1.  
STAT1 is phosphorylated on a key tyrosine residue, Y701, and translocates as a dimer to the 
nucleus to initiate transcription, binding to gamma-activated sequence (GAS) elements in the 
promoters of responsive genes (22-24). Phosphorylation at a key serine residue, S727, is thought 
to facilitate maximal STAT1 transcriptional activity (25-27).  One of the key early response 
genes regulated by STAT1 is interferon regulatory factor-1 (Irf1) (28, 29), itself a transcription 
factor, the absence of which also increases susceptibility to Toxoplasma infection (30).  
 
Given the vital impact on parasite survival, it may not be surprising that Toxoplasma possesses 
mechanisms to counteract the IFNγ/STAT1 pathway.  This has been demonstrated in a variety of 
cell types, including bone marrow-derived macrophages (BMDM), microglia, astroglia, the 
monocyte/macrophage RAW264.7 cell line, as well as human and murine fibroblasts.  The 
parasite has been shown to block IFNγ-mediated upregulation of MHC class I and II molecules, 
class II transactivator (CIITA), inducible nitric oxide synthase, the chemokine monokine induced 
by IFNγ (MIG), interferon-inducible GTPase 1 (IIGP1) and IRF1 (31-39).  In addition, genome-
wide microarray analyses in human fibroblasts and murine macrophages have described global 
inhibition of IFNγ-mediated gene expression in infected cells (40-42).   
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The molecular mechanism of inhibition remains unclear.  Some discrepancy exists as to whether 
Toxoplasma targets STAT1 itself.  One study performed in RAW264.7 cells at a high 
multiplicity of infection (MOI) concluded that infection blocked IFNγ-mediated STAT1 
phosphorylation, likely via upregulation of suppressor of cytokine signaling-1 (SOCS1) (39), 
while another study implicated partial STAT1 dephosphorylation in the nuclei of infected human 
fibroblasts (40).  However, other studies found that STAT1 phosphorylation and nuclear 
translocation were unimpaired in infected cells, suggesting instead a block in IFNγ-mediated 
gene transcription (38, 41, 42).   The mechanism by which this occurs likely involves impaired 
recruitment of histone modifying enzymes such as BRG-1 to certain gene promoters, thereby 
rendering native chromatin inactive for transcription (41).  However, the particular parasite 
factors or signaling pathways involved in the inhibition remain unknown. 
 
In our study, we sought to investigate the impact of Toxoplasma infection on the IFNγ/STAT1 
pathway in primary bone marrow-derived murine dendritic cells (BMDC).  Dendritic cells serve 
as an important early target of in vivo infection, playing a critical role in parasite dissemination 
throughout the host (43-45).  They also play a pivotal role in immune initiation (46), and their 
genetic deletion results in acute susceptibility to T. gondii (47, 48).  We unexpectedly discovered 
that Toxoplasma alone induces STAT1 phosphorylation and nuclear translocation in infected 
BMDC, regardless of strain type.  In addition, we observed synergistic STAT1 phosphorylation 
when infected cells were treated with IFNγ.  Electrophoretic mobility shift assays (EMSAs) 
revealed the presence of an aberrant GAS-binding complex that increased during the infection 
period in the presence of IFNγ.  However, transcription of IFNγ/STAT1-responsive genes was 
impaired in infected cells.  Binding of STAT1 to the native Irf-1 promoter in response to IFNγ 
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was also abrogated.  These findings reveal that Toxoplasma triggers phosphorylation of STAT1 
that nonetheless is unable to act as a transcription factor for typical IFN-γ-regulated genes. 
 
Materials and Methods 
Ethics Statement 
All experiments with animals in this study were performed in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health.  The protocols were approved by the Institutional Animal Care and Use 
Committee at Cornell University (Permit Number: 1995-0057).  All efforts were made to 
minimize animal suffering. 
 
Mice and Parasites 
Female C57BL/6 mice of 6-8 weeks of age were purchased from either the Jackson Laboratory 
or Taconic Farms.  All mice were housed under specific pathogen-free conditions at the 
Transgenic Mouse Core Facility at Cornell University’s College of Veterinary Medicine, which 
is accredited by the Association for the Assessment and Accreditation of Laboratory Animal 
Care.  Tachyzoites of the Toxoplasma strains RH (type I), PTG (type II), M774.1 (type III), 
cps1-1 (type I attenuated strain), and ∆ROP16 (RH/type I background) were maintained by 
biweekly passage on human foreskin fibroblast monolayers (American Type Tissue Collection) 
in DMEM (Life Technologies) supplemented with 1% bovine growth serum (Hyclone), 100 
U/ml penicillin (Life Technologies), and 0.1 mg/ml streptomycin (Life Technologies).  The RH 
parasites deficient in the rhoptry kinase ROP16 (∆ROP16) were generated as described 
previously (49) and were kindly provided by D. Bzik and B. Fox (Dartmouth Medical Center). 
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The attenuated uracil auxotroph strain cps1-1 (50) was supplemented with 250 nM uracil during 
passage to permit replication.  Parasite cultures were tested every 6-8 weeks for Mycoplasma 
contamination using a commercial PCR-ELISA based kit (Roche Applied Systems). 
 
Bone Marrow-Derived Dendritic Cell (BMDC) Culture 
Bone marrow was flushed from the femur and tibia of a C57BL/6 mouse and prepared as a single 
cell suspension in BMDC medium composed of RPMI 1640 (Fisher Scientific) supplemented 
with 10% fetal calf serum (Hyclone), 100 U/ml penicillin (Life Technologies), 0.1 mg/ml 
streptomycin (Life Technologies), 50 μM 2-mercaptoethanol (Sigma) and 20 ng/ml GM-CSF 
(Peprotech).  Cells were plated on 100 x 15 mm standard sterile polystyrene Petri dishes (Fisher 
Scientific) and cultured for 9 days at 37°C in 5% CO2.  Fresh BMDC medium was added on day 
3.  On day 6, fresh BMDC medium containing 50 mM 2-mercaptoethanol was added.  On day 8, 
200 ng of GM-CSF was added per plate.  On day 9, non-adherent cells (BMDC) were collected 
and resuspended in DMEM (Life Technologies) supplemented with 10% bovine growth serum 
(Hyclone), 50 mM 2-mercaptoethanol (Sigma) and the following reagents from Life 
Technologies: 100 U/mL penicillin (Life Technologies), 0.1 mg/ml streptomycin (Life 
Technologies), 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, and 3% HEPES (1M). 
 
In vitro Infections and Stimuli 
Infection of BMDCs was accomplished through addition of tachyzoites to cell cultures at a ratio 
of 3:1 (parasites:BMDCs) followed by brief centrifugation (200 x g, 3 min) to initiate contact 
between cells and parasites.  In other experiments, cells were treated with recombinant murine 
IFNγ (100 ng/mL, Peprotech) or first pre-infected with tachyzoites for two hours followed by 
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IFNγ treatment.  For cytochalasin D experiments, BMDC were pretreated for 10 min at 4°C with 
cytochalasin D (Calbiochem) at a final concentration of 1 μM or with the solvent DMSO (Sigma) 
alone.  Cells were then infected with tachyzoites or treated with recombinant murine IFNγ for 6 
hours in the continued presence of the drug.  For the supernatant transfer experiments, 
supernatants from cells infected with tachyzoites or treated with IFNγ overnight were collected, 
centrifuged to remove cellular debris, and filtered through 0.2 μM filters (Corning) prior to 
addition to untreated cells.   
 
Immunoblot Analysis 
The following primary antibodies from Cell Signaling were used in immunoblotting studies: 
anti-phospho-STAT1-Tyr 701 (catalog no. 9167), anti-phospho-STAT1-Ser727 (catalog no. 
9177), and anti-PARP (catalog no. 9542).  The Rab5a antibody (catalog no. sc-309) was obtained 
from Santa Cruz Biotechnology.  Cells (3x10
6
/sample) were fractionated into cytoplasmic and 
nuclear fractions using a nuclear extract kit (Active Motif) as directed.  Samples were 
subsequently diluted with 2x reducing SDS sample buffer.  After 5 min at 100°C, samples were 
separated by 10% SDS-PAGE and proteins were subsequently electrotransferred onto 
nitrocellulose membranes (Whatman).  The membranes were blocked for one hour at room 
temperature in Tris-buffered saline containing 0.1% Tween 20, pH 7.6, (TBST) and 5% nonfat 
dry milk prior to the addition of primary antibody overnight at 4°C in TBST containing 5% 
bovine serum albumin (BSA) (Calbiochem).  Membranes were subsequently washed with TBST 
prior to detection of primary antibody binding with a horseradish peroxidase-conjugated anti-
rabbit IgG (Jackson ImmunoResearch, catalog no. 111-035-144) in TBST containing 5% nonfat 
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dry milk for one hour at room temperature.  Membranes were washed in TBST prior to 
visualization of bands using a chemiluminescence detection system (Thermo Scientific). 
 
Flow Cytometry 
BMDC were infected with the type 1 parasite strain RH at a ratio of 0.5 parasites per cell and 
harvested for flow cytometric analysis after 20 hours.  Samples were fixed for 10 minutes at 
room temperature with 3% formaldehyde, followed by permeabilization for 30 minutes at 4°C 
with ice-cold 100% methanol.  Cells were plated at 2x10
6
 per well in a 96-well plate and washed 
twice with FACS buffer (1% BSA in PBS).  Cells were stained with anti-phospho-STAT1-
Tyr701 (Cell Signaling, catalog no. 9167) diluted in FACS buffer for 1 hour at room temperature.  
Samples were washed twice with FACS buffer prior to addition of an antibody mixture for 30 
minutes at room temperature containing goat-anti-rabbit-Alexa Fluor 647 (Life Technologies, 
catalog no. A21245) to detect the primary p-STAT1 antibody, and anti-p30-FITC (Argene, 
catalog no. 12-132) to detect Toxoplasma-infected cells.  Samples were again washed with 
FACS buffer prior to analysis on a FACS Calibur flow cytometer (BD Biosciences).  Data were 
subsequently analyzed using FlowJo software (Tree Star). 
 
Transcription Factor DNA-binding ELISA 
The presence of activated STAT1 complexes capable of binding to consensus oligonucleotides 
was assessed in BMDC nuclear extracts using the TransAM STAT Family Transcription Factor 
Assay Kit (Active Motif), per manufacturer’s instructions.  BMDC were either infected with the 
RH strain of parasites (ratio of 3 parasites per cell) or treated with recombinant murine IFNγ 
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(Peprotech) for six hours prior to analysis.  The STAT consensus nucleotide coated on the 96-
well plates consisted of the following sequence: 5’-TTCCCGGAA-3’. 
 
Electrophoretic Mobility Shift Assay (EMSA) 
To further confirm STAT1 binding-activity in nuclear extracts, EMSA was performed using a 
LightShift Chemiluminescent EMSA kit, per manufacturer’s instructions (Thermo Scientific).  
Briefly, complementary oligonucleotides (5’-CATTTCGGGGAAATCGATC-3’ and 5’-
GATCGATTTCCCCGAAATG-3’; IDT Technologies) designed against the GAS sequence of 
the Irf-1 promoter (Ng et al, 2011) were biotinylated at the 5’ end prior to annealing equimolar 
quantities of each to create a labeled probe.  Equal volumes of nuclear extract (from 3x10
6
 cells) 
were then incubated for 20 minutes with 200 fmol of biotinylated probe, 1 μg poly(I)-poly(C), 
binding buffer (Thermo Scientific), 2.5% glycerol, 50 mM KCl, 1 mM DTT, and 1 mM EDTA.  
Supershift assays were performed by the addition of 2 μg of supershift grade rabbit anti-STAT1α 
p91 (Santa Cruz Biotechnology, sc-591x) or normal rabbit IgG (Santa Cruz Biotechnology, sc-
2027) for 20 minutes on ice prior to the addition of nuclear extract at room temperature for an 
additional 20 minutes.  The protein-DNA complexes were resolved on a native 5% 
polyacrylamide gel (Bio-Rad) in 0.5x TBE buffer prior to transfer to a positively charged nylon 
membrane (Bio-Rad).  Transferred DNA was crosslinked to the membrane using a commercial 
UV light crosslinking instrument (UV Stratalinker 2400, Stratagene) at 120 mJ/cm
2
 using the 
auto crosslink function.  Shifts of the biotinylated DNA probe were detected using a streptavidin-
horseradish peroxidase conjugate and chemiluminescent substrate (Thermo Scientific). 
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Quantitative Reverse Transcriptase PCR 
BMDC (3x10
6) were treated with IFNγ and/or infected with the RH parasite strain prior to 
isolation of total RNA using the E.Z.N.A Total RNA Miniprep kit (Omega Bio-Tek).  Samples 
were treated on column with DNase I (Agilent Technologies) during the total RNA isolation.  
cDNA was synthesized from total RNA using qScript cDNA SuperMix (Quanta Biosciences).  
Quantitative PCR was performed on cDNA samples using the SYBR green method (Quanta 
Biosciences) and the ABI Prism 7500 sequence detection system (Applied Biosystems).  
Expression of target genes was normalized to the housekeeping gene GAPDH, and the relative 
expression of treated samples versus an untreated control sample was calculated using the ∆∆CT 
method.  The primer sequences employed were: Irf1 forward: 5’-
TTGGCATCATGGTGGCTGT-3’; Irf1 reverse: 5’-AAGGAGGATGGTCCCCTGTTT-3’; 
Lrg47 forward: 5’-GAGACTGTGGCAACATTGTCCC-3’, Lrg47 reverse: 5’-
CCGATGACTCGAAGTGCATTG-3’; GAPDH forward: 5’-AATGGTGAAGGTCGGTGTG-3’, 
GAPDH reverse: 5’-GTGGAGTCATACTGGAACATGTA-3’; Irf1 promoter forward: 5’-
AGCTCTACAACAGCCTGATTTCCC-3’, Irf1 promoter reverse: 5’-
GCGCCGCGAAGAAATCTAAACACT-3’. 
 
Chromatin Immunoprecipitation (ChIP) 
An anti-total-STAT1α antibody (ChIP grade, Santa Cruz Biotechnology, sc-591x) was used to 
precipitate STAT1-bound chromatin fragments.  Normal rabbit IgG (Santa Cruz Biotechnology, 
sc-2027) was used as a negative control antibody.  Assays were performed using the Magna 
ChIP G Chromatin Immunoprecipitation kit (Millipore, catalog no. 17-611) according to the 
manufacturer’s instructions.  Briefly, BMDC (107/sample) were collected and fixed in 1% 
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formaldehyde for 5 minutes at room temperature.  Fixation was stopped by addition of glycine to 
the mixture.  Samples were washed with cold PBS and resuspended in cell lysis buffer 
(Millipore) supplemented with protease inhibitors for 15 minutes at 4°C.   Resulting nuclear 
pellets were spun down and resuspended in nuclear lysis buffer (Millipore) prior to chromatin 
shearing by sonication in an ice bath with twelve, thirty second pulses at high power using the 
Bioruptor (Diagenode).  Immunoprecipitation of the sheared chromatin was carried out overnight 
at 4°C via addition of dilution buffer (Millipore), antibody (2 μg), and protein G magnetic beads.  
Beads were washed, protein/DNA crosslinks were reversed, proteins were digested with 
Proteinase K, and immunoprecipitated DNA was eluted per manufacturer’s instructions.  The 
retrieved DNA was then subjected to amplification by quantitative real-time PCR using 
promoter-specific primers.  Immunoprecipitated samples were normalized to respective input 
controls (10% of input sheared chromatin). 
 
Statistical Analysis 
Statistically significant differences between groups were assessed using the unpaired Student’s 
T-test.  Values for p<0.05 were considered significant.  All experiments were performed a 
minimum of three times. 
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Results 
Toxoplasma alone induces rapid and sustained phosphorylation and nuclear translocation 
of STAT1 in BMDC 
In order for STAT1 to be active as a transcription factor, it must be phosphorylated on a key 
tyrosine residue (Tyr701) prior to translocation to the nucleus (51).  To determine if parasites 
alone induce activation of STAT1, murine BMDC were infected with representative strains of 
the three primary clonal lineages of Toxoplasma (Type I – RH, Type II – PTG, Type III – 
M774.1), then fractionated into nuclear and post-nuclear extracts prior to immunoblot analysis 
with a phospho-STAT1-Tyr701 specific antibody (Figure 2.1A).  Cells treated with IFNγ (100 
ng/ml) served as a positive control.  As expected, BMDC responded to IFNγ treatment with 
robust STAT1 phosphorylation and nuclear translocation, peaking at the early 30 minute time 
point.   Unexpectedly, infection with Toxoplasma alone also induced phosphorylation and 
nuclear translocation of STAT1, independent of strain type. (Figure 2.1A).  In contrast to IFNγ, 
Toxoplasma-mediated STAT1 phosphorylation was slower to develop, reaching peak levels at 
later timepoints.  STAT1 phosphorylation declined over time with the type III strain M774.1 
(Figure 2.1A), and this correlated with poor survival of that particular strain.  Infection with 
another type III strain (CTG) resulted in sustained STAT1 activation (data not shown).  
Phosphorylation of a key serine residue (Ser727) is thought to be required for maximal 
transcriptional activity of STAT1 (25).  Although not as strong as with IFNγ treatment, 
Toxoplasma infection was capable of inducing sustained STAT1 Ser727 phosphorylation (Figure 
2.1A).  Therefore, Toxoplasma infection alone induces activation of STAT1 and mediates its 
translocation to the nucleus. 
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Figure 2.1.  Toxoplasma induces STAT1 phosphorylation and nuclear translocation in 
BMDC.  (A)  BMDC were left in medium alone (Med), infected with type I (RH), II (PTG) or 
III (M774.1) strains of Toxoplasma (3:1 ratio of parasites to cells), or treated with murine IFNγ 
(100 ng/ml), prior to fractionation into cytoplasmic (C) and nuclear (N) extracts at the time 
points indicated.  Samples were subjected to immunoblot analysis for phospho-Tyr701-STAT1 
(pY-STAT1) and phospho-Ser-STAT1 (pS-STAT1).  PARP and Rab5a served as loading 
controls for nuclear and cytoplasmic fractions, respectively.  (B)  Cells were infected with live 
parasites of the three strains as in (A) or exposed to heat-inactivated (HI) tachyzoites for six 
hours.  Cytoplasmic and nuclear fractions were collected and immunoblot analyis was performed 
as in (A).  (C)  RH parasites were pre-treated for 10 min on ice with 1 μM cytochalasin D (CytD) 
prior to infection in the continued presence of the drug.  Cells treated with the solvent DMSO 
alone served as controls.  Cells were fractionated after six hours and subjected to immunoblot 
analysis for pY-STAT1.  (D and E)  BMDC were treated with IFNγ or infected with RH in 
comparison with either the cps1-1 replication-deficient strain (D) or the ∆ROP16 strain (E).  
Samples were fractionated after 6 and 20 hours and subjected to immunoblot analysis for pY-
STAT1.  All experiments were repeated at least three times with similar results. 
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STAT1 activation requires invasion by live parasites, and is independent of parasite 
replication and the rhoptry kinase ROP16 
To further explore the mechanism by which parasites could trigger STAT1 phosphorylation, 
BMDC were infected with live parasites or treated with heat-inactivated tachyzoites prior to 
immunoblot analysis.  As evident in Figure 2.1(B), heat-inactivated parasites were unable to 
initiate STAT1 phosphorylation.  To confirm a requirement for active invasion, BMDC were 
infected with Toxoplasma in the presence of cytochalasin D, a drug that blocks actin 
polymerization and thereby also interferes with parasite gliding motility required for cell 
invasion (52).  STAT1 phosphorylation and nuclear translocation were largely absent in the 
presence of the drug, whereas the response to IFNγ stimulation was unaffected (Figure 2.1C).  
Taken together, these results indicate a requirement for active invasion by live tachyzoites for 
parasite-mediated STAT1 activation. 
 
Given the kinetics of parasite-induced STAT1 activation, with increasing levels of 
phosphorylated STAT1 detected at six hours and beyond, we next asked whether parasite 
replication could play a role.  To address this question, a replication-deficient strain known as 
cps1-1 was compared to the parental strain, RH, in terms of STAT1 activation.  The cps1-1 strain 
lacks an enzyme essential for uracil synthesis, and therefore parasite replication does not occur in 
uracil-free medium (50).  BMDC were infected with either RH or cps1-1 in the absence of uracil 
prior to immunoblot analysis.  There was no detectable difference in STAT1 phosphorylation 
between the two strains (Figure 2.1D), indicating that replication of the parasite was not required.  
The requirement for invasion by live parasites for STAT1 phosphorylation implicated a parasite-
derived secretory kinase. The rhoptry kinase ROP16 is known to directly phosphorylate STAT3 
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and STAT6 (53, 54) resulting in inhibition of proinflammatory cytokine production and 
promotion of arginase-1-dependent growth control (49, 55). We therefore asked whether STAT1 
could be a collateral target of ROP16 by comparing BMDC infected with the parental RH strain 
with a ROP16-deleted strain (∆ROP16).  As shown in Figure 2.1E, robust STAT1 
phosphorylation was maintained even in the absence of ROP16. 
 
STAT1 activation is confined to infected cells  
We next asked whether the increasing amount of phosphorylated STAT1 over time occurred 
through secretion of a soluble DC factor in response to infection.  To address this, supernatants 
from BMDC infected overnight were collected, centrifuged and filtered to remove parasites and 
cell debris, then transferred to uninfected BMDC.  Cells treated with supernatants were 
compared with infected cells by immunoblot analysis of pY-STAT1.  IFNγ treatment served as a 
positive control.  Cells infected with each of the three parasite strains (I, II, III) or treated with 
IFNγ demonstrated the expected STAT1 phosphorylation response (Figure 2.2A).  Transferred 
supernatant containing IFNγ was also capable of inducing STAT1 activation, but supernatant 
from infected cells was not sufficient, regardless of strain type (Figure 2.2B).  From these results, 
we conclude that a soluble, secreted factor arising from infection is not involved in parasite-
triggered STAT1 activation. 
 
A closely related possibility was that parasite-initiated upregulation of a DC surface membrane-
bound molecule might trigger STAT1 activation in bystander cells. To address this possibility, 
BMDC were infected with a low infection ratio of 0.5 parasites per cell overnight prior to flow 
cytometric analysis for pY-STAT1 expression (Figure 2.2C-E).  The cell population was first 
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analyzed in terms of infection status (p30/SAG-1 positive, Figure 2.2C), then gated into separate 
uninfected (Figure 2.2D) and infected (Figure 2.2E) subpopulations to compare pY-STAT1 
expression (blue line) versus the isotype control (red line).  Unlike the uninfected group (Figure 
2.2D), cells infected with RH showed a shift in pY-STAT1 expression relative to isotype control 
(Figure 2.2E), confirming that STAT1 phosphorylation is confined to infected cells. 
 
 
 
Figure 2.2.  STAT1 phosphorylation is confined to infected cells.  (A) BMDC were left in 
medium alone (Med), infected with type I (RH), type II (PTG) or type III (M774.1) strains of 
Toxoplasma (3:1 ratio of parasites to cells) or treated with murine IFNγ (100 ng/ml).  After 22 
hours supernatants were collected (22hr sup), centrifuged and filtered to remove debris and 
parasites, and subsequently transferred to additional untreated/uninfected BMDC for an 
additional 20 hours (B).   For all samples (A and B), cytoplasmic (C) and nuclear (N) fractions 
were prepared and subjected to immunoblot analysis with phospho-Tyr701-STAT1 (pY-STAT1).  
PARP and Rab5a served as cytoplasmic and nuclear loading controls, respectively.  (C - E)  
Cells were infected with the RH strain at a ratio of 0.5 parasites/cell for 20 hours, then subjected 
to intracellular staining for Toxoplasma (anti-p30/SAG-1) and pY-STAT1 prior to flow 
cytometric analysis.  BMDC were gated on uninfected (D) and infected (E) populations to assess 
pY-STAT1 expression (blue lines) relative to staining with an isotype control antibody (red 
lines).  All experiments were repeated at least twice with similar results. 
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Parasite-induced nuclear STAT1 binds IFN-γ-activated sequences (GAS) in vitro  
Since Toxoplasma infection triggered STAT1 phosphorylation and nuclear translocation, we 
asked whether the activated STAT1 was indeed functional.  When IFNγ-activated STAT1 
homodimers translocate to the nucleus, they recognize and bind a palindromic IFNγ-activated 
consensus sequence (GAS) in the promoters of responsive genes in order to initiate transcription 
(56).  To assess STAT1 binding, a transcription factor binding assay was performed whereby 
nuclear extracts from IFNγ-treated or parasite-infected BMDC were incubated with plate-
immobilized STAT1 consensus sequences.  Binding activity was subsequently detected using an 
anti-STAT1 antibody and quantified using an ELISA-based method.  As shown in Figure 2.3, 
treatment with the positive control IFNγ or infection with the parasite strain RH (Tg) induced 
significant STAT1 binding activity. Addition of a competitive oligonucleotide (cOligo) reduced 
STAT1 binding to the medium control activity (set to 1), establishing binding specificity.  
Addition of a mutated oligo (mOligo) that could not compete for binding restored STAT1 
binding activity to initial values in both cases.  We conclude that Toxoplasma-triggered nuclear 
STAT1 is capable of recognizing and binding IFNγ-responsive consensus sequences. 
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Figure 2.3.  Toxoplasma induces in vitro STAT1 binding activity in BMDC.  Nuclear extracts 
were prepared from cells infected with the RH parasite strain (Tg, Toxoplasma gondii; 3:1 
parasites to cells) or treated with IFNγ (100 ng/ml) for 6 hours.  The in vitro binding activity of 
nuclear STAT1 to solid phase IFNγ-activated sequence (GAS) oligonucleotides was assessed 
using an ELISA-based method.  Binding activity is expressed as fold increase over cells cultured 
in medium alone (Med, value of 1).  +cOligo, addition of soluble competitive oligonucleotides; 
+mOligo, addition of mutated non-competitive oligonucleotides.  The experiment was repeated 
three times with similar results.  *, p < 0.05 comparing nuclear extracts alone with nuclear 
extracts plus cOligo.   
 
Toxoplasma and IFNγ together result in synergistic STAT1 phosphorylation and consensus 
sequence binding 
The ability of Toxoplasma to induce STAT1 binding to consensus sequences was surprising, 
given that others have shown that the parasite blocks IFNγ-mediated STAT1-dependent activity 
(38, 39, 41, 42). To determine what impact the parasite may have on IFNγ-induced STAT1 
phosphorylation, BMDC were pre-infected with Toxoplasma for two hours followed by 
subsequent IFNγ treatment.  Cells were infected with Toxoplasma or treated with IFNγ alone for 
comparison, and analyzed by immunoblotting for pY-STAT1.  Toxoplasma alone or IFNγ 
treatment alone triggered STAT1 phosphorylation and nuclear translocation as expected (Figure 
2.4A).  To our surprise, Toxoplasma and IFN-γ together provided a synergistic signal resulting in 
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greatly enhanced STAT1 phosphorylation. Synergistic STAT1 phosphorylation levels were 
maintained and even increased with IFNγ treatment over time (Figure 2.4A).   
 
We next asked whether pre-infection could also enhance IFNγ-induced STAT1 binding to 
labeled gamma-activated sequence (GAS) oligonucleotides from the Irf-1 promoter in an 
electrophoretic mobility shift assay (EMSA).  Upon binding of its receptor, IFNγ triggers 
formation of a phosphorylated STAT1 homodimer known as gamma-activated factor (GAF) that 
is capable of binding to GAS elements in responsive promoters (51).  As expected, 30 minutes of 
IFNγ stimulation resulted in strong binding to the labeled GAS oligonucleotides (Figure 2.4B).  
Addition of anti-STAT1 antibody but not normal rabbit IgG resulted in a supershift, indicating 
that the single complex contained STAT1, consistent with GAF (Figure 2.4C).  When 
Toxoplasma alone was added to cells, no consistent shifts were detected (Figure 2.4B), although 
this is likely due to lack of assay sensitivity because oligonucleotide binding was observed in the 
transcription factor ELISA (Figure 2.3).  Previous studies have indicated that Toxoplasma pre-
infection reduces GAF formation in IFNγ-treated cells (32, 41).  However, when BMDC were 
pre-infected for two hours and subsequently treated with IFNγ for 30 minutes, no reduction in 
GAF was observed (Figure 2.4B).  Additionally, synergistic GAF formation was evident 
following IFNγ treatment for 2, 4 or 22 hours (Figure 2.4B).  Interestingly, Toxoplasma in 
combination with IFNγ also induced an aberrant complex with lower electrophoretic mobility 
than GAF.  We further explored this through a time course, noting that formation of this second 
complex increased over time, peaking at 22 hours (Figure 2.4B).  Supershift experiments 
confirmed that the aberrant complex also contained STAT1 (Figure 2.4C).  Taken together, these 
 87 
data demonstrate that Toxoplasma pre-infection of BMDC leads to synergistic activation and 
binding of atypical STAT1 complexes to GAS sequences in response to IFNγ. 
 
 
 
 
Figure 2.4.  Toxoplasma synergizes with IFNγ in terms of phosphorylation and in vitro 
binding activity of STAT1.  BMDC were left in medium alone (Med), infected with 
Toxoplasma (Tg, RH strain) at a ratio of 3 parasites per cell, treated with IFNγ (100 ng/ml), or 
infected with Toxoplasma followed 2 hours later by IFNγ treatment for the indicated times.  In 
(A), cells were fractionated into cytosolic (C) and nuclear (N) extracts prior to immunoblot 
analysis for phospho-Tyr701-STAT1 (pY-STAT1).  PARP and Rab5a served as loading controls 
for nuclear and cytoplasmic fractions, respectively.  In (B) and (C), nuclear extracts were tested 
for binding to biotinylated probes containing the gamma-activated sequence (GAS) from the Irf-
1 promoter by EMSA.  Supershift assays were also performed with samples in (C) using an 
antibody against STAT1α or normal rabbit IgG as a negative control.  Experiments were 
repeated at least three times with similar results.  GAF, gamma-activated factor (STAT1 
homodimer). 
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Toxoplasma blocks IFNγ-induced, STAT1-dependent responses despite STAT1 activation 
Given the evidence of STAT1 activation and binding in Toxoplasma-infected BMDC, we 
hypothesized that in this cell type, tachyzoites may promote IFNγ/STAT1-dependent gene 
expression, even though in other cell types the parasite has the opposite effect.  To address this, 
we utilized real-time quantitative PCR to examine the expression of known STAT1-dependent 
genes triggered by IFNγ stimulation, including the transcription factor interferon regulatory 
factor 1 (Irf1) (28, 29), and members of the p47 GTPase family known to be essential for 
survival during in vivo infection, Lrg-47 and Igtp (17, 20, 57, 58).  As expected, treatment with 
IFNγ resulted in induction of both Irf1 (Figure 2.5A) and Lrg-47 (Figure 2.5B), with peak fold 
induction over untreated samples at two hours post treatment.  However, despite evidence of 
activated STAT1 in infected cells, Toxoplasma infection alone did not result in induction of the 
same genes (Figure 2.5A and B).  Furthermore, when cells were first pre-infected for two hours 
followed by IFNγ stimulation, expression of the IFNγ-inducible target genes was blocked by 
presence of the parasite (Figure 2.5A and B).  Expression of the p47 GTPase Igtp was also 
examined with similar results (data not shown).   
 
To further explore the mechanism behind the parasite-mediated block in gene expression, we 
next asked whether activated STAT1 present in the nucleus could bind to the native promoter of 
an IFNγ responsive gene.  Toxoplasma is known for the ability to interfere with permissive 
chromatin remodeling and thereby prevent binding of transcription factors to various promoters 
(41, 59, 60).  To address this possibility in BMDC, we performed chromatin 
immunoprecipitation (ChIP) assays using an anti-STAT1 antibody.  Precipitated DNA was 
subsequently amplified by quantitative PCR using primers specific for the Irf1 promoter.  As 
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anticipated, IFNγ induced strong STAT1 binding to the native Irf1 promoter (Figure 2.5C).  In 
contrast, pre-infection with Toxoplasma resulted in blockage of IFNγ-mediated binding while 
infection alone resulted in little to no binding (Figure 2.5C).  Taken together with the gene 
expression results (Figure 2.5A and B), these data indicate that although activated STAT1 can 
bind target oligonucleotides (Figure 2.3, Figure 2.4B and C) and translocate into the nucleus of 
infected cells (Figure 2.1), transcriptional activity at STAT1-dependent, IFNγ-responsive genes 
remains blocked by the parasite.  Therefore, our data reinforce the importance of an IFNγ-
transcriptional blockade as an immune evasion mechanism in dendritic cells.  We also 
demonstrate that the parasite itself triggers phosphorylation and nuclear translocation of STAT1. 
The function of STAT1 in the latter context remains to be determined. 
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Figure 2.5.  Toxoplasma blocks IFNγ-driven STAT1-dependent gene induction.  BMDC 
were infected with the RH strain of T. gondii (Tg, ratio of 3 parasites/cell), treated with treated 
IFNγ (100 ng/ml), or pre-infected for 2 hours with RH prior to addition of IFNγ (Tg+IFNγ). At 
the indicated time points post cytokine treatment, total RNA was harvested and reverse-
transcribed to cDNA prior to qPCR amplification of the IFNγ-responsive, STAT1-dependent 
genes Irf-1 (A) and Lrg-47 (B).  Fold change in gene expression is expressed relative to BMDC 
in medium alone.  Samples were normalized to the house-keeping gene GAPDH.  To assess 
native chromatin binding, ChIP was performed using an anti-STAT1α antibody followed by 
qPCR amplification with primers specific for the Irf-1 promoter (C).  Experimental conditions 
are replicated as in (A and B), with a time point of 2 hours shown.  In (C), fold change in 
promoter binding is expressed relative to untreated cells (Med).  Samples were normalized to 
input chromatin.  Experiments were repeated at least three times with similar results. 
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Discussion 
Subversion of host immune responses, particularly those induced by the IFNγ/STAT1 signaling 
cascade, is now recognized as a key feature that contributes to the success of Toxoplasma as a 
parasitic organism. Although IFNγ is required for host defense, the response must also be 
partially counteracted to allow persistent life-long infection.  Blockade of IFNγ-mediated 
transcription in infected cells as a means of immune evasion has been previously demonstrated in 
a range of cell types.  In our study, we further highlight the prime importance of immune evasion 
in dendritic cells that are strategically situated at the front line of the host response to infection. 
 
A key signaling intermediate downstream of IFNγ in anti-parasite immune responses is the 
transcription factor, STAT1.  We initially anticipated that Toxoplasma would interfere with 
STAT1 activity in BMDC, either during the phosphorylation process as previously demonstrated 
in RAW264.7 cells (39) or by blocking downstream transcription as supported by others (36, 38, 
40-42).  Therefore, we were surprised to discover that Toxoplasma itself induces STAT1 
phosphorylation and nuclear translocation.  Concurrent with our work, another group recently 
published similar findings in human fibroblasts, confirming our results (42).  We considered the 
possibility that STAT1 could be activated by the parasite rhoptry kinase ROP16, since that 
kinase is already known to phosphorylate STAT3 and STAT6 (53, 54). However, in contrast to 
the other group’s findings (42), we found that parasite-induced STAT1 phosphorylation is not 
dependent on the rhoptry kinase ROP16 because we observed STAT1 activation in response to a 
Type II strain, which possesses an inactive ROP16 allele. Furthermore, a Type I strain in which 
ROP16 was genetically deleted retained STAT1 activation capability.  The reason for this 
discrepancy is unclear, but could be due to the species and cell type differences between studies.  
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Nevertheless, we conclude that Toxoplasma induces ROP16-independent STAT1 
phosphorylation and nuclear translocation in BMDC. 
 
We do not yet know how STAT1 is activated by the parasite.   However, we note that although 
ROP16 plays a role in maintaining STAT3 activation in infected cells, there is a substantial 
ROP16-independent STAT3 phosphorylation response during early infection (49). We 
considered whether this unknown ROP16-independent pathway could also be responsible for 
parasite-induced STAT1 phosphorylation. However, this scenario seems unlikely given that 
robust ROP16-independent STAT3 phosphorylation occurs very rapidly (within the first 15 
minutes) whereas parasite-induced STAT1 phosphorylation increases gradually over time.  In 
terms of STAT1 phosphorylation, active invasion by parasites is necessary. Yet, in the presence 
of cytochalasin D, a drug that prevents invasion while allowing discharge of rhoptries but not 
dense granules (61), STAT1 activation is prevented. This raises the possibility that a dense 
granule protein might activate STAT1, particularly insofar as dense granule protein GRA15 has 
recently been implicated in NFκB activation in the host cell (62).  We note in that study 
activation of NFκB by GRA15 occurs with delayed kinetics, requiring ~4 hours after infection to 
achieve substantial p65 nuclear accumulation.  The kinetics correlate with those we see during 
Toxoplasma-mediated STAT1 activation.  We do not anticipate that GRA15 itself targets STAT1, 
given that only type II parasites express the active protein whereas we see strain-independent 
STAT1 phosphorylation, but nonetheless another dense granule protein could be responsible. 
 
Interestingly, the combination of T. gondii and IFNγ synergized to stimulate potent STAT1 
activation and nuclear translocation. It is not clear whether synergistic phosphorylation is 
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mediated via cross-talk of parasite and IFNγ-induced signaling pathways, or rather whether 
failure to dephosphorylate activated STAT1 could be the cause.  It is possible that parasite 
infection down-regulates the IFNγ-induced expression of phosphatases such as suppressor of 
cytokine signaling 1 (SOCS1), known to negatively regulate STAT1 signaling. In this regard, 
IFNγ-mediated SOCS1 expression has been shown to be repressed by the parasite (40, 41). 
However, other data suggest that Toxoplasma induces SOCS1 expression in a ROP16-dependent 
manner (39, 55).  Clearly, further work is required to determine the biologically relevant role, if 
any, of Toxoplasma-mediated interference of phosphatase activity. 
 
In addition to synergistic STAT1 phosphorylation, we observed formation of an aberrant 
STAT1-containing complex, capable of binding to GAS oligonucleotides in vitro.  A similar 
complex was noted by Lang et al in murine macrophages (41). In that study, Toxoplasma 
reduced IFNγ-mediated STAT1 homodimer formation by inducing formation of the aberrant 
complex. We did not observe a similar reduction and in fact both complexes increased over the 
24 hour time course of infection.  We also did not observe GAF formation in response to IFNγ at 
time points beyond 30 minutes by EMSA despite still being able to detect phosphorylated 
STAT1 in the nucleus by immunoblot analysis.  We attribute this to a difference in assay 
sensitivity, given that IFNγ-mediated STAT1 phosphorylation is substantially reduced at later 
time points as part of a negative feedback response (Figures 2.1A and 2.4A).  Assay sensitivity 
differences may also explain why we could detect an ~2-fold increase in oligonucleotide binding 
in response to IFNγ after 6 hours by the ELISA-based method (Figure 2.3) that was not seen later 
on with the EMSA method at a similar time point (Figure 2.4B).  Regardless, an aberrant 
STAT1-containing complex did accumulate substantially over time in the parasite plus IFNγ-
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treated group.  Thus, it is possible that the additional parasite or host proteins involved may play 
a role in the mechanism of inhibition of IFNγ/STAT1-dependent gene transcription.  Such a 
protein could allow binding of STAT1 to oligonucleotide sequences in vitro, but alter 
interactions with native chromatin and/or chromatin modifiers to prevent in vivo transcriptional 
activity of STAT1.   
 
Our data corroborate previous studies with other cell types showing that Toxoplasma blocks the 
transcription of IFNγ-responsive, STAT1-dependent genes.  This occurs despite the parasite's 
ability to activate STAT1. It is possible that Toxoplasma-activated STAT1 retains function in the 
regulation of a unique subset of genes, distinct from IFNγ-responsive, STAT1-dependent genes 
such as Irf1 and the p47-GTPases.  Indeed, a microarray study performed in bone marrow-
derived macrophages identified a subset of IFNγ-responsive genes that were up-regulated by the 
presence of the parasite (41).  That study was not performed in STAT1 null macrophages to 
determine whether STAT1 was required for the increase in transcription.  It would be of interest 
in the future to perform microarray studies in infected BMDC in the presence and absence of 
STAT1 to determine what role, if any, Toxoplasma-activated STAT1 plays in the host response 
to infection.  
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CHAPTER 3 
Unraveling the Mechanisms of STAT1 Phosphorylation and Inhibition of  
IFNγ/STAT1-dependent Transcriptional Activity by Toxoplasma gondii
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Abstract 
Evasion of the host immune response is critical to success for the protozoan parasite, 
Toxoplasma gondii.  Critical to host defense is the antimicrobial cytokine, IFNγ.  STAT1 is an 
important transcription factor responsible for many IFNγ-dependent antimicrobial effector 
functions.  Although the parasite can block IFNγ-dependent STAT1 transcriptional responses, 
some STAT1 phosphorylation is induced by Toxoplasma alone, which is further enhanced by 
addition of IFNγ.  How exactly the parasite inhibits IFNγ-dependent STAT1 activity, induces 
STAT1 phosphorylation, and causes synergistic STAT1 phosphorylation with IFNγ remains 
unknown.  Here we show that the parasite inhibits STAT1 transcriptional activity independently 
of strain type in murine dendritic cells.  The inhibition likely occurs independently of STAT3, 
despite evidence of STAT1/STAT3 association in infected cells.  In investigating parasite-
induced STAT1 phosphorylation further, we find the parasite rhoptry proteins ROP18 and 21 are 
not responsible.  In addition, we exclude parasite-triggered GiPCR, PI3K/AKT and MyD88-
dependent TLR pathways in the mechanism of STAT1 phosphorylation and synergy with IFNγ.  
By contrast, we find that IFNγ-mediated induction of a negative regulator of IFNγ signaling, 
SOCS1, is repressed by the parasite, correlating with the observed synergistic STAT1 levels in 
the presence of IFNγ.  These results serve to further enhance our knowledge about how 
Toxoplasma modulates STAT1 phosphorylation and transcription, pointing out new directions 
for future mechanistic studies. 
 
 
104 
 
Introduction 
Approximately 30% of the world’s human population is infected with the highly successful 
protozoan parasite, Toxoplasma gondii (1).  For most healthy individuals, the infection is 
asymptomatic; however, consequences can be severe for the immuno-compromised (2).  
According to the Centers for Disease Control 2011 estimates for foodborne illness, this member 
of the phylum Apicomplexa ranks 2
nd
 among pathogens causing foodborne-related deaths and 4
th
 
in terms of hospitalizations in the United States (3).  In addition, this parasite causes severe 
abnormalities or death in neonates that acquired the infection in utero (4).  Acute infections can 
be managed with a lengthy course of potentiated sulfa antibiotics, but potentially serious side 
effects can occur (5).  In addition, the parasite can establish a life-long infection by the 
establishment of cysts within tissues, with potential to recrudesce later in life (6).  Acquiring a 
better understanding of how this protozoan hijacks the host immune response is therefore of 
great interest in the design of future therapeutics and prophylactics. 
 
Most Toxoplasma isolates found in people and domestic animals in North America can be 
assigned to three main clonal lineages, designated as type I, type II and type III (7).  A fourth 
clonal type has also recently been described in North American wildlife (8, 9).  The clonal 
lineage of the parasite is important as this can influence the ability of the Toxoplasma to 
modulate the host’s immune response and thereby impact the clinical outcome of infection.  In 
mice, type I strains are universally lethal during acute infection, whereas type II and III strains 
are much less virulent and are capable of establishing chronic infection (10).  Although type II 
strains are most commonly isolated from people in North America, type I strains have been 
implicated more frequently in cases of ocular disease (11).  Despite high sequence similarity, the 
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three strains differ in some key proteins that are secreted into the host cell upon invasion.  
ROP16 is an example of key rhoptry protein known to regulate the host immune response.  
ROP16 from type I and III strains phosphorylates STATs 3 and 6 (12, 13), leading to inhibition 
of pro-inflammatory cytokine signaling and promotion of arginase-1-dependent growth control 
(14, 15).  Additional strain-dependent parasite molecules shown to modulate host immune 
responses include ROP18 (reviewed in (16)), ROP5 (17-21), and the dense granule protein, 
GRA-15 (15, 22, 23).  These mechanisms and others for inhibition of host responses become 
vital as the parasite is known to trigger host signaling pathways including several toll-like 
receptors as well as GiPCRs, PI3K/AKT, and MAPKs (reviewed in (24)).  The balance between 
pathogen detection and immune evasion helps determine survival of the pathogen versus the 
host. 
 
Among the most important immune system components targeted by Toxoplasma is the interferon 
gamma (IFNγ) response to the parasite.  This cytokine, produced largely by T cells and NK cells, 
is critical to controlling parasite replication through various antimicrobial mechanisms in both 
mice and humans (25-30).  IFNγ exerts its effects through activation of a Janus kinase 
(JAK)/signal transducer and activator of transcription (STAT) pathway.  Briefly, binding of IFNγ 
to its receptor stimulates phosphorylation of key JAK molecules (JAKs 1 & 2), resulting in JAK-
mediated phosphorylation of the receptor.  STAT1 is then recruited to the receptor and is in turn 
phosphorylated on a key tyrosine residue (Y
701
).  STAT1 homodimers form and translocate to 
nucleus where they initiate gene transcription (31-33).  One of the genes induced in a STAT1-
dependent manner is interferon regulatory factor-1 (Irf1), itself a transcription factor that induces 
transcription of additional genes (34, 35).  STAT1 has been shown to be critical to survival of 
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acute Toxoplasma infection (36, 37), while mice deficient in IRF1 also demonstrate increased 
susceptibility (38).  Thus, the IFNγ/STAT1 pathway is a prime target for immune-evasion by the 
parasite. 
 
Toxoplasma has previously been shown to block IFNγ-mediated gene expression at the level of 
key individual genes, such as Irf1, as well as globally as determined by microarray analysis (23, 
39-50).  This inhibitory capacity has been identified in a variety of cell types including bone 
marrow-derived macrophages (BMDM), dendritic cells (BMDC), human fibroblasts, the 
RAW264.7 monocyte/macrophage cell line, astrocytes, and microglia.  Recent studies implicate 
a mechanism involving impairment of transcription factor binding within the nucleus, likely 
involving regulators of chromatin remodeling (23, 46, 49, 50).  In those studies, IFNγ-induced 
STAT1 phosphorylation remained intact in the presence of parasite.  However, one study in 
RAW264.7 cells indicated that parasite-mediated expression of suppressor of cytokine signaling-
1 (SOCS1), a key regulator of IFNγ/JAK/STAT1 signaling, could block IFNγ-induced STAT1 
phosphorylation (47).  In contrast, others show Toxoplasma can block IFNγ-mediated 
upregulation of Socs1 expression (48, 49).  In addition, we and others have recently shown that 
the parasite infection alone can trigger STAT1 phosphorylation (23, 50), which is enhanced by 
the subsequent addition of IFNγ (50).  Despite this, transcriptional responses to IFNγ remain 
blocked by the parasite.  The parasite molecules involved in STAT1 phosphorylation and 
inhibition of IFNγ-dependent transcription remain unknown. 
 
In this study, we sought to further unravel the mechanisms behind parasite-mediated inhibition of 
IFNγ-induced STAT1 transcriptional activity, parasite-induced STAT1 phosphorylation, and the 
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reason for synergistic STAT1 phosphorylation when combined with IFNγ.  As in our previous 
study, we utilized bone marrow-derived dendritic cells.  DCs are a key cell type in the early 
immune response to Toxoplasma infection, participating in immune activation as well as 
dissemination of the parasite throughout the host (51-54).  This importance is further highlighted 
by studies where mice depleted of DCs succumb to acute infection (55, 56).  Previously, we 
confirmed that parasite-mediated inhibition of STAT1 transcriptional activity also occurs in DCs 
(50).  Here we show that this inhibition occurs independently of parasite strain type and likely 
without STAT3 involvement, despite evidence of STAT1/STAT3 interaction in infected cells.  
We also previously demonstrated that the STAT3/6-directed parasite kinase ROP16 did not 
mediate STAT1 activation (50). Here we show that the rhoptry kinases ROP18 and the 
presumptive kinase ROP21, are also not required for STAT1 phosphorylation.  Further, we found 
no evidence for involvement of parasite-triggered MyD88-, GiPCR- or PI3K/AKT-dependent 
pathways for either parasite-induced STAT1 phosphorylation or synergy with IFNγ.  
Interestingly, infection alone induced modest Socs1 induction that was dependent upon ROP16.  
However, IFN-γ-mediated Socs1 induction was blocked by Toxoplasma regardless of the 
presence or absence of functional ROP16.  Impaired expression of this negative regulator of 
IFNγ signaling by the parasite correlated with the synergistic phospho-STAT1 levels observed.  
These findings provide additional information that will provide new directions in defining the 
precise mechanisms at play. 
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Materials & Methods 
Ethics Statement 
All experiments were performed in strict accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals of the National Institutes of Health.  The Institutional 
Animal Care and Use Committee (IACUC) at Cornell University (permit number 1995-0057) 
approved all protocols prior to use.  Animal suffering was minimized to the greatest extent 
possible. 
 
Mice and Parasites 
Female C57BL/6 mice of 6-8 weeks of age were purchased from either Taconic Farms or the 
Jackson Laboratory.  Female myeloid differentiation primary response gene 88 (MyD88) knock-
out mice (on a partially backcrossed background – 129/Ola x C57BL/6), originally generated by 
Akira et al (57), were kindly provided by Ling Qi (Cornell University).  All mice were 
subsequently housed at the Transgenic Core Mouse Facility (TMCF) under specific pathogen-
free conditions at Cornell University’s College of Veterinary Medicine, which is accredited by 
the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC).  
The following Toxoplasma gondii strain tachyzoites were maintained by bi-weekly passage in 
human foreskin fibroblast (HFF; the American Type Tissue Collection) monolayers in DMEM 
(Life Technologies) supplemented with 1% bovine growth serum (Hyclone), 100 U/ml penicillin 
(Life Technologies) and 0.1 mg/ml streptomycin (Life Technologies): RH (type I), PTG (type 
II), CTG (type III), a ROP18-deleted strain (ΔROP18I), a ROP21-deleted strain (ΔROP21I) and a 
ROP16-deleted strain on an RH background (ΔROP16I).  The rhoptry deleted strains were 
constructed as previously described (14, 58). Parasite cultures were routinely tested every 6-8 
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weeks using a commercial PCR/ELISA-based kit (Roche diagnostics) for Mycoplasma 
contamination. 
 
Bone Marrow-Derived Dendritic Cell (BMDC) Culture 
A single cell suspension was prepared from marrow that was flushed from a femur and tibia of a 
C57BL/6 mouse and reconstituted in BMDC “low” medium consisting of RPMI 1640 (Fisher 
Scientific) supplemented with 100 U/ml penicillin (Life Technologies), 0.1 mg/ml streptomycin 
(Life Technologies), 10% fetal calf serum (Hyclone), 50 μM of 2-mercaptoethanol (Sigma) and 
20 ng/ml of granulocyte/monocyte-colony stimulating factor (GM-CSF, Peprotech).  Cells were 
plated on 100 x 15 mm sterile polystyrene Petri dishes (Fisher Scientific) and incubated at 37°C 
at 5% CO2 for a total period of 9 days.  On day 3, BMDC were supplemented with fresh BMDC 
“low” medium.  On day 6, cells were supplemented with BMDC “high” medium, which 
contained 50 mM of 2-mercaptoethanol (Sigma).  On day 8, GM-CSF alone was added at 200 ng 
per plate.  The non-adherent cells (BMDC) were harvested on day 9, counted, and plated at 3 x 
10
6
 for in vitro infections or cytokine stimulations unless otherwise specified.  Cells were plated 
in complete medium (cDMEM) consisting of DMEM (Life Technologies) supplemented with 
10% bovine growth serum (Hyclone), 50 μM 2-mercaptoethanol (Sigma) and the following 
reagents from Life Technologies: 0.1 mg/ml streptomycin, 100 U/ml penicillin, 3% HEPES, 0.1 
mM non-essential amino acids, and 1mM sodium pyruvate. 
 
In vitro Infections, Stimuli, and Inhibitor Treatments 
Unless otherwise noted, in vitro infections of BMDC with Toxoplasma were performed by the 
addition of 3 parasites per cell.  Synchronization of parasite contact with cells was achieved by 
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brief centrifugation (200 x g, 3 min).  For some samples, cells were treated with 100 ng/ml of 
recombinant interferon-gamma (IFNγ, Peprotech).  In some cases, BMDC were first pre-infected 
with Toxoplasma for 2 hours, followed by IFNγ stimulation for varying time points.  For the 
inhibitor experiments, BMDC were first pre-treated with 50 ng/ml of pertussis toxin (Sigma) or 
50 ng/ml of Wortmannin (Sigma) prior to infection or treatment with IFNγ.   
 
Immunoblot Analysis 
Cells (3 x 10
6
 per sample) were fractionated into cytoplasmic and nuclear fractions using a 
nuclear extract kit (Active Motif) as indicated.  Samples were diluted with 2x SDS sample 
reducing buffer and boiled for 5 minutes.  Proteins were separated by 10% SDS-PAGE, followed 
by electro-transfer to nitrocellulose membranes (Whatman).  Membranes were blocked for 1 
hour at room temperature in Tris-buffered saline containing 0.1% Tween-20 at pH 7.6 (TBST) 
supplemented with 5% nonfat dry milk.  Washes with TBST were performed prior to incubation 
of membranes overnight at 4°C in primary antibody diluted in TBST with 5% bovine serum 
albumin (Calbiochem).  Primary antibodies used included the following (all purchased from Cell 
Signaling): anti-phospho-STAT1-Tyr-701 (catalog no. 9167), anti-phospho-STAT3-Tyr-705 
(catalog no. 9131), anti-PARP (catalog no. 9542) and anti-Rab5a (catalog no. 2143).  
Membranes were washed again prior to incubation with horseradish peroxidase-conjugated anti-
rabbit IgG (Jackson ImmunoResearch, catalog no. 111-035-144) in blocking buffer.  After 
additional wash steps, protein bands were observed using a chemiluminescent detection system 
(Thermo Scientific).  
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Quantitative Reverse Transcriptase PCR (qPCR) 
BMDC were infected with parasite or treated with cytokine for varying time points prior to 
harvesting samples.  Total RNA was isolated using the E.Z.N.A Total RNA Miniprep kit 
(Omega Bio-Tek), which included an on-column DNase digestion step (Agilent Technologies) to 
remove any residual DNA.  cDNA was synthesized from total RNA using qScript cDNA 
SuperMix (Quanta Biosciences).  Quantitative PCR was performed using cDNA as the template 
using SYBR Green chemistry (Quanta Biosciences) and ABI Prism 7500 sequence detection 
system (Applied Biosystems).  The relative expression of target genes in the experimental 
samples were compared to medium alone control samples using the ΔΔCT method, after 
normalization of the target genes to the house-keeping gene GAPDH.  The primer sequences 
used were Irf1 forward: 5’-TTGGCATCATGGTGGCTGT-3’; Irf1 reverse: 5’-
AAGGAGGATGGTCCCCTGTTT-3’; Socs1 forward: 5’- TGTAGCAGCTTGTGTCTGG-3’; 
Socs1 reverse: 5’- CCTGGTTTGTGCAAAGATACTG-3’; Gapdh forward: 5’-
AATGGTGAAGGTCGGTGTG-3’, Gapdh reverse: 5’-GTGGAGTCATACTGGAACATGTA-
3’ (all primers were purchased from IDT Technologies).   
 
Co-Immunoprecipitation Assay 
BMDC were infected with parasites or stimulated with cytokine for the desired time periods.  
Cells were then harvested, wash once in cold PBS and resuspended in 1x lysis buffer (Cell 
Signaling) supplemented with 1 mM fresh PMSF.  Samples were incubated for 10 minutes on ice 
prior to brief sonication for 3 pulses of 5 seconds each.  Cell lysates were then microcentrifuged 
for 10 minutes at 14,000 x g to remove cellular debris and then incubated with primary antibody 
overnight (1:100 dilution).  Primary antibodies were the same as used for immunoblotting.  
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Protein A/G agarose beads (Thermo Scientific) were added to each sample and incubated for 2 
hours at 4°C.  The beads were washed five times with 1x cell lysis buffer, then resuspended in 2x 
SDS reducing sample buffer and boiled to release the antibody complexes.  Beads were pelleted 
and the supernatants were subjected to immunoblot analysis. 
 
Electrophoretic Mobility Shift Assay (EMSA) 
To confirm STAT1 binding to appropriate oligonucleotide probes in nuclear extracts, a 
chemiluminescent EMSA assay was performed using a kit (LightShift kit; Thermo Scientific) as 
indicated.  Briefly, nuclear extracts were incubated for 20 minutes with 200 fmol of biotinylated 
probe designed to include the gamma-activated sequence (GAS) from the Irf1 promoter.  The 
probe consisted of complementary oligonucleotides (5’-CATTTCGGGGAAATCGATC-3’ and 
5’-GATCGATTTCCCCGAAATG-3’; IDT Technologies) labeled at the 5’ ends with biotin that 
were subsequently annealed in equimolar quantities.  Other binding components in the reaction 
included binding buffer (Thermo Scientific), 1 μg poly(I)-poly(C), 1 mM DTT, 1 mM EDTA, 
2.5% glycerol and 50 mM KCl.  In the case of supershift experiments, 2 μg of the appropriate 
antibody was added to the reaction mixture for 20 minutes on ice prior to the addition of the 
nuclear extract for an additional 20 minutes at room temperature.  Supershift-grade antibodies 
were purchased from Santa Cruz Biotechnology and included rabbit anti-STAT1α p91 (catalog 
no. sc-591x) and rabbit anti-STAT3 (clone k-15, catalog no. sc-483), while normal rabbit IgG 
served as a negative control (catalog no. sc-2027).  Resolution of protein-DNA complexes was 
performed via native gel electrophoresis using 5% polyacrylamide gels (Bio-Rad) in 0.5x TBE 
buffer.  The complexes were electrotransferred to a positively-charged nylon membrane followed 
by cross-linking of the DNA to the membrane using a commercial UV light cross-linking 
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instrument (UV Stratalinker 2400, Stratagene) at 120 mJ/cm
2
 using the auto cross-link function.  
Gel shifts were detected using streptavidin-horseradish peroxidase conjugate and 
chemiluminescent substrate (Thermo Scientific). 
 
Statistical Analysis 
Statistically significant differences between experimental groups were determined using the 
unpaired Student’s t-test.  A difference was considered statistically significant if p < 0.05.  
Experiments were performed at least three times. 
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Results 
Inhibition of IFNγ-driven STAT1 transcriptional activity occurs independently of 
Toxoplasma strain type 
We and others have previously documented the ability of the parasite to inhibit IFNγ-driven gene 
expression (23, 46, 48-50).  Although inhibition is thought to involve modulation of chromatin 
remodeling, further details of the mechanism remain unclear.  To address this further, we 
infected BMDC with representatives of the three clonal lineages of Toxoplasma to determine 
whether parasite strain type was an important key to inhibition.  Previously, inhibition was found 
to occur independently of strain type in a HEK293 cell line transduced with a stable GAS 
reporter and in RAW264.7 cells by microarray analysis (23).  We assessed inhibition of IFNγ-
induced expression of interferon regulatory factor 1 (Irf1) by qPCR after pre-infection with the 
different parasite strains.  None of the parasite strains induced significant Irf1 expression on their 
own, whereas IFNγ triggered ~20-22 fold increase (Figure 3.1A).  When cells were pre-infected 
prior to IFNγ addition, both type I and type II strains significantly reduced Irf1 expression with 
no significant difference noted between strains (Figure 3.1A).  Further evidence of a strain-
independent response was apparent when comparing the type I strain with the ROP16-deleted 
strain.  As seen in Figure 3.1B, inhibition of Irf1 expression did not require the presence of 
ROP16.  A type III strain (CTG) was also examined; although this strain could block Irf1 
transcription in some experiments, the inhibition was not always consistent (data not shown).  
We conclude that inhibition of IFNγ-driven STAT1-dependent transcriptional activity does not 
rely on strain-type differences. 
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Figure 3.1.  Toxoplasma-mediated inhibition of IFNγ-induced Irf1 expression occurs in a 
parasite strain-independent manner.  (A)  Comparison of type I versus type II strains in the 
ability to inhibit Irf1 expression.  BMDC were treated with medium alone (Med), IFNγ (100 
ng/ml), or infected with a type I (RH) or type II (PTG) strain of Toxoplasma at a ratio of 3 
parasites per cell for 2 hours.  Some samples were first pre-infected with parasite for 2 hours, 
followed by IFNγ treatment for an additional two hours (I+IFNγ, II+IFNγ).  Total RNA was 
prepared and reverse-transcribed to cDNA prior to qPCR analysis for the Irf1 gene.  Fold change 
in gene expression is plotted relative to medium alone samples (set to 1).  Samples were 
normalized to the house-keeping gene GAPDH.  (B)  Comparison of a ΔROP16 strain with the 
parental type I (RH) strain.   Experiment was performed as in (A) with the exception of the 
parasite strain types used (type I – RH versus Δ16I – ΔROP16 on an RH background).  
Experiments were performed three times with similar results.  * = p < 0.05; ** = p < 0.01, *** = 
p < 0.001 when compared to IFNγ treatment alone.  Ns, not significant. 
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Despite evidence of STAT1/STAT3 association, STAT3 does not contribute to aberrant 
complex formation 
In thinking further about an inhibition mechanism, we considered that the parasite is able to 
induce phosphorylation of both STAT1 and STAT3.  Although partially dependent on ROP16, 
there is also some ROP16/strain-independent STAT3 phosphorylation that occurs in infected 
cells that could potentially play a role (14).  In addition, there was some evidence in the literature 
that STAT3 can associate with STAT1 and lead to impairment of some STAT1-pro-
inflammatory responses (59-61).  To investigate this further in dendritic cells, we performed co-
immunoprecipitation assays to assess STAT1/STAT3 interactions in infected cells.  When cell 
lysates were immunoprecipitated and then immunoblotted for pY-STAT1, we could detect pY-
STAT1 as expected in parasite alone, IFNγ-treated, and parasite plus IFNγ treated groups for 
both time points (Figure 3.2A).  When the same samples were immunoblotted for pY-STAT3, 
we successfully pulled down STAT3 in both Toxoplasma alone and parasite plus IFNγ groups.  
A small amount of STAT3 could be detected with IFNγ alone at 30 minutes that subsequently 
disappeared by 20 hours (Figure 3.2A).  This is not completely unexpected as some STAT3 
phosphorylation in response to IFNγ has been previously reported by others (62).  The reverse 
co-immunoprecipitation experiment was performed to confirm the STAT1/STAT3 interaction.  
As shown in Figure 3.2B, after immunoprecipitation for pY-STAT3, we were able to pull down 
pY-STAT1 in response to parasite alone at 20 hours, as well as in the parasite plus IFNγ group 
for both time points.  Thus, we were able to show an association between STAT1 and STAT3 in 
infected cells, particularly with additional IFNγ treatment, but whether that association was 
functionally relevant required further investigation. 
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Figure 3.2.  STAT3 associates with STAT1 in infected cells, yet does not contribute to 
parasite-induced aberrant STAT1 complex formation.  (A)  BMDC were treated with 
medium alone (Med), IFNγ, or infected with Toxoplasma (Tg, RH strain) at ratio of 3 parasites 
per cell for the time points indicated.  For some samples, cells were first pre-infected with 
parasite for 2 hours followed by treatment with IFNγ for the specified time periods (Tg+γ).  Cells 
were lysed and subjected to immunoprecipitation (IP) using an antibody against phospho-
STAT1-Tyr701 (pY-STAT1).  pY-STAT1 immunoprecipitated samples were then analyzed by 
immunoblot analysis (IB) for pY-STAT1 as a control, and phospho-STAT3-Tyr705 in a co-
immunoprecipitation assay.  (B)  Experiment was performed as in (A), except that samples were 
initially immunoprecipitated with an anti-pY-STAT3 antibody, followed by immunoblot analysis 
for both pY-STAT3 and pY-STAT1.  (C)  BMDC were treated with medium alone or first pre-
infected with Toxoplasma for 2 hours prior to IFNγ addition for 22 hours (Tg 2h + IFNγ 22h).  
At that time, nuclear extracts were prepared and subjected to analysis by a chemiluminescent 
electrophoretic mobility shift assay (EMSA).  A biotinylated probe containing a gamma-
activated sequence (GAS) from the Irf1 promoter was utilized.  Supershift assays were also 
performed using antibodies directed against STAT1 (αSTAT1), STAT3 (αSTAT3), or normal 
rabbit IgG (rab IgG) as a negative control.  GAF, gamma-activated factor (STAT1 homodimer).  
Experiments were performed three times with similar results. 
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We and others had previously shown that Toxoplasma can induce the formation of a gamma-
activated site (GAS)-binding aberrant STAT1-containing complex by EMSA (49, 50).  We 
speculated that whatever was binding to STAT1 in the abnormal complex could play a role in 
inhibition of IFNγ-driven transcriptional responses.  Given the evidence in Figures 3.2A-B that 
STAT3 could associate with STAT1 in infected cells, we hypothesized that STAT3 could be 
contributing to the aberrant complex formation.  To address this, we infected cells for 2 hours 
with Toxoplasma followed by IFNγ stimulation for 22 hours, as these conditions induced the 
most robust aberrant complex formation in the previous study.  An EMSA assay was performed, 
with assessment of Irf-1 GAS sequence binding indicated by the presence of gel shifts.  In the 
absence of any additional antibody, two distinct gel shifts were observed as expected – one 
consistent with gamma-activated factor (GAF, STAT1 homodimer) and a second aberrant 
complex of lesser mobility (Figure 3.2C).   Addition of an αSTAT1 antibody supershifted both 
bands, as expected, whereas the rabbit IgG control antibody had no effect (Figure 3.2C).  
However, when an αSTAT3 antibody was added instead, a supershift was not detected (Figure 
3.2C).  Therefore, although STAT1 can associate with STAT3 in infected cells, this association 
does not explain the aberrant complex formation potentially involved in inhibition of IFNγ-
mediated transcription.  Attempts were also made to identify unique protein bands for further 
analysis in infected cells following STAT1 immunoprecipitation (data not shown).  However, 
such attempts were unsuccessful, leaving the identity of the mysterious binding partner yet to be 
discovered. 
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STAT1 phosphorylation induced by Toxoplasma does not require the parasite rhoptry 
kinases ROP18 and ROP21 
Previously we had shown that the parasite rhoptry kinase ROP16, although already known to 
induce STAT3 phosphorylation, was not required for parasite-mediated STAT1 phosphorylation 
in BMDC (50).  This did not, however, rule out involvement of other rhoptry kinases.  Given our 
access to the deleted rhoptry kinase strains ΔROP18 and ΔROP21, we investigated whether these 
parasite proteins could contribute to the mechanism of parasite-mediated STAT1 
phosphorylation.  ROP18 has been identified in forward genetic screens as a key virulence 
determinant known to phosphorylate certain immunity-related GTPases (IRGs), thereby reducing 
their accumulation at the parasitophorous vacuole membrane (in coordination with another key 
virulence determinant, ROP5) and consequently preventing parasite destruction (reviewed in 
(16)).  In addition, this parasite kinase has been shown to mediate degradation of the host 
endoplasmic reticulum-resident transcription factor activating transcription factor 6 beta 
(ATF6β), leading to impairment of initiation of CD8 T cell adaptive immune responses (63, 64).  
ROP21 is of unknown function, although its nucleotide acid sequence predicts it to be an active 
kinase. While ROP21 has not been identified as a parasite virulence determinant thus far, it has 
been shown to localize to the parasitophorous vacuole membrane, and later during in infection, 
the host cytosol (65).  To determine whether these rhoptry kinases could be involved in STAT1 
phosphorylation, we performed in vitro infections in BMDC.  Nuclear and cytoplasmic extracts 
were assessed for STAT1 tyrosine phosphorylation in cells infected with the wild-type RH strain 
versus the ROP18- and ROP21-deleted strains.  RH parasites and the positive control IFNγ 
induced STAT1 tyrosine phosphorylation as expected in both experiments, at both the 6 hour and 
22 hour time points (Figure 3.3A, B).  However, there were no discernible differences in STAT1 
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phosphorylation when comparing the RH strain to either the ΔROP18 (Figure 3.3A) or ΔROP21 
(Figure 3.3B) strains at either time point examined.  Therefore, we conclude that in addition to 
ROP16, neither ROP18 nor ROP21 are required for Toxoplasma-induced STAT1 tyrosine 
phosphorylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.  ROP18 and ROP21 are not required for Toxoplasma-induced STAT1 
phosphorylation.  (A) BMDC were left in medium alone (Med), treated with IFNγ (100 ng/ml), 
or infected with RH (type 1 parasite) or the ROP18-deleted strain (Δ18) at a 3:1 ratio of parasites 
to cells.  After 6 or 22 hours, cytoplasmic and nuclear extracts were prepared and subjected to 
immunoblot analysis for phospho-STAT1-Tyr701 (pY-STAT1).  PARP and Rab5a served as 
nuclear and cytoplasmic loading controls, respectively.  (B)  BMDC were treated as in (A), with 
the exception that infection with RH was compared to that of a ROP21-deleted strain (Δ21).  
Experiments were performed twice with similar results. 
 
Parasite-mediated STAT1 phosphorylation and synergy with IFNγ do not require MyD88-, 
GiPCR- or PI3K-dependent pathways 
Not only were we seeking a mechanism for parasite-induced STAT1 phosphorylation, but we 
were also interested in understanding why synergistic levels of phospho-STAT1 were achieved 
in the combined presence of Toxoplasma plus IFNγ (50).  In thinking about possible mechanisms 
for both, we investigated other host signaling pathways already known to be triggered by the 
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parasite.  It is well-established that cross-talk that can occur between signaling pathways, such as 
between the toll-like receptor (TLR) and IFNγ-receptor pathways (66-69).  Such signaling 
interactions could potentially lead indirectly to STAT1 phosphorylation in infected cells or even 
explain synergistic phospho-STAT1 levels when parasite and IFNγ were combined.   
 
Toxoplasma is known to activate several TLR pathways through various parasite ligands (Figure 
3.4A).  In fact, MyD88, an important adaptor protein downstream of all TLRs except for TLR3 
(57, 70), is critical for survival during in vivo Toxoplasma infection (71, 72).  
Glycosylphosphoinositol (GPI) anchors derived from Toxoplasma have been shown to activate 
TLRs 2 and 4; however, these TLRs are not thought to be critical to the immune response as 
mice deficient in those TLRs have a mild to no phenotype (73, 74).  TLR11, which recognizes 
Toxoplasma profilin-like protein, is thought to play a role in dendritic cell sensing of the parasite; 
however, TLR11-deficient animals are only modestly affected in terms of survival compared to 
MyD88-deficient mice (75, 76).  Recently, TLR12 was identified as a key sensor of Toxoplasma 
profilin, with TLR12-deficient mice demonstrating acute susceptibility to infection (77, 78).  In 
addition, TLRs 7 and 9 have been recently shown to recognize parasite RNA and DNA, 
respectively (78).  Although deficiency of these individual nucleic-acid sensing TLRs have no to 
modest impact on infection survival, it has become clear that the endosomal MyD88-coupled 
TLRs as group (TLRs 7, 9, 11, 12) act in concert to impart innate resistance to Toxoplasma (78, 
79).  To investigate whether TLR signaling could impact STAT1 phosphorylation, we compared 
infected wild-type and MyD88-deficient BMDC with IFNγ serving as a positive control.  As 
expected, IFNγ-mediated STAT1 phosphorylation was unaffected by the absence of MyD88 
(Figure 3.4B).  When infected cells were compared, it was clear that MyD88-dependent 
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signaling was not required for parasite-mediated STAT1 phosphorylation at both early and late 
time points (Figure 3.4B).  To investigate whether signaling pathway cross-talk could account 
for synergistic STAT1 phosphorylation, we compared wild-type and MyD88 knock-out BMDC 
after first pre-infecting with parasite, followed by IFNγ stimulation.  As seen in Figure 3.4B, 
there was no appreciable difference in STAT1 phosphorylation levels between these groups at 
either early or late time points.  Therefore, TLR signaling pathways dependent on MyD88 are 
not required for either STAT1 phosphorylation due to parasite infection alone or due to synergy 
with IFNγ.   
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Figure 3.4.  Toxoplasma-mediated STAT1 phosphorylation and synergy with IFNγ do not 
require the TLR adaptor protein MyD88.  (A)  Schematic illustrating how Toxoplasma 
ligands activate various TLRs in a MyD88-dependent fashion both on the cell surface and within 
intracellular compartments.  Activation of MyD88-dependent TLRs ultimately leads to activation 
of NFκB and MAP kinase signaling cascades, resulting in pro-inflammatory cytokine 
production.  Tg, Toxoplasma gondii; TgPRF, Toxoplasma profilin; GPI, 
glycosylphosphatidylinositol-anchored proteins.  (B)  Wild-type (WT) BMDC were compared 
with MyD88 knock-out DC (KO) in terms of STAT1 tyrosine phosphorylation.  DC were left in 
medium only (Med), treated with IFNγ (100 ng/ml), or infected with Toxoplasma gondii (Tg, RH 
strain) at a ratio of 3 parasites per cell for the specified time points.  For some samples, BMDC 
were pre-infected with the parasite for 2 hours, followed by IFNγ stimulation for the time points 
indicated (Tg+γ).  Cytoplasmic and nuclear extracts were prepared and subjected to immunoblot 
analysis for phospho-STAT1-Tyr701 (pY-STAT1).  PARP and Rab5a served as nuclear and 
cytoplasmic loading controls, respectively.  The experiment was performed twice with similar 
results. 
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We next considered whether G protein coupled receptor (GPCR)-mediated signaling could 
account for the observed STAT1 phosphorylation response.  Chemokine receptors are known to 
signal through G proteins with an inhibitory alpha subunit (Gαi) (80).  Toxoplasma has 
previously been shown to induce cysteine-cysteine chemokine receptor (CCR)-5-dependent 
interleukin-12 (IL12) production in dendritic cells (81) by secreting Toxoplasma cyclophilin-18 
(TgCyc18) (82).  TgCyc18 has also been shown to induce IL12 and tumor necrosis factor alpha 
(TNFα) in macrophages as well as NO production leading bradyzoite conversion, all in a CCR5-
dependent manner (83).  In addition, Toxoplasma is known to trigger phosphorylation of protein 
kinase B (PKB)/AKT in a non-CCR5 but GiPCR-dependent manner (84).  To explore whether 
GiPCR signaling could play a role in STAT1 phosphorylation, we treated cells with pertussis 
toxin (PTx), which uncouples the Gi protein from the GiPCR via ADP-ribosylation of the Giα 
subunit (85) (Figure 3.5A).  As expected, cells treated with IFNγ as a positive control were 
unaffected by a blockade of GiPCR signaling (Figure 3.5B).  Of note, when BMDC were treated 
with pertussis toxin, some basal STAT1 phosphorylation was observed in the medium alone 
control group at all time points examined (Figure 3.5B).  PTx has been previously reported to 
induce STAT1 phosphorylation in brain endothelial cells, although the mechanism is unknown 
(86).  Regardless, taking the basal STAT1 level into account, it is clear that the STAT1 
phosphorylation response to parasite alone remains intact in the presence of PTx (Figure 3.5B).  
In addition, when cells are infected with Toxoplasma prior to IFNγ treatment, synergistic STAT1 
phosphorylation persists in the presence of the toxin (Figure 3.5B).  We conclude that parasite-
mediated STAT1 tyrosine phosphorylation and synergy with IFNγ do not require GiPCR-
dependent signaling. 
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Figure 3.5.  Gi protein-coupled receptors (GiPCRS) are not required for Toxoplasma-
induced STAT1 phosphorylation or synergy with IFNγ.  (A)  Schematic of a GiPCR-
dependent pathway triggered by Toxoplasma, with the site of action of pertussis toxin (PTx) 
indicated.  The parasite is known to trigger AKT/PKB phosphorylation (pathway indicated in 
bold) in macrophages in a manner sensitive to PTx.  (B)  BMDC were pre-treated with pertussis 
toxin (PTx, 50 ng/ml) for 2 hours or incubated in medium only, prior to the addition of medium 
alone (Med), Toxoplasma (Tg, RH strain) at a ratio of 3 parasites per cell, or IFNγ (100 ng/ml) in 
the continued presence of the drug for the time points indicated.  For some samples, BMDC were 
pre-infected with the parasite for 2 hours, followed by IFNγ stimulation for the specified time 
points (Tg+γ).  Cytoplasmic and nuclear extracts were prepared and subjected to immunoblot 
analysis for phospho-STAT1-Tyr701 (pY-STAT1).  PARP and Rab5a served as nuclear and 
cytoplasmic loading controls, respectively.  The experiment was performed twice with similar 
results. 
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Finally, we considered whether a phosphoinositide 3-kinase (PI3K)-dependent signaling pathway 
could be involved.  As illustrated in Figure 3.6A, Toxoplasma is known to trigger PKB/AKT 
phosphorylation in dependence not only on an unknown GiPCR, but also on PI3K (84).  In 
addition, the parasite can trigger production of a variety of chemokines in macrophages in a 
PI3K-dependent manner (87).   A requirement for PI3K signaling can be explored by treating 
cells with the specific and potent inhibitor, wortmannin (88) (Figure 3.6A).  We treated BMDC 
with wortmannin or with the solvent DMSO alone prior to infecting cells for a STAT1 
phosphorylation time course.  As anticipated, there was no requirement for PI3K in IFNγ-
induced STAT1 tyrosine phosphorylation (Figure 3.6B).  When Toxoplasma-infected cells were 
compared, STAT1 phosphorylation was unaffected by wortmannin treatment (Figure 3.6B).  
Finally, we observed no decrease in synergistic STAT1 phosphorylation when infected cells 
were treated with IFNγ in the presence of inhibitor (Figure 3.6B).  In summary, parasite-
triggered STAT1 tyrosine phosphorylation does not require PI3K, MyD88 or GiPCRs nor does 
the observed synergy with IFNγ rely on cross-talk with such pathways. 
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Figure 3.6.  Phosphoinositide 3-kinase (PI3K) activity is not required for the observed 
impacts of Toxoplasma on STAT1 phosphorylation.  (A)  Diagram of a PI3K-dependent 
pathway initiated by Toxoplasma, with the site of action of the selective PI3K inhibitor, 
wortmannin (Wtm), indicated.  The parasite is known to cause AKT/PKB phosphorylation in 
macrophages in a wortmannin-sensitive manner (pathway indicated in bold).  (B)  BMDC were 
pre-treated with wortmannin (Wtm, 50 ng/ml) or an equivalent concentration of DMSO only 
(solvent control) for two hours prior to addition of medium alone (Med), Toxoplasma (Tg, RH 
strain) at a ratio of 3 parasites per cell, or IFNγ (100 ng/ml) in the continued presence of the drug 
for the time points indicated.  For some samples, BMDC were first pre-infected with the parasite 
for 2 hours, followed by IFNγ stimulation for the time points specified (Tg+γ).  Cytoplasmic and 
nuclear extracts were prepared and subjected to immunoblot analysis for phospho-STAT1-
Tyr701.  PARP and Rab5a served as nuclear and cytoplasmic loading controls, respectively.  The 
experiment was performed twice with similar results. 
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Parasite-mediated inhibition of IFNγ-induced SOCS1 may drive elevated phospho-STAT1 
levels 
One possible mechanism to explain the high levels of phosphorylated STAT1 in infected cells 
treated with IFNγ is signaling pathway synergy.  However, at least in the case of MyD88, 
GiPCRs, and PI3K, that did not appear to be the case (Figures 3.4-3.6).  Alternatively, 
Toxoplasma could be interfering with the regulation of the IFNγ-signaling response, preventing 
the normal dephosphorylation of STAT1.  A key regulator protein induced by IFNγ is suppressor 
of cytokine signaling 1 (SOCS1), a phosphatase that decreases STAT tyrosine phosphorylation 
indirectly by interfering with the upstream Janus kinase (JAK) activity (89).  To determine what 
involvement SOCS1 may play in dendritic cells, we examined Socs1 expression by qPCR 
following IFNγ stimulation or parasite infection.  Given that a strain-dependent induction of 
Socs1 by Toxoplasma had been previously reported in other cell types (15, 47, 90), we initially 
compared a virulent type I strain with a less virulent type II strain.  The type II strain did not 
induce significant Socs1 expression, whereas the type I strain triggered a significant 10-12 fold 
increase (Figure 3.7A).  Furthermore, the ability of the type I strain to induce Socs1 was 
confirmed to be dependent on the rhoptry kinase ROP16, as parasites of the deleted strain (Δ16I) 
could not induce comparable expression (Figure 3.7C).  Parasite induction of Socs1 was modest 
in comparison to IFNγ, however, which triggered ~60-90-fold increases in Socs1 expression 
(Figure 3.7B, D).  However, when infected cells were subsequently treated with IFNγ, Socs1 
levels were significantly reduced in a strain-independent manner ~3 fold when compared to IFNγ 
alone (Figure 3.7B, D).  In summary, although Toxoplasma induces modest ROP16-dependent 
Socs1 expression, IFNγ-mediated upregulation of that key JAK-STAT1 signaling regulator is 
blocked by the parasite.  This suggests a mechanism for the observed high levels of phospho-
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STAT1, whereby the parasite blocks the normal IFNγ-induced negative feedback loop mediated 
in part by SOCS1. 
 
 
 
Figure 3.7.  Despite modest ROP16-dependent induction of Socs1 by Toxoplasma alone, the 
parasite blocks IFNγ-induced Socs1 expression independently of strain type.  (A, C)  BMDC 
were treated with medium alone (Med), IFNγ (100 ng/ml), or infected with various Toxoplasma 
strains (Type I – RH (I), Type II – PTG (II), or ΔROP16 on an RH background (Δ16I)) at a ratio 
of 3 parasites per cell for 2 hours.  Total RNA was prepared and reverse-transcribed to cDNA 
prior to qPCR analysis of the IFNγ-responsive Socs1 gene.  Fold change in gene expression is 
plotted relative to medium alone samples (set to 1).  Samples were normalized to the house-
keeping gene GAPDH.  (B, D)  Cells were treated, prepared, and analyzed as in (A, C), with the 
exception that for some samples, BMDC were first pre-infected with Toxoplasma for 2 hours 
prior to addition of IFNγ for another 2 hours (I+IFNγ, II+IFNγ, Δ16I+IFNγ).  Experiments were 
performed three times with similar results.  * = p < 0.05; ** = p < 0.01, *** = p < 0.001 when 
compared to IFNγ treatment alone.  Ns, not significant. 
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Discussion 
From our studies and others, it has become clear that blockade of IFNγ/STAT1-dependent 
transcriptional responses is a key component of immune evasion by Toxoplasma.  By blocking 
such responses, parasites can successfully maintain the integrity of the parasitophorous vacuole 
against antimicrobial effector mechanisms.  This borrowed time in turn allows the parasite to 
eventually convert to the persistent, life-long state of the bradyzoite, secure within a tissue cyst.  
Yet, paradoxically, the parasite is able to induce some degree of STAT1 phosphorylation on its 
own, in the absence of IFNγ.  Indeed, parasites synergize with IFN-γ to induce high amounts of 
STAT1 phosphorylation. In this study, we ruled out mechanisms for STAT1 transcriptional 
inhibition, phosphorylation and synergy, while implicating parasite-mediated inhibition of IFNγ-
driven Socs1 expression in the mechanism of phospho-STAT1 accumulation. 
 
The precise mechanism of how Toxoplasma inhibits IFNγ/STAT1-dependent gene transcription 
remains unclear.  We speculated that STAT3 could play a role in the inhibition of STAT1 
activity, given that the parasite induces STAT3 phosphorylation directly via ROP16, which has 
profound effects on inhibition of pro-inflammatory cytokine production (12, 14, 15, 91).  In 
addition, there is some evidence to suggest that STAT3 can antagonize STAT1 activity (61, 92).  
However, inhibition of IFNγ-induced gene expression occurs independently of the parasite strain 
type.  Thus, the rhoptry kinase ROP16, which is the major inducer of STAT3 phosphorylation in 
infected cells of the type I or type III clonal lineages, is unlikely to contribute in a major way to 
inhibition of STAT1 activity, a conclusion supported by microarray data performed in the 
RAW264.7 cell line (23).  However, STAT3 involvement could not be completely ruled out as 
some phosphorylation also occurs independently of ROP16 in infected cells.  We found that 
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STAT3 could associate with STAT1 in infected cells.  However, STAT3 was not detected as part 
of an aberrant STAT1-containing GAS-binding complex, a complex speculated to play a role in 
STAT1 inhibition.  Whether STAT3 could contribute to STAT1 inhibition by some other 
mechanism requires further study. 
 
Another intriguing possibility is that the parasite induces transcriptionally active STAT1/STAT3 
heterodimers, which could regulate a distinct subset of genes from IFNγ.  The absence of STAT3 
binding by EMSA could be explained by STAT1/STAT3 heterodimers recognizing a consensus 
sequence distinct from GAS. This hypothesis could explain the role of STAT1 phosphorylation 
in response to parasite alone while also allowing for inhibition of IFNγ transcription by another 
mechanism.  On the other hand, it is possible that what we detected through co-
immunoprecipitation assay was not a STAT1/STAT3 heterodimer, but rather an indirect 
association through an intermediate.  This interpretation could explain the STAT1/3 association 
in response to IFNγ treatment, as IFNγ can induce phosphorylation of both proteins through 
common JAK molecules (62).  Furthermore, the enhanced association of STAT1 and 3 in the 
combined presence of parasite and IFNγ could occur due to impairment of SOCS expression, 
allowing IFNγ-triggered JAKs to continuously induce STAT1/3 phosphorylation.  The functional 
relevance of the parasite-induced STAT1/STAT3 association will be a future area of interest to 
pursue.   
 
STAT1 phosphorylation in Toxoplasma-infected cells without IFNγ stimulation has recently 
been characterized by us and Saeij and colleagues (23, 50).  The mechanism by which this occurs 
remains unknown.  We previously ruled out involvement of the rhoptry kinase ROP16, known to 
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phosphorylate host STAT3 and STAT6 (50).  Here, we rule out involvement of additional 
parasite rhoptry proteins, ROP18 and ROP21.  From our previous work, we would not 
necessarily have expected a polymorphic rhoptry kinase to play a role, as STAT1 
phosphorylation occurs in infected dendritic cells regardless of parasite strain type (50).  This 
complicates elucidation of the mechanism of STAT1 phosphorylation, as most of the key 
secreted parasite effector proteins have been identified and characterized through pair-wise 
genetic crosses between strain types, with subsequent analysis for genome loci that account for 
virulence differences (reviewed in (93)).  It seems more likely that the parasite molecule 
accounting for STAT1 phosphorylation is not involved in determining such virulence 
differences, but rather is a common feature among the three main strain types.  Indeed, the 
dominant Toxoplasma clonal lineages only differ from one another by ~1-2% in terms of genome 
sequence (10), so to have a strain-independent response would not be unexpected.   
 
We hypothesize that a parasite dense granule protein may be responsible, as the delayed kinetics 
of STAT1 phosphorylation compared to STAT3 phosphorylation would suggest (50).  Dense 
granule protein exocytosis does not generally occur until the parasite has completed 
parasitophorous vacuole formation, continuing throughout the intracellular infection (94, 95).  In 
addition, the similar delayed kinetics of NF-κB activation due to activity of the dense granule 
protein GRA-15 lend further support to this idea (22).  Although GRA-15 appears to be active in 
type II strains only, another dense granule protein expressed independent of strain type, such as 
GRA-7 (96), would be a candidate effector.  At this point it remains unclear whether parasite-
activated STAT1 serves a purpose during infection distinct from that of IFNγ, or whether STAT1 
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is activated in a bystander fashion at low levels, rendered irrelevant due to potent downstream 
transcriptional repression. 
 
Toxoplasma blocks IFNγ/STAT1-dependent transcription, yet does not negatively impact 
STAT1 phosphorylation in response to IFNγ in the majority of cell types examined.  In fact, in 
infected dendritic cells we observed synergistic levels of STAT1 phosphorylation.  We 
speculated that this could be a result of signaling pathway cross-talk.  We found that other major 
signaling pathways triggered by the parasite did not play a role in either STAT1 tyrosine 
phosphorylation by the parasite alone, or in the observed synergy with IFNγ.  Although MyD88 
does not appear to play role in terms of TLR-mediated pathways, we cannot rule out the possible 
involvement of other TLR adaptors, namely TRIF/TICAM-1. In addition, we ruled out GiPCR 
and PI3K pathway involvement in STAT1 activation and synergy with IFNγ through inhibitor 
experiments.  It remains possible that cross-talk with another untested signaling pathway 
initiated by the parasite could contribute to elevated STAT1 levels. 
 
We also considered whether the parasite could be blocking normal regulation of the 
IFNγ/STAT1 pathway.  IFNγ-triggered STAT1 phosphorylation occurs rapidly and is quickly 
tempered by the activity of several phosphatases (97).  We confirmed that Toxoplasma can 
inhibit IFNγ-triggered expression of a key phosphatase, Socs1, in dendritic cells and that this 
inhibition occurs independently of parasite strain type.  This result corroborates microarray data 
collected in other cell types that noted inhibition of IFNγ-driven Socs1 expression (48, 49).  
Socs1 inactivates a Janus kinase downstream of the IFNγ receptor, thereby preventing IFNγ from 
triggering additional STAT1 tyrosine phosphorylation (98).  By preventing Socs1 expression, 
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that level of regulation is lost, allowing the Janus kinase to activate STAT1 continuously in the 
presence of IFNγ.  Thus, inhibition of this key phosphatase is likely to explain how synergistic 
levels of phospho-STAT1 accumulate over time.  To further corroborate this finding, it would be 
of interest to over-express SOCS1 and determine whether the synergistic effects of T. gondii on 
phospho-STAT1 levels are abrogated.  Other phosphatases known to regulate IFNγ/JAK/STAT1 
signaling such as the protein tyrosine phosphatases SHP-1 and SHP-2 as well as the nuclear 
phosphatase TC-45 could also potentially be targeted and contribute to elevated phospho-STAT1 
levels (97).  However, because these phosphatases were not identified among the IFNγ-inducible 
genes down-regulated by Toxoplasma gondii (48, 49), inhibition of Socs1 expression remains the 
most likely explanation for the synergistic phospho-STAT1 levels observed. 
 
Interestingly, even though Toxoplasma blocks IFNγ-triggered Socs1 expression, the parasite 
itself induces a modest amount of Socs1 in a ROP16-dependent manner, in line with findings in 
other cell types (15, 47, 90).  It is unclear at this time what role parasite-induced, strain-
dependent Socs1 may play, but it does not appear to affect STAT1 phosphorylation insofar as the 
latter is induced in a strain-independent manner.  However, SOCS1 has been shown to negatively 
regulate TLR signaling (99).  It is conceivable that the parasite induces SOCS family proteins as 
part of an immune evasion mechanism to counteract TLR or other Toxoplasma-sensing pathways 
while blocking IFNγ-mediated gene expression in another manner.  Further work is needed to 
identify targets and the functional outcome of parasite-induced SOCS1 in infected cells.  In 
summary, we have identified inhibition of Socs1 expression as a likely mechanism for 
synergistic STAT1 phosphorylation in infected cells treated with IFNγ, while also ruling out  
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some key potential mechanisms for STAT1 phosphorylation and inhibition of STAT1 activity by 
Toxoplasma. 
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Summary of findings 
Interferons are critical for host control of a wide variety of pathogens, including viruses, 
intracellular bacteria, and protozoa.   STAT1 is a key downstream signaling molecule activated 
by both type I (IFNα/β) and type II (IFNγ) interferons.  In fact, STAT1 loss of function 
mutations in humans are linked to increased susceptibility to mycobacterial and viral infections 
(1-3).  Inhibition of interferon and/or STAT1-dependent activity is thus a key strategy employed 
by many intracellular pathogens to evade the host immune response.  Both type I and II 
interferons have anti-viral properties, although type I interferons are particularly important as 
they are directly induced in virus-infected cells (4).  Viruses have evolved multiple strategies for 
evasion of IFNα/β responses, including those that target STAT1 for inactivation (4).  IFNγ and 
STAT1 are essential in the control of various intracellular bacteria and protozoa.  Intracellular 
bacteria such as Mycobacterium tuberculosis and enteropathogenic Escherichia coli can interfere 
with IFNγ-dependent transcriptional responses/chromatin remodeling (5, 6) or STAT1 activation 
(7, 8), respectively, to promote survival.  In addition, the protozoan Leishmania has been shown 
to promote STAT1 degradation as a means of regulating the IFNγ response (9).  Related to the 
topic of this thesis, Toxoplasma is another example of a protozoan that hijacks the IFNγ/STAT1 
pathway to facilitate survival.  The content of this thesis confirms the importance of blocking this 
pathway in a key immune cell type, the dendritic cell.  In addition, I further investigate the 
mechanisms by which Toxoplasma impairs IFNγ-mediated STAT1 transcriptional responses 
while paradoxically triggering STAT1 phosphorylation upon infection alone. 
 
The data in Chapter 2 surprisingly reveal that infection of dendritic cells with Toxoplasma in the 
absence of IFNγ is enough to trigger sustained STAT1 phosphorylation and nuclear 
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translocation.  The parasite initiates both tyrosine and serine phosphorylation at key residues of 
STAT1.  Phosphorylation can be weakly detected as early as 30 minutes post-infection, but does 
not achieve peak levels until several hours later.  This occurs in contrast to the cytokine IFNγ, 
which induces rapid and robust STAT1 phosphorylation within the first 30 minutes that 
subsequently declines over time.  Furthermore, when DCs are infected with Toxoplasma prior to 
IFNγ treatment, synergistic levels of phosphorylated STAT1 are obtained.  Activation of STAT1 
occurs independently of parasite strain type when comparing representatives of the three main 
clonal lineages.  In agreement with this, the rhoptry kinase ROP16 does not play a role, despite 
the ability of this parasite kinase to induce STAT3/6 phosphorylation.  Further investigation 
reveals that live parasites are required for STAT1 phosphorylation.  Furthermore, the parasites 
must actively invade cells rather than just attaching to the cell surface as experiments with 
cytochalasin D treatment confirm.  Use of a replication-deficient strain shows that parasite 
replication is not required to maintain STAT1 phosphorylation.  Transfer of supernatant from 
infected cells to uninfected cells confirms that a soluble mediator is not responsible for the 
observed response.  In addition, STAT1 phosphorylation is confined to infected cells, indicating 
that surface contact between infected and uninfected cells is also not a possible mechanism. 
 
I next looked at the ability of parasite-induced STAT1 to bind to DNA.  Parasite alone is able to 
induce modest STAT1 binding to GAS elements in a transcription factor binding ELISA, 
although chemiluminescent EMSA does not appear to be sensitive enough to detect this.  
However, cells that were pre-infected with the parasite and subsequently treated with IFNγ 
demonstrate synergistic levels of STAT1 GAS binding by EMSA.  In addition, an aberrant 
STAT1-containing complex is identified in infected cells in addition to the classic gamma-
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activated factor (STAT1 homodimer) induced by IFNγ alone.  However, despite evidence of 
STAT1 binding to consensus sequences, ChIP assays reveal that the parasite does not induce 
STAT1 binding to the native Irf1 promoter.  In addition, the parasite blocks IFNγ-induced 
STAT1 promoter recruitment.  In agreement with this, transcription of IFNγ/STAT1 responsive 
genes including Irf1 and the p47 GTPases are also blocked by Toxoplasma.  Therefore, although 
the parasite can induce STAT1 phosphorylation in synergy with IFNγ in DCs, transcription of 
IFNγ-induced STAT1 responsive genes remains blocked. 
 
In Chapter 3, I further define the mechanisms by which Toxoplasma inhibits IFNγ-induced 
STAT1 transcriptional activity, induces STAT1 phosphorylation, and synergizes with IFNγ in 
terms of STAT1 phosphorylation.  I show that inhibition of STAT1 transcriptional activity by the 
parasite occurs independently of parasite strain type.  In agreement with this, ROP16-deleted 
parasites are equally able to inhibit STAT1 transcription compared to wild-type, eliminating 
ROP16-dependent STAT3 activation as a contributor to STAT1 inhibition.  Furthermore, I show 
that STAT3 does not contribute to aberrant STAT1 complex formation by EMSA through a 
supershift experiment, making STAT3 a less likely culprit for STAT1 inhibition.  However, 
STAT1/STAT3 interactions are detected in infected cells, raising the possibility that parasite-
induced STAT3 may participate in regulating a different subset of genes via STAT1/3 
heterodimers.  In terms of STAT1 phosphorylation by the parasite, it is clear that the rhoptry 
molecules ROP18 and ROP21 do not contribute, as infections with mutant strains demonstrate.  
In addition, GiPCR-, PI3K-, and MyD88-dependent pathways triggered by the parasite upon 
invasion also do not contribute to either parasite-induced STAT1 phosphorylation or the synergy 
observed with the IFNγ pathway.  I also investigated whether inhibition of a key regulator of 
155 
 
IFNγ-dependent JAK/STAT1 signaling, SOCS1, could explain the synergistic levels of 
phosphorylated STAT1 observed in infected cells treated with IFNγ.  It is clear that the parasite 
downregulates Socs1 expression induced by IFNγ, strongly implicating Socs1 inhibition in the 
mechanism for enhanced STAT1 phosphorylation.  Interestingly, the parasite alone also induces 
a modest level of strain-dependent Socs1 expression, in dependence on the rhoptry kinase 
ROP16.  Parasite-induced Socs1 cannot account for STAT1 inhibition, given that transcriptional 
inhibition occurs independently of strain type, but could potentially play a role in the strain-
dependent inactivation of TLR-induced pro-inflammatory cytokine production.  This chapter 
serves to rule out several potential key players in the mechanism of STAT1 phosphorylation and 
transcriptional inhibition, while implicating inhibition of SOCS1 as the cause of synergistic 
phosphorylated STAT1 levels. 
 
Future directions and unanswered questions 
It is clear from prior in vivo studies that STAT1, in addition to IFNγ, is essential in host 
resistance to Toxoplasma infection (10, 11).  Despite the parasite’s efforts at blocking 
IFNγ/STAT1-dependent signaling in infected cells, uninfected cells of the innate immune system 
are capable of responding to the cytokine, ready to eliminate the parasite upon future encounter.  
It is unclear at this time which cell types are essential for STAT1-mediated resistance in vivo.  
Dendritic cells are considered the key IL12 producers in vivo during Toxoplasma infection and 
help initiate adaptive immune responses, but macrophages also possess a potent arsenal of 
STAT1-dependent antimicrobial effector mechanisms (12).  Conditional ablation of STAT1 in 
dendritic cell versus macrophage subsets using Cre/Lox technology followed by infection with 
Toxoplasma would help to identify the relative importance of STAT1 signaling in innate cell 
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types.  A precedent for this has already been established during Listeria infection, where 
macrophage STAT1 is considered protective while DC STAT1 has no effect on host survival 
(13).  However, DC STAT1 does contribute positively to secondary responses in vaccinated 
animals upon challenge.  Similar studies could be performed with Toxoplasma to determine 
relative impact on survival of macrophage versus dendritic cell STAT1 during acute infection 
and as well as during secondary responses in a vaccination model. 
 
The data presented in Chapter 2 demonstrate that Toxoplasma can induce STAT1 
phosphorylation in the absence of additional IFNγ.  In agreement with my work, another recent 
study had a similar finding in infected human fibroblasts, although those authors found ROP16 
to be required for STAT1 phosphorylation (14).  However, this is not the case for murine 
dendritic cells, leaving the mechanism yet to be defined.  The data support a direct effect of 
Toxoplasma on host cell signaling, rather than induction of a soluble mediator.  In addition, the 
delayed kinetics of STAT1 phosphorylation is comparable to the kinetics of NF-κB activation 
induced by the parasite dense granule protein GRA15 (15).  In agreement with this, induction of 
STAT1 phosphorylation is inhibited by cytochalasin D treatment, which prevents host cell 
invasion as well as dense granule protein release by the parasite (16).  Taken together, the data 
implicate a parasite-derived effector protein in STAT1 phosphorylation that is likely derived 
from the dense granules.  Unlike GRA15 activity, STAT1 phosphorylation by the parasite occurs 
in a strain-independent manner.  Future work to identify a strain-independent GRA protein may 
serve to identify the parasite molecule responsible.  To this end, GRA7 is expressed by all three 
strain types and may be a viable candidate to explore through use of deletion mutants (17).  
Additional GRA proteins known to associate with the parasitophorous vacuole membrane 
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include GRA3, 5, 8, and 10 (18).  Deletion mutants of these parasites could be 
acquired/constructed and analyzed for ability to induce STAT1 phosphorylation.  It may also be 
possible to acquire dense granule protein fractions from the different parasite strains to determine 
if dense granule protein is indeed involved. 
 
The question remains as to why Toxoplasma induces STAT1 phosphorylation in the first place.  
Saeij and colleagues suggest that STAT1 phosphorylated in response to Toxoplasma infection is 
transcriptionally inactive, given that IFNγ-responsive genes are transcriptionally repressed.  
Furthermore, they suggest that ROP16 may phosphorylate STAT1 less efficiently compared to 
STATs3 and 6, with STAT1 being an accidental target (14).  My data in murine dendritic cells 
does not rule out the possibility of bystander STAT1 activation by some parasite kinase, but it is 
clear that ROP16 does not play a role as STAT1 phosphorylation occurs independently of this 
molecule and parasite strain type in general.  However, it is also possible that Toxoplasma-
induced STAT1 may modulate transcription of a subset of genes distinct from the antimicrobial 
genes activated by IFNγ.  The mechanism by which this might occur is unclear, but could 
involve formation of complexes with other transcription factors at different gene promoters.  To 
investigate this possibility further, it would be of interest to compare Toxoplasma-infected 
STAT1 knock-out DCs with infected wild-type counterparts and perform microarray analysis to 
determine which host genes, if any, are positively or negatively regulated by the parasite in a 
STAT1-dependent manner.  It is possible that parasite-controlled STAT1 activation plays a role 
in modulation of the host immune response or contributes to parasite survival through impacts on 
other pathways. 
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Data from Chapters 2 and 3 address inhibition of IFNγ-mediated STAT1 transcriptional activity 
by Toxoplasma.  This work is the first to demonstrate inhibition of IFNγ responses by the 
parasite in the dendritic cell, an immune cell type that is critical during in vivo infection.  Further 
work is required to identify what parasite molecule(s) carry out STAT1 inhibition, as well as the 
mechanism by which this occurs.  Work performed in bone marrow-derived macrophages 
demonstrates that Toxoplasma can impair transcription-permissive histone acetylation as well as 
recruitment of the BRG1 component of a chromatin remodeling complex to the CIITA promoter 
(19).  However, BRG1 is not required for IFNγ-induced remodeling of the Irf1 promoter (20), 
suggesting that BRG1 may not the direct target of the parasite.   
 
Interestingly, the parasite causes formation of aberrant STAT1-containing complexes that retain 
the ability to bind GAS oligonucleotides by EMSA, but not the native promoters of IFNγ-
responsive genes in ChIP assays.  Attempts to identify contributors to this complex by myself  
(Chapter 3) and others (19) have ruled out involvement of host STAT3, STAT2, and IRF9 but 
have so far failed in identifying the specific host or parasite proteins involved.  It is tempting to 
speculate that the parasite secretes a protein upon invasion that binds to STAT1 and could 
account for the aberrant STAT1 complex formation (Figure 4.1).  This interaction may allow 
binding to DNA oligonucleotides but could still impair association with key chromatin 
modifiers/remodelers such as BRG1 that are needed to establish stable native promoter binding 
and transcription.  This would not be without precedent as an adenoviral protein, E1A, has been 
shown to inhibit STAT1 activity through direct interaction with STAT1, independent of the 
ability of E1A to compete with STAT1 for binding to the histone acetylase p300/CBP (21).  
Mycobacterium tuberculosis can also impair chromatin remodeling at the IFNγ-responsive 
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CIITA promoter in dependence upon a 19 kDa lipoprotein, although the exact mechanism by 
which this occurs is still unclear (6).  It has also been shown that impaired chromatin remodeling 
occurs at the TNFα promoter in Toxoplasma-infected macrophages (22).  However, the 
mechanism behind inhibition of LPS-induced IL12 and TNFα production is different from 
STAT1 inhibition, as the former is strain/ROP16-dependent (23) while the latter is not.  For 
STAT1 inhibition, future studies should focus on identifying the additional components in the 
aberrant STAT1 complex.  Attempts to immunoprecipitate native STAT1 in primary cells 
directly or indirectly via GAS oligonucleotide probes have so far failed to yield candidates.  To 
improve sensitivity, it may be useful to transfect or transduce STAT1-deficient cells with a 
tagged STAT1 construct prior to infecting them and performing a pull-down assay using beads 
directly conjugated to antibodies against the tag.  Upon elution, the “prey” including STAT1 and 
any associated molecules could be separated by gel electrophoresis.  Candidate protein bands 
could then be submitted for mass spectrometric analysis.  If a candidate Toxoplasma protein is 
identified, a mutant parasite could be generated to confirm if that protein plays a role in STAT1 
transcriptional inhibition. 
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Figure 4.1.  Proposed model for Toxoplasma-induced STAT1 phosphorylation and 
inhibition of IFNγ-driven STAT1 transcription.  Toxoplasma establishes intracellular 
infection within the parasitophorous vacuole (1).  The parasite may then secrete a protein capable 
of binding to STAT1 (2).  At this point, the cell may come into contact with the cytokine IFNγ, 
which initiates a JAK/STAT1 signaling cascade upon binding to its receptor subunits (3).  
Activated JAKs phosphorylate STAT1 (4), forming dimers that translocate to the nucleus (5).  
However, the Toxoplasma STAT1-binding protein may then interact with STAT1 in the nucleus, 
preventing stable binding to native promoters of responsive genes (6) by impairing interactions 
with histone modifying and chromatin remodeling enzymes (7).  This prevents transcription of 
various IFNγ-responsive genes including the negative regulator of IFNγ signaling, SOCS1 (8).  
As a result, SOCS1 cannot impair JAK activation as it normally would (9), resulting in 
accumulation of phospho-STAT1 in infected cells.  In addition, another unknown Toxoplasma 
protein speculated to be a dense granule protein (GRA) may also trigger STAT1 
phosphorylation, the function of which remains unknown. 
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It is also apparent from the data in Chapter 3 that Toxoplasma can significantly inhibit IFNγ-
induced Socs1 expression in DCs.  This is consistent with microarray data from infected human 
fibroblasts and murine macrophages treated with IFNγ (19, 24).  Given that SOCS1 normally 
downregulates IFNγ signaling by inactivating JAK activity, this could explain why high levels of 
phosphorylated STAT1 accumulate in infected cells treated with IFNγ.  Further work to confirm 
this correlation would entail overexpression of SOCS1 in infected cells treated with IFNγ to see 
if the high level of phosphorylated STAT1 is subsequently lost.  Despite this increased level of 
phosphorylated STAT1, Toxoplasma is still able to mediate inhibition of IFNγ-driven STAT1 
transcriptional responses, rendering the STAT1 non-functional. 
 
Paradoxically, Toxoplasma alone is also able to induce modest Socs1 expression in a ROP16-
dependent manner, as seen by us and others (25-27).  However, SOCS1 does not appear to 
contribute to parasite-mediated inhibition of IFNγ signaling, given that STAT1 inhibition occurs 
independently of strain type.  Another possibility is that parasite-induced SOCS1 contributes to 
inhibition of TLR signaling by the parasite.  One study suggests that SOCS1 can regulate 
stability of the NF-κB subunit p65/RelA (28) while another indicates that SOCS1 may target 
IRAK1 (29).  Strong evidence also exists for SOCS1 targeting of Mal/Tirap, an adaptor protein 
for TLRs 2 and 4.  Mal/Tirap is phosphorylated on a tyrosine residue by Bruton’s tyrosine kinase 
(BTK) which facilitates interaction of Mal with SOCS1 (30).  SOCS1 subsequently mediates 
ubiquitination and proteasomal degradation of Mal (30).  TRAF6 can no longer interact with Mal 
and this impairs subsequent serine phosphorylation of NF-κB that is required for transcriptional 
activity. Under these conditions, initial NFκB activation is unaffected (31, 32).   
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It is known that Toxoplasma inhibits LPS-induced IL12 and TNFα production in a ROP16-
dependent manner, involving STAT3 activation (23).  However, it is unclear how STAT3 exerts 
this effect.  STAT3 can, however, induce expression of Socs1, at least in terms of IL10 signaling 
(33).  Given the known effect STAT3 can have on Socs1 expression, I propose that ROP16-
activated STAT3 induces Socs1 expression.  This in turn could negatively regulate certain TLR 
pathways, thereby contributing to inhibition of proinflammatory cytokine production (Figure 
4.2).  This could explain how the parasite impairs NF-κB binding to the TNFα promoter and 
transcription (22) and/or contribute to inhibition of TLR-induced MAPK activation (34).   
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Figure 4.2.  Proposed model for inhibition of TLR signaling by Toxoplasma-induced 
SOCS1.  Upon host cell invasion, Toxoplasma secretes the rhoptry kinase ROP16 (1), which in 
turn phosphorylates host cell STAT3 (2).  STAT3 translocates to the nucleus where it induces 
transcription of unknown genes in infected cells (3), which may include Socs1 given its ROP16-
dependent expression (4).  SOCS1 is known to negatively regulate TLR pathways, with the 
TLR4 pathway provided as an example (5).  Depending on the TLR or host cell involved, 
SOCS1 may target the adaptor protein Mal (6), the IRAK molecules (7), or NF-κB itself (8) for 
degradation.  This in turn can affect activation or transactivation of NF-κB and/or activation of 
the MAPK cascade, leading to impaired pro-inflammatory cytokine production in Toxoplasma-
infected cells subsequently exposed to TLR ligands (9). 
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However, this mechanism is unlikely to explain the initial inhibition of NFκB nuclear 
accumulation observed in macrophages infected with parasites alone (35), given the time needed 
for protein synthesis.  Therefore, it is likely that the initial phase of NFκB inhibition occurs 
through a separate mechanism.  Along these lines, it is known that in addition to ROP16, 
Toxoplasma can rapidly inject a serine-threonine phosphatase into the nucleus upon invasion 
(36).  Presumably one of these molecules could alter the localization of NFκB early on, thereby 
preventing nuclear accumulation until the second phase mediated by STAT3 transcriptional 
activity could begin.  Given that type II strains only induce NFκB activation after 4 hours or so 
(15), it is possible that the initial phase of NFκB activity is blocked equally by all parasite 
strains, permitting establishment of infection.  Type I and III strains would then have the added 
advantage of further impairing proinflammatory cytokine production at later timepoints through 
the ROP16/STAT3/SOCS1 mechanism.  This hypothesis could be tested initially by comparing 
proinflammatory cytokine production in infected cells in the presence or absence of SOCS1.  
Socs1 knock-out mice do exist although they die in the first few weeks after birth (37).  
Socs1/IFNγ double knock-out mice survive longer and may be a better option for acquiring 
primary cells (38).  If successful, further work could be done to confirm STAT3 involvement in 
Socs1 induction and to confirm the negative impacts on TLR activity.  It is also possible that 
Toxoplasma-induced STAT3 triggers expression of additional proteins that may also contribute 
to TLR regulation. 
 
In summary, my work has shown that Toxoplasma can inhibit IFNγ/STAT1-dependent activity 
in the dendritic cell, a key cell type in the immune response to infection.  Paradoxically, I 
observe that the parasite can also induce STAT1 phosphorylation independent of cytokine 
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stimulation.  The parasite’s impact on Socs1 expression is complex, but may shed new light on 
how the parasite inhibits TLR-induced pro-inflammatory cytokine production.  Further work as 
outlined above is required to further dissect the mechanisms by which these processes occur, as 
well as to determine what role Toxoplasma-activated STAT1 may play.  Nonetheless, this work 
has contributed to our knowledge of how Toxoplasma successfully evades the host immune 
response. 
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